UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year Ended December 31, 2014
Commission File Number 333-190080
BIOSIG TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation
or organization)
12424 Wilshire Boulevard, Suite 745
Los Angeles, California
(Address of principal executive office)
Securities registered pursuant to Section 12(g) of the Act: None
26-4333375
(IRS Employer Identification No.)
90025
(Zip Code)
(310) 820-8100
(Registrant’s telephone number, Including area code)
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined by Rule 405 of the Securities Act. Yes ¨ No x
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ¨ No x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained
herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨
Non-accelerated filer ¨
(Do not check if a smaller reporting company)
Accelerated filer ¨
Smaller reporting company x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
The aggregate market value of the voting common equity held by non-affiliates as of June 30, 2014, based on the estimated market price of
the Common Stock $5,475,670. For purposes of this computation, all officers, directors, and 5 percent beneficial owners of the registrant are
deemed to be affiliates. Such determination should not be deemed an admission that such directors, officers, or 5 percent beneficial owners
are, in fact, affiliates of the registrant.
As of February 20, 2015, there were 12,226,300 shares of registrant’s common stock outstanding.
Table of Contents
TABLE OF CONTENTS
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
PAGE
3
16
31
31
31
31
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Selected Financial Data
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures about Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosures
Controls and Procedures
Other Information
32
32
32
37
F-1 – F-25
38
38
38
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accounting Fees and Services
PART I
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
PART II
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
PART III
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
PART IV
Item 15.
Exhibits, Financial Statement Schedules
Signatures
39
42
45
47
49
50
51
Table of Contents
ITEM 1 – BUSINESS
PART I
This Annual Report on Form 10-K (including the section regarding Management's Discussion and Analysis of Financial Condition
and Results of Operations) contains forward-looking statements regarding our business, financial condition, results of operations and
prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of
such words are intended to identify forward-looking statements, but are not deemed to represent an all-inclusive means of identifying forward-
looking statements as denoted in this Annual Report on Form 10-K. Additionally, statements concerning future matters are forward-looking
statements.
Although forward-looking statements in this Annual Report on Form 10-K reflect the good faith judgment of our Management, such
statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to
risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the
forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation,
those specifically addressed under the heading “Risks Factors” below, as well as those discussed elsewhere in this Annual Report on Form 10-
K. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report
on Form 10-K. We file reports with the Securities and Exchange Commission (“SEC”). You can read and copy any materials we file with the
SEC at the SEC's Public Reference Room at 100 F Street, NE, Washington, DC 20549. You can obtain additional information about the
operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet site
(www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with
the SEC, including us.
We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may
arise after the date of this Annual Report on Form 10-K. Readers are urged to carefully review and consider the various disclosures made
throughout the entirety of this annual Report, which attempt to advise interested parties of the risks and factors that may affect our business,
financial condition, results of operations and prospects.
Corporate Structure
We were initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the
state of Delaware in 2011. The Company and its efforts are principally devoted to improving the quality of cardiac recordings obtained during
ablation of atrial fibrillation (AF) and ventricular tachycardia (VT). The Company has not generated any revenue to date and consequently its
operations are subject to all risks inherent in the establishment of a new business enterprise.
Business Overview
We are a medical device company that is developing a proprietary technology platform to minimize noise and artifacts from cardiac
recordings during electrophysiology studies and ablation. We are developing the PURE EP System, a surface electrocardiogram and
intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required
during electrophysiology studies and ablation procedures.
The PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System is designed to assist electrophysiologists in
making clinical decisions in real-time by providing information that, we believe, is not easily obtained, if at all, from any other equipment
presently used in electrophysiology labs. PURE EP System’s ability to acquire high fidelity cardiac signals will potentially increase these
signals’ diagnostic value, and therefore offer improved accuracy and efficiency of the EP studies and related procedures.
We are developing signal processing tools within the PURE EP System, which we call confidence indexes. We believe that these
will assist electrophysiologists in further differentiating true signals from noise, and will provide guidance in identifying ablation targets.
3
Table of Contents
Since June 2011, we have collaborated with physicians affiliated with the Texas Cardiac Arrhythmia Institute at St. David’s Medical
Center in Austin, Texas for initial technology validation. The physicians affiliated with the Texas Cardiac Arrhythmia Institute has provided
us with digital recordings obtained with conventional electrophysiology recording systems during different stages of electrophysiology
studies. Using our proprietary signal processing tools that are part of the PURE EP System, we analyzed these recordings and successfully
removed baseline wander, noise and artifacts from the data thereby providing better diagnostic quality signals.
We are focused on improving the quality of cardiac recordings obtained during ablation of atrial fibrillation, the most common
cardiac arrhythmia, and ventricular tachycardia, an arrhythmia evidenced by a fast heart rhythm originating from the lower chambers of the
heart, which can be life-threatening. Cardiac ablation is a procedure that corrects conduction of electrical impulses in the heart that cause
arrhythmias. During this invasive procedure, a catheter is usually inserted using a venous access into a specific area of the heart. A special
radiofrequency generator delivers energy through the catheter to small areas of the heart muscle that cause the abnormal heart
rhythm. According to a 2009 article in Circulation: Arrhythmia and Electrophysiology, ablation is superior to pharmacological treatments and
is becoming a first line of therapy for certain patients with arrhythmias (“Treatment of Atrial Fibrillation With Antiarrhythmic Drugs or
Radiofrequency Ablation,” Circulation: Arrhythmia and Electrophysiology 2: 349-361 (2009)).
Our overall goal is to establish our proprietary technology as a new platform that will have the following advantages over the
electrophysiology recording systems currently available on the market:
●
●
●
●
Higher quality cardiac signal acquisition for accurate and more efficient electrophysiology studies;
Precise, uninterrupted, real time evaluations of electrograms;
Reliable cardiac recordings to better determine precise ablation targets, strategy and end point of procedures;
and
A portable device that can be fully integrated into existing electrophysiology lab environments.
If we are able to develop our product as designed, we believe that the PURE EP System and its signal processing tools will contribute
to an increase in the number of procedures performed in each electrophysiology lab and possibly improved patient outcomes.
Our significant scientific achievements to date include:
●
●
Initial system concept validation has been performed in collaboration with physicians at the Texas Cardiac
Arrhythmia Institute at St. David’s Medical Center in Austin, Texas in June 2011. The Texas Cardiac
Arrhythmia Institute provided challenging recordings obtained with electrophysiology recording systems
presently in use at the institute during various electrophysiology studies. Our technology team successfully
imported the data into the PURE EP System software and using proprietary signal processing, the PURE EP
System software was able to reduce baseline wander, noise, and artifacts from the data and therefore provide
better diagnostic quality signals.
We have established clinical and/or advisory relationships for both technology development and validation
studies with physicians and researchers affiliated with the following medical centers: Texas Cardiac
Arrhythmia Institute, Austin, TX; Cardiac Arrhythmia Center at the University of California at Los Angeles,
Los Angeles, CA; Mount Sinai Medical Center, New York, NY; Beaumont Medical Center, Detroit, MI;
University Hospitals Case Medical Center, Cleveland, OH; The Heart Rhythm Institute, University of
Oklahoma Health Sciences Center, Oklahoma City, OK; and Mayo Clinic in Rochester, MN.
4
Table of Contents
●
●
●
●
●
●
As part of our pre-clinical trials, physicians affiliated with the Texas Cardiac Arrhythmia Institute,
University Hospitals Case Medical Center and Mount Sinai Medical Center provide us with recordings from
challenging ablation procedures, mainly for ventricular tachycardia and atrial fibrillation, where the
attending electrophysiologists face clinical dilemmas with the recordings obtained by their current recording
systems. We believe that the recordings that the PURE EP System software has provided them, which show
a reduction in baseline wander, noise, and artifacts, are of higher diagnostic value than the original
recordings.
The Cardiac Arrhythmia Center at the University of California at Los Angeles and Dr. Kalyanam
Shivkumar have played a significant role in the initial functional testing of our hardware. Dr. Shivkumar
and his team have enabled us to learn the connectivity of the lab and its devices that pertain to where our
PURE EP System will fit in. In June 2013, we commenced our first proof of concept animal study with the
assistance of Dr. Shivkumar in order to further test the components of the PURE EP System hardware, as
further explained below.
We are developing a confidence index that will assist electrophysiologists in further differentiating true
signals from noise, which may potentially provide guidance in identifying ablation targets. The confidence
index is expected to be an integral part of the software of the PURE EP System, which we believe will
significantly facilitate the locating of ablation targets.
In the second and third quarters of 2013, we performed and finalized testing of our proof of concept unit by
initially using an electrocardiogram/intracardiac simulator at our lab, and subsequently by obtaining animal
recordings from the animal lab at the University of California at Los Angeles. As part of the testing, we
simultaneously recorded electrocardiogram and intracardiac signals on our proof of concept unit and GE’s
CardioLab recording system. An identical signal was applied to the input of both systems and the monitor of
our proof of concept unit was positioned next to the monitor of GE’s CardioLab recording system to allow
for visual comparison. We believe that our proof of concept unit performed well as compared to GE’s
CardioLab recording system, in that the electrocardiogram and intracardiac signals displayed on our proof of
concept unit showed less baseline wander, noise and artifacts compared to signals displayed on GE’s
CardioLab recording system. However, because this was a proof of concept test, without any clearly
established protocols, we cannot present this data for publication and we do not have any independent
verification or peer review of these findings.
In the third quarter of 2013, we analyzed the results of our proof of concept unit to determine the final
design of the PURE EP System prototype. Because the proof of concept unit was designed to verify the
capabilities of the main components of the PURE EP System, we established a list of tasks necessary to
complete the prototype (which we intend to use for end-user preference studies, animal studies and in-human
recordings). The PURE EP System prototype is presently assembled.
In the fourth quarter of 2014, we appointed Dr. Samuel J. Asirvatham from Mayo Clinic as a member of our
Scientific Advisory Board and initiated plans for animal studies at Mayo Clinic. We expect to perform our
initial study there in April 2015.
We are currently conducting testing of the assembled components of the PURE EP System prototype in order to validate the design
of the prototype. We believe such testing will be completed by the end of the first quarter of 2015. To date, we have not conducted any
studies of the data produced by our technology that have been subjected to any third-party review, as would be required for the publication of
a formal study.
5
Table of Contents
We intend to conduct formal animal studies and initial human clinical trials using the PURE EP System prototype, using formal
protocol and study designs. These formal animal studies and human clinical trials are intended to demonstrate the clinical relevance of the
PURE EP System and its advantages as compared to electrophysiology recorders currently on the market, which we believe will demonstrate
the value of the PURE EP System to physicians and clinicians. Our objective is to complete our initial animal study in April 2015 at Mayo
Clinic. We have also begun planning and implementing steps for obtaining 510(k) approval from the U.S. Food and Drug Administration for
the PURE EP System. We believe that by the first half of 2016, we will have obtained 510(k) marketing clearance from the FDA and will be
able to commence marketing and commercialization of the PURE EP System. Our ability to achieve the aforementioned milestones will be
principally determined by our ability to obtain necessary financing and regulatory approvals, among other factors.
Because we are an early development stage company, with our initial product under development, we currently do not have any
customers. We anticipate that our initial customers will be hospitals and other health care facilities that operate electrophysiology labs.
Our Industry
Electrophysiology is the study of the propagation of electrical impulses throughout the heart. Electrophysiology studies are focused
on the diagnosis and treatment of arrhythmias, a medical condition in which conduction of electrical impulses within the heart vary from the
normal. Such conditions may be associated with significant health risks to patients. The invasive cardiac electrophysiology study for the
evaluation of cardiac conduction disorders has evolved rapidly from a research tool to an established clinical treatment. This technique
permits detailed analyses of the mechanism underlying cardiac arrhythmias and determines precise locations of the sites of origin of these
arrhythmias, thereby aiding in treatment strategies.
Pharmacological, or medicine-based, therapies have traditionally been used as initial treatments, but they often fail to adequately
control the arrhythmia and may have significant side effects. Catheter ablation is now often recommended for an arrhythmia that medicine
cannot control. Catheter ablation involves advancing several flexible catheters into the patient’s blood vessels, usually either in the femoral
vein, internal jugular vein or subclavian vein. The catheters are then advanced towards the heart. Electrical impulses are then used to induce
the arrhythmia and local heating or freezing is used to ablate (destroy) the abnormal tissue that is causing it. Catheter ablation of most
arrhythmias has a high success rate and multiple procedures per patient have been found to be more successful.
One study found that arrhythmia-free survival rates after a single catheter ablation procedure were 40%, 37%, and 29% at one, two
and five years, respectively, with most recurrences over the first six months (“Catheter Ablation for Atrial Fibrillation - Are Results
Maintained at 5 Years of Follow-Up?” J Am Coll Cardiol. 2011;57(2):160-166). Another study stated that catheter ablation of atrial
fibrillation has been shown to be effective in approximately 80% of patients after 1.3 procedures per patient, with approximately 70% of such
patients requiring no further antiarrhythmic drugs during intermediate follow-up (Updated Worldwide Survey on the Methods, Efficacy, and
Safety of Catheter Ablation for Human Atrial Fibrillation Circulation: Arrhythmia and Electrophysiology. 2010; 3: 32-38).
Catheter ablation is usually performed by an electrophysiologist (a specially trained cardiologist) in a catheterization lab or a
specialized electrophysiology lab. It is estimated that there are about 2,000 electrophysiology labs in the U.S. and 2,000 electrophysiology
labs outside the U.S., each with an electrophysiology recording system costing an average of $250,000. We believe that the current value of
the electrophysiology recording device market in the U.S. is approximately $500 million, based upon the number of electrophysiology labs in
U.S. and the average cost of the recording system in each lab. With the potential of 12 million atrial fibrillation patients by the year 2050
(according to the Atrial Fibrillation Fact Sheet, February 2010, published by the Centers for Disease Control and Prevention) and
improvements in technology for atrial fibrillation ablation therapy, significant growth is predicted for the number of hospitals building
electrophysiology labs. A July 2012 report published by the Millennium Research Group predicted rapid growth in the U.S. market for
electrophysiology mapping and ablation devices from 2012 to 2016, due to the medical community’s growing focus on treating atrial
fibrillation. The report further predicts that even with advances in drug treatments and management devices to treat or manage arrhythmias, the
electrophysiology mapping and ablation device market will be sustained by the continued development of advanced technologies that decrease
ablation procedure times and improve success rates. According to the report, Electrophysiology Devices Market - Global Industry Analysis,
Size, Share, Growth, Trends and Forecast, 2013 – 2019, analysts forecast the global market for EP devices will grow at a 12.1 percent
compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019.
6
Table of Contents
Treatment of Atrial Fibrillation and Ventricular Tachycardia
We believe that the clearer recordings and additional information provided by the PURE EP System may improve outcomes during
electrophysiology studies and ablation procedures for a variety of arrhythmias. For patients who are candidates for ablation, an
electrophysiology study is necessary to define the targeted sites for the ablation procedure. Two common, yet complex, conditions for which
ablation procedures are performed are atrial fibrillation and ventricular tachycardia. We believe that in the near future, the PURE EP System
may have a great impact on assisting ablation strategies for these conditions.
Most cardiac arrhythmias are well understood and ablation simply requires destroying a small area of heart tissue possessing electrical
abnormality. In contrast, complex arrythmias, such as atrial fibrillation and ventricular tachycardia, have complex pathophysiology and
because knowledge of their origins and mechanisms are incomplete, ablation treatments for these arrhythmias are largely empirical. Catheter
ablation is now an important option to control recurrent ventricular tachycardias (“EHRA/HRS Expert Consensus on Catheter Ablation of
Ventricular Arrhythmias,” Europace (2009)11 (6): 771-817). Catheter ablation of ventricular tachycardia in nonischemic heart diseases can be
challenging, and outcomes across different diseases are incompletely defined (“Catheter Ablation of Ventricular Tachycardia in Nonischemic
Heart Disease,” Circulation: Arrhythmia and Electrophysiology (2012) 5: 992-1000). In addition, limitations of atrial fibrillation ablation
include the use of catheters designed for pinpoint lesions to perform large area ablations in a point-by-point fashion, and the dexterity required
to perform the procedure (“New Technologies in Atrial Fibrillation Ablation,” Circulation (2009)). Furthermore, the length of these
procedures exposes the physician and staff to extensive radiation, requiring them to wear heavy lead vests. Consequently, ablating atrial
fibrillation and ventricular tachycardia have been regarded as being extremely difficult. Therefore, access to these procedures has been limited
to being performed by only especially well-trained cardiologists; however, advancements in new technologies and techniques show a strong
growth rate for these procedures.
According to the National Institute of Health National Heart Lung and Blood Institute, there are more than 3 million Americans
suffering with atrial fibrillation and about 850,000 patients are hospitalized annually. As many as 600,000 new cases of atrial fibrillation are
diagnosed each year. Despite the fact that physicians have been performing radiofrequency ablations since the 1990s, catheter-based treatment
is offered to less than 3% of the atrial fibrillation patient population in the U.S. and Europe. According to Millennium Research Group
(MRG), the global authority on medical technology market intelligence, an increasing proportion of diagnosed atrial fibrillation cases are now
being treated via ablation, as both physician confidence and the devices used in these procedures improve. A growing amount of positive
clinical data has been demonstrating the efficacy of AF ablation when compared to the traditional first-line treatment of anti-arrhythmic drugs.
As a result, AF ablation will be the fastest growing procedure type in this market, increasing at an average annual rate of 16 percent from 2012
to 2016. The American College of Cardiology Foundation/American Heart Association Task Force reported that catheter-directed ablation of
atrial fibrillation represents a substantial achievement that promises better therapy for a large number of patients presently resistant to
pharmacological or electrical conversion to sinus rhythm (“2011 ACCF/AHA/HRS Focused Update on the Management of Patients With
Atrial Fibrillation (Updating the 2006 Guideline)”). However, rates of success and complications may vary, sometimes considerably.
According to the Heart Rhythm Society, ventricular tachycardia is the most dangerous arrhythmia since it may result in ventricular
fibrillation, a rapid chaotic heartbeat in the lower chambers of the heart. Because the fibrillating muscle cannot contract and pump blood to
the brain and vital organs, ventricular fibrillation is the number one cause of sudden cardiac death accounting for more than 350,000 deaths in
the U.S. each year. Ventricular tachycardia is typically treated with implantable cardioverter defibrillators, or ICDs, or a combination of
ablation along with an ICD. The American College of Cardiology/American Heart Association Task Force on Practice Guidelines/European
Society of Cardiology Committee for Practice Guidelines, or ACC/AHA/ESC, 2009 guidelines recommend ablation in patients who either
have sustained predominantly monomorphic ventricular tachycardia that is drug resistant, are drug intolerant or do not wish for long-term drug
therapy. According to a recent study, catheter ablation has been found to reduce ventricular tachycardia/ventricular fibrillation recurrences and
thereby ICD interventions, including ICD shocks, by approximately 75% in patients that have undergone multiple ICD shocks (Kuck, “Should
Catheter Ablation be the Preferred Therapy for Reducing ICD Shocks? Ventricular Tachycardia in Patients With an Implantable Defibrillator
Warrants Catheter Ablation,” Circulation: Arrhythmia and Electrophysiology (2009; 2: 713-720)). More importantly, according to Kuck,
catheter ablation is the only treatment that can terminate and eliminate incessant ventricular tachycardia and acutely abolish electrical storm in
ICD patients. Typically, patients who receive ICDs are at high risk for recurrent arrhythmia; hence, most patients receive one or more ICD
therapies for spontaneous arrhythmias after implantation. Despite the technological evolution of ICD systems, more than 20% of shocks are
due to supraventricular arrhythmia and hence are inappropriate. Although the ICD aborts ventricular tachycardia/ventricular fibrillation, many
patients continue to have symptoms. These shocks are physically and emotionally painful and lead to poor quality of life and adverse
psychological outcomes in patients and their families.
7
Table of Contents
According to Dr. Srijoy Mahapatra, the status of ventricular tachycardia ablation is growing at a 14-17% growth rate due to the fact
that ablation of ventricular tachycardia may help patients feel better and live longer, despite the risks, including the occurrence of stroke, and
the modest success rates. The success of ventricular tachycardia ablation varies, depending on the patient’s specific heart condition that
caused ventricular tachycardia. The procedure is most effective in patients with otherwise normal hearts, in whom the success rate exceeds
90%. In patients with structural heart disease resulting from scar or cardiomyopathy, success rates range between 50% and 75% at six to 12
months. In cases in which a patient experiences a recurrence, two of three patients will still have less ventricular tachycardia than before the
initial ablation (Circulation. 2010; 122: e389-e391). Therefore, we believe that ablation will continue to become a preferred treatment for
ventricular tachycardia, especially in light of the challenges presented by ICD therapies; this increase in demand for ablation procedures will
likely also increase the demand for technological advances in medical devices essential to ablation procedures, including electrophysiology
recorders, in order to better support and ablation procedures.
Electrophysiology Lab Environment and Electrophysiology Recording Systems
The electrophysiology lab environment and recording systems create significant amounts of noise and artifacts during
electrophysiology procedures. Current surface and intracardiac recording systems typically consist of large workstations interconnected by a
complex set of cables that contribute to significant amounts of noise during signal acquisition.
Additional noise and artifacts generated from the electrophysiology lab equipment further hamper recordings of small
electrophysiological potentials. Preserving spaciotemporal (space and time) characteristics of the signal in a very challenging
electrophysiology recording environment is a difficult task. To remove noise and artifacts, recorders that are currently on the market offer a
family of low pass, high pass and notch filters, but these filters alter signal information context.
The shape and amplitude of electrocardiograms, unipolar and bipolar electrograms, and, consequently, reconstructed endocardial and
epicardial maps, are influenced not only by electrophysiological and structural characteristics of the myocardial tissue involved, but with
characteristics of the recording system. Amplitude and morphology of electrocardiogram and intracardiac signals are significantly affected by
filters used to remove noise. Because of the number of amplitude and interval measurements made during an electrophysiology study, it is
imperative that the recording system faithfully acquires surface electrocardiogram and intracardiac electrograms. We believe that the
recording systems that are currently available on the market are ineffective in preserving the optimal amount of original information contained
in the cardiac signals.
In addition, the electrophysiology lab consists of sophisticated equipment that requires an electrophysiologist to mentally integrate
information from a number of sources during procedures. There are numerous monitors in an electrophysiology lab that provide and display
this variety of information. An electrophysiologist needs to evaluate the acquired cardiac signals and the patient’s responses to any induced
arrhythmias during the procedure. However, it is difficult for an electrophysiologist to synthesize the disparate information produced by the
numerous monitors in the lab and calculate the real-time, three-dimensional orientation of the anatomy and the location of the recording and
ablation catheters. As the number of electrophysiology procedures increase, a variety of diagnostic and therapeutic ablation catheters are
becoming more widely available and new highly specialized catheters are being developed. In addition, remote robotic and magnetic
navigation systems are being developed to address limitations of dexterity in controlling the catheter tip, especially during complex
arrhythmia ablation procedures. We believe that, considering the improvements being made with respect to other equipment used in the
electrophysiology lab and the continual increase of ablation procedures, the electrophysiology recorders currently available on the market are
not sufficiently advanced with respect to the quality of their recordings to deliver adequate results. We believe that the PURE EP System will
be able to deliver superior quality of recordings that will allow it to successfully integrate with the other advanced equipment found in the
electrophysiology lab.
The requirement for optimal signal integrity is further amplified during ablation treatments of atrial fibrillation and ventricular
tachycardia. Presently, one of the main objectives of the atrial fibrillation ablation procedure is to precisely identify, ablate and eliminate
pulmonary vein potentials and one of the main objectives of the ventricular tachycardia procedure is to map the arrhythmia substrate and
precisely identify, ablate and eliminate small abnormal potentials. The information provided by recorders is essential for an
electrophysiologist
termination of both pulmonary vein potentials and ventricular
tachycardia. Therefore, it is important that the recording system’s noise removal technique does not alter appearance and fidelity of these
potentials. As a result, it is necessary that any new signal processing preserves signal fidelity as much as possible during electrophysiology
recordings; otherwise, the signals that are needed to guide the ablation procedures will be difficult to distinguish due to noise interference.
to determine ablation strategy during
8
Table of Contents
Our Products
We intend to bring to the electrophysiology market the PURE EP System, an electrocardiogram/intracardiac recorder that will be
coupled with an array of software tools intended for electrophysiology studies and procedures ranging from simple diagnostic tests to ablation
for the most complex cases of arrhythmias. We believe that this system will provide unique recording capabilities because we are developing
it to allow precise, uninterrupted, real-time evaluations of electrocardiograms and electrograms, and allow electrophysiologists to obtain data
that cannot be acquired from present day recorders.
The PURE EP System uses a combination of analog and digital signal processing to acquire and display cardiac data. Because our
technology consists of proprietary hardware, software and algorithms, the original cardiac data is not distorted. In addition, we are developing
a library of software tools that are designed to be configured to fit the needs of electrophysiologists in different settings and/or for different
arrhythmia treatments. With the software, the PURE EP System can be positioned to provide information that can be used by
electrophysiologists to help guide the ablation catheter; shorten procedure times; and can reduce the complexity of maneuvers necessary for
identifying ablation targets for various arrhythmias, including atrial fibrillation and ventricular tachycardia. The PURE EP system is intended
to be used in addition to existing electrophysiology recorders. We believe that the less distorted cardiac data provided by the PURE EP
system will increase the workload ability and enhance the capabilities of the typical electrophysiology laboratory.
Initial Analysis
According to S. J. Asirvatham, MD, et. al. (“Signals and Signal Processing for the Electrophysiologist,” Circ Arrhythm
Electrophysiol. 2011;4:965-973), recording environments in a typical electrophysiology laboratory presents challenging situations. S. J.
Asirvatham, MD, et. al., state, “Successful mapping and ablation in the electrophysiology laboratory is critically dependent on acquiring
multiple, low-amplitude, intracardiac signals in the presence of numerous sources of electric noise and interference and displaying these
signals in an uncomplicated and clinically relevant fashion, with minimal artifacts. This represents a significant engineering challenge and, in
real-life electrophysiology laboratory, is not always successful.”
To determine and validate the state of present electrophysiology recording technology in the field, we completed a detailed analysis
of the effect of filters used by existing EP recorders to reduce noise on spaciotemporal characteristics of electrocardiograms and intracardiac
electrograms. We used a custom built electrocardiogram/intracardiac simulator with a database of various electrocardiogram signals combined
with electrophysiology signals, along with waveforms from publicly available databases. The ability to faithfully reproduce database
waveforms generated by an electrocardiogram/intracardiac simulator was tested using the PURE EP System and conventional
electrophysiology recorders, the GE CardioLab and St. Jude EP-WorkMate.
We evaluated the signal quality (amplitude, morphology and duration) of the different recorders, along with the ability of the
recorders to reduce noise level and remove baseline wander, which are the cardiac signals that have shifted from the isoelectric line (the base
line of the signal tracing). The electrocardiogram and intracardiac signals subjected to the PURE EP System’s signal processing showed less
baseline wander, noise and artifacts compared to the conventional electrophysiology recorders (as evidenced in the picture below from our
initial validation). Further, spaciotemporal characteristics of signals were greatly distorted by the conventional electrophysiology system,
particularly when a notch filter was used, as compared to the recording of the same spaciotemporal characteristics by the PURE EP System. A
notch filter is used to remove a specific frequency from the signal, especially either 60Hz in the U.S. and 50Hz in Europe, and can be
implemented in hardware or software.
To date, we have not conducted any studies of the data produced by our technology that have been subjected to any third-party
review, as would be required for the publication of a formal study. If we are able to demonstrate a similar level of success in removing
baseline wander and reducing noise level for our planned pre-clinical, animal and clinical studies and trials, we believe that the PURE EP
System’s signal processing will become a vital part of electrophysiology labs and will greatly assist in the ablation treatment for complex
arrhythmias, including atrial fibrillation and ventricular tachycardia.
Proof of Concept Testing
We developed the PURE EP System’s proof of concept unit, which is the version of the product prior to prototype. The proof of
concept unit was designed using separate analog and digital boards to allow for easier debugging and to demonstrate single channel
electrocardiogram and intracardiac acquisition capabilities.
9
Table of Contents
The proof of concept unit was built to (i) verify that the PURE EP System performs in line with our intended design of the product,
(ii) validate a portion of the hardware design that we intend to use in the prototype, and (iii) verify the software used by the PURE EP
System. The main objectives of the proof of concept unit were to demonstrate that the system’s hardware and software have the ability to
faithfully records small cardiac signals in an electrophysiology laboratory environment and to obtain initial performance results.
In the second and third quarters of 2013, we performed and finalized testing of our proof of concept unit by initially using an
electrocardiogram/intracardiac simulator at our lab, and subsequently by obtaining animal recordings from the animal lab at the University of
California at Los Angeles. As part of the testing, we simultaneously recorded electrocardiogram and intracardiac signals on our proof of
concept unit and GE’s CardioLab recording system. An identical signal was applied to the input of both systems and the monitor of our proof
of concept unit was positioned next to the monitor of GE’s CardioLab recording system to allow for visual comparison. We believe that our
proof of concept unit performed well as compared to GE’s CardioLab recording system, in that the electrocardiogram and intracardiac signals
displayed on our proof of concept unit showed less baseline wander, noise and artifacts compared to signals displayed on GE’s CardioLab
recording system. However, because this was a proof of concept test, without any clearly established protocols, we cannot present this data
for publication and we do not have any independent verification or peer review of these findings.
Subsequently, in the third quarter of 2013, we analyzed the results of our proof of concept unit to determine the final design of the
PURE EP System prototype. Because the proof of concept unit was designed to verify the capabilities of the main components of the PURE
EP System, we established a list of tasks necessary to complete the prototype (which we intend to use for end-user preference studies, animal
studies and in-human recordings).
The PURE EP System prototype is presently assembled and operational.
Proof of Concept Testing at UCLA’s EP Lab
The current PURE EP System prototype
10
Table of Contents
Growth Strategy
Technology and Development Plan
Our technology team consists of six engineers with expertise in digital signal processing, low power analog and digital circuit design,
software development, embedded system development, electromechanical design, testing and system integration, and the regulatory
requirements for medical devices. We have also entered into collaboration agreements with advisors and medical institutions in the fields of
cardiology and electrophysiology, including the Texas Cardiac Arrhythmia Institute (see “–Strategic Alliances”). We currently intend to
outsource manufacturing, assembling, and testing.
We are currently conducting testing of the assembled components of the PURE EP System prototype in order to validate the design
of the prototype. We believe such testing will be completed by first quarter of 2015 To date, we have not conducted any studies of the data
produced by our technology that have been subjected to any third-party review, as would be required for the publication of a formal study.
We intend to conduct formal animal studies and initial human clinical trials using the PURE EP System prototype, using formal
protocols and study designs. These formal animal studies and human clinical trials are intended to demonstrate the clinical relevance of the
PURE EP System and its advantages as compared to electrophysiology recorders currently on the market, which we believe will demonstrate
the value of the PURE EP System to physicians and clinicians. Our objective is to complete our next animal study in April 2015. We have
also begun planning and implementing steps for obtaining 510(k) approval from the U.S. Food and Drug Administration for the PURE EP
System. We believe that by the first half of 2016, we will have obtained 510(k) marketing clearance from the FDA and will be able to
commence marketing and commercialization of the PURE EP System. Our ability to achieve the aforementioned milestones will be
principally determined by our ability to obtain necessary financing and regulatory approvals, among other factors. In the fourth quarter of
2013, the development of our PURE EP System product was delayed due to decisions made by our former chief executive officer and
president, who terminated most of our engineering team and sought to develop a different technology, as opposed to the PURE EP System,
with a different engineering team. After the resignation of our former chief executive officer and president from his positions with us in
November 2013, we decided to continue the development of our PURE EP System product, as opposed to the different technology pursued by
our former chief executive officer and president, and therefore re-hired our original engineering team. The change in development strategy
with respect to our products and subsequent return to our development strategy resulted in significant delays in the timing of the achievement
of our anticipated milestones for our PURE EP System product.
Strategic Alliances
We formed a scientific advisory board in order to foster collaborations with physicians in the global electrophysiology market to help
test and commercialize our PURE EP System. We also plan to develop studies, beginning with studies with physicians and researchers
affiliated with the UCLA Cardiac Arrhythmia Center, the Texas Cardiac Arrhythmia Institute, and Mayo Clinic that are intended to
demonstrate clinical advantages, build scientific evidence and accelerate technology awareness and market adoption of the PURE EP
System. Thus far, we have we have developed both formal, compensated relationships with physicians and researchers, as well as more
informal relationships with physicians and researchers that have provided us with data to be read by the PURE EP System, as well as advice
and consulting services at no cost to us.
Beginning in the second quarter of 2011, we have collaborated, and continue to collaborate, with Dr. Andrea Natale of the Texas
Cardiac Arrhythmia Institute and Dr. Luigi Di Biase of the Montefiore Einstein Center for Heart and Vascular Care in New York, who had
previously worked with other companies such as St. Jude Medical, Boston Scientific, Biosense Webster, Inc., and Medtronic, Inc. Drs. Natale
and Di Biase have provided their advisory and consulting services to us at no cost. We have also developed informal advisory relationships
with physicians and researchers at other electrophysiology centers including Beaumont Medical Center, Detroit, MI, and the Heart Rhythm
Institute at the University of Oklahoma Health Sciences Center. These relationships consist of the physicians and researchers reviewing our
data and technology and providing us advice. To date, we have not entered into any agreements with these physicians and researchers, nor
have we compensated them in any way. As explained below, we have entered into formal agreements with physicians affiliated with
University Hospitals Case Medical Center in Cleveland, University of California at Los Angeles Cardiac Arrhythmia Center and Mount Sinai
Hospital Cardiovascular Institute in New York. We plan to perform our initial animal study at Mayo Clinic in April of 2015.
11
Table of Contents
On March 30, 2012, we entered into a consulting agreement with Dr. Mauricio Arruda, who is affiliated with University Hospitals
Case Medical Center in Cleveland, pursuant to which Dr. Arruda would provide us with advisory services related to the development and
implementation of software and/or hardware designed for the purpose of mapping cardiac signals during electrophysiologic studies in
exchange for a fee of $3,000 per day or occurrence or $300 per hour, depending upon the nature of the services we requested, in addition to
reimbursement for reasonable expenses. Our agreement with Dr. Arruda renews annually unless terminated by either party at least 30 days
prior to the renewal.
On February 12, 2013, we entered into a consulting agreement with Dr. Rony Shimony, who is affiliated with Mount Sinai Hospital
Cardiovascular Institute in New York, pursuant to which Dr. Shimony would provide us with advisory services related to our PURE EP
System in exchange for a grant of an option to purchase 283,750 shares of our common stock with an exercise price of $2.09 per share with the
following vesting schedule: (i) 48,611 shares vest on the first, second and third monthly anniversaries of the February 12, 2013, and (ii) one
twenty fourth (1/24) of the remaining 137,917 shares vest on each monthly anniversary of the February 12, 2013, provided on each such
vesting date Dr. Shimony is still providing services to us. We will also reimburse Dr. Shimony for reasonable expenses. Our agreement with
Dr. Shimony has a term of two years unless otherwise earlier terminated by either party.
On April 1, 2013, we entered into a consulting agreement with Dr. Vivek Reddy, who is affiliated with Mount Sinai Hospital
Cardiovascular Institute in New York, pursuant to which Dr. Reddy would provide us with advisory services related to our PURE EP System
in exchange for a grant of an option to purchase 30,000 shares of our common stock with an exercise price of $2.09 per share and vesting in
equal amounts every month for nine months, in addition to reimbursement for reasonable expenses. Our agreement with Dr. Reddy has a term
of one year unless otherwise earlier terminated by either party.
In June 2013, we commenced our first proof of concept animal study with the assistance of our director Dr. Kalyanam Shivkumar,
who is affiliated with the Cardiac Arrhythmia Center at the University of California at Los Angeles. Dr. Shivkumar is not receiving any
additional compensation for his assistance with our animal study.
On October 7, 2014, we entered into a consulting agreement with Dr. Samuel J. Asirvatham, who is affiliated with Mayo Clinic in
Rochester, Minnesota, pursuant to which Dr. Asirvatham would serve in a consulting capacity as a member of the Company’s Scientific
Advisory Board and perform services involving the technology development of the PURE EP System in exchange for $350 per hour. Our
agreement with Dr. Asirvatham has a term of one year unless otherwise earlier terminated by either party.
Competition
The electrophysiology market is characterized by intense competition and rapid technological advances. There are currently four
large companies that share the majority of the electrophysiological recording market share. They produce the following electrophysiology
recording systems, each with a unit price of approximately $250,000 per unit:
●
●
●
●
GE’s CardioLab Recording System was developed in the early 1990s by Prucka Engineering and was
acquired by GE in 1999.
Bard’s LabSystem PRO EP Recording System was originally designed in the late 1980s. CR Bard’s
electrophysiology business was acquired by Boston Scientific in 2013.
Siemens developed the Axiom Sensis XP in 2002.
St. Jude Medical’s EP-WorkMate Recording System was acquired from EP MedSystems in 2008, which had
received approval for the product from the U.S. Food and Drug Administration in 2003.
Based upon our analysis of data taken from patent applications filed with the U.S. Patent and Trademark Office and 510(k) approval
applications filed with the U.S. Food and Drug Administration, we believe that the above recording systems are built on relatively old
technologies and all use the identical approach in applying digital filters to remove noise and artifacts. We are of the opinion that such an
approach sacrifices cardiac signal fidelity and, in the case of ablation, the filters have a direct impact on the ablation strategy of an
electrophysiologist. The imprecise method to remove noise and artifacts used by the old recorders could be a contributing factor to the
multiple (or repeated) ablation procedures that are frequently required in order to completely cure patients from atrial fibrillation and
ventricular tachycardia. We are not currently aware of any other companies that are developing new recording technology for
electrophysiology recorders.
12
Table of Contents
Suppliers
The PURE EP System contains proprietary hardware and software modules that are assembled into the system. Hardware boards
contain components that are available from different distributors. The parts used to manufacture analog and digital boards are readily available
from a number of distributors or manufacturers. We obtained components from various suppliers and have assembled our first prototype in-
house. We envision outsourcing manufacturing of the complete PURE EP System to a local medical device manufacturer in California.
Research and Development Expenses
Research and development expenses for the fiscal years ended December 31, 2014 and 2013 were $547,996 and $992,207,
respectively.
Sales, Marketing and Customer Service
We plan to implement a market development program prior to launch of our PURE EP System. As the product progresses through
development and testing, we intend to gather the data produced by the PURE EP System’s processing and presenting electrocardiogram and
intracardiac signals and use such data for posters, presentations at cardiology conferences, and, if appropriate, submissions to scientific
journals. We believe that as we gather additional data from our existing proof of concept tests and our planned animal and clinical studies and
user preference studies, we will be able to better determine the focus of our marketing efforts.
We also plan to leverage our relationships with cardiac research and treatment centers to gain early product evaluation and validation.
We believe that through these efforts, we may be able to gain preliminary acceptance of our PURE EP product by experienced professionals
and academics in the electrophysiology field.
We also intend to simultaneously develop a branding strategy to introduce and support the PURE EP System. The strategy may
include our presence at major relevant cardiology meetings on a national and regional basis to engage and educate physicians concerning the
PURE EP System and any of our other products, as well as engaging in a variety of other direct marketing methods. We also intend to develop
a small direct sales force together with a distribution network that has existing relationships with hospitals and electrophysiologists. We
believe that we may be able to begin commercial sales of the PURE EP System in 2016.
Intellectual Property
Patents
Our success depends in large part on our ability to establish and maintain the proprietary nature of our technology. Our co-founder
and former chief technology officer, Budimir S. Drakulic, Ph.D., conceived of the proprietary elements of the PURE EP System in 2009 and
2010. We filed a patent application with the U.S. Patent and Trademark Office in December 2013 directed at systems and methods for the
evaluation of electrophysiology systems. In March 2014, the inventors listed on the patent application filed in December 2013 assigned all of
their rights to the patent application to us. In December 2014, we filed this patent application under the Patent Cooperation Treaty (PCT) with
the US Receiving Office. In addition, we filed a patent application with the U.S. Patent and Trademark Office in October 2013 directed at
the use of electrocardiography sensing for control of radiofrequency renal denervation.
13
Table of Contents
We intend to file one or more additional patents in the U.S. in the future. Our patent application filed in October 2013 combines a
specific treatment, radiofrequency ablation, with our core cardiac signal system. The combined system is designed to connect with
radiofrequency ablation catheters and simultaneously monitor cardiac signals during a radiofrequency ablation procedure, such as a
radiofrequency ablation procedure to treat cardiac arrhythmias and/or to denervate the area in close proximity to a blood vessel (e.g. renal
denervation). Our patent application filed in December 2013, on the other hand, represents a significant portion of our core proprietary
intellectual property. Our patent application filed in December 2013 describes a system that can show comparative output of any two cardiac
signal systems—such as the PURE EP System as compared to a competitor system, thus showing the value of the PURE EP System.
This patent application describes signal processing evaluators that assess how well a cardiac signal system reading a cardiac signal
(such as the PURE EP System or another system) filters out noise, such as non-cardiac signals or other body-generated artifacts. Such noise is
filtered by such systems with varying success, thus, an evaluator such as described in the patent application may be used to provide
comparison data for a particular system versus another given the same or similar input. The patent application also describes a simulator that
can send a simulated signal to a cardiac signal system (the PURE EP System or another system) in order to challenge such cardiac signal
system to filter out typical noise. These are adjunct technologies can be used to show the value of the PURE EP System as compared to other
systems existing in the market. The additional patent applications that we intend to file in the U.S. in the future are expected to represent
portions of the hardware and software technology associated with our PURE EP System, which technology includes a cardiac signal system
that reads cardiac signals and filters such cardiac signals from noise such as non-cardiac signals or other body-generated artifacts. Upon filing
of such patent applications, we believe that the novel aspects of our PURE EP System should be subject to pending patent application;
however, we cannot be assured that all of the patents related to our patent applications, if any, will be granted.
We believe that our existing rights to the technology relating to the proprietary elements of the PURE EP System and the invention
rights not contained in our patent applications are based upon the fiduciary duties owed to us by Dr. Drakulic when he served as an officer and
director of our company, which obligated him to grant us rights to technology essential to our products. In addition, under the work-for-hire
doctrine, we have rights to all works of authorship (including for software products developed related to the PURE EP System) by our
employees acting within the scope of their employment.
Trademarks
Our trademark application to register “PURE EP” in the U.S. is pending.
Government Regulation
Our solutions include software and hardware, which will be used for patient diagnosis and, accordingly, are subject to regulation by
the U.S. Food and Drug Administration and other regulatory agencies. U.S. Food and Drug Administration regulations govern, among other
things, the following activities that we perform and will continue to perform in connection with:
●
●
●
●
●
●
●
●
Product design and development;
Product testing;
Product manufacturing;
Product labeling and packaging;
Product handling, storage, and installation;
Pre-market clearance or approval;
Advertising and promotion; and
Product sales, distribution, and servicing.
U.S. Food and Drug Administration’s Pre-market Clearance and Approval Requirements
The U.S. Food and Drug Administration classifies all medical devices into one of three classes. Devices deemed to pose lower risks
are placed in either Class I or II, which requires the manufacturer to submit to the U.S. Food and Drug Administration a pre-market
notification, known as a PMN, and a 510(k) approval, requesting clearance of the device for commercial distribution in the U.S. Class III
devices are devices which must be approved by the pre-market approval process. These tend to be devices that are permanently implanted
into a human body or that may be necessary to sustain life. For example, an artificial heart meets both these criteria. Based on analysis of
predicate devices, we believe that our products will be classified as Class II.
14
Table of Contents
Pursuant to U.S. Food and Drug Administration guidelines, Class II devices include a programmable diagnostic computer, which is a
device that can be programmed to compute various physiologic or blood flow parameters based on the output from one or more electrodes,
transducers, or measuring devices; this device includes any associated commercially supplied programs. Because the PURE EP System is a
surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram
and electrograms, we believe it will be classified as a Class II device. We must, therefore, first receive a 510(k) clearance from the U.S. Food
and Drug Administration for our PURE EP system before we can commercially distribute it in the U.S. In the event that our PURE EP system
is classified as a Class III device, which we believe is unlikely to occur, the U.S. Food and Drug Administration regulatory approval process
and the subsequent commercialization of our product will require significantly greater time and resources than if it is classified as a Class II
device, which would require us to reassess our strategic business plan of operations.
510(k) Clearance Process
For our PURE EP System, we must submit a pre-market notification to the U.S. Food and Drug Administration demonstrating that
the proposed device is substantially equivalent to a previously cleared 510(k) device, a device that was in commercial distribution before May
28, 1976 for which the U.S. Food and Drug Administration has not yet called for the submission of pre-market approval applications, or is a
device that has been reclassified from Class III to either Class II or I.
The U.S. Food and Drug Administration’s 510(k) clearance process usually takes three to six months from the date the application is
submitted and filed with the U.S. Food and Drug Administration, but it can take significantly longer. A device that reaches market through the
510(k) process is not considered to be “approved” by the U.S. Food and Drug Administration. They are generally referred to as “cleared” or
“510(k) cleared” devices. Nevertheless, it can be marketed and sold in the U.S.
After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would
constitute a major change in its intended use, will require a new 510(k) clearance or could require a pre-market approval, which requires more
data and is generally a significantly longer process than the 510(k) clearance process. The U.S. Food and Drug Administration requires each
manufacturer to make this determination initially, but the U.S. Food and Drug Administration can review any such decision and can disagree
with a manufacturer’s determination. If the U.S. Food and Drug Administration disagrees with a manufacturer’s determination, the U.S. Food
and Drug Administration can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or a pre-
market approval is obtained.
Pervasive and continuing U.S. Food and Drug Administration regulation
After a medical device is placed on the market, numerous U.S. Food and Drug Administration regulatory requirements apply,
including, but not limited to the following:
●
●
●
●
●
Quality System regulation, which requires manufacturers to follow design, testing, control, documentation
and other quality assurance procedures during the manufacturing process;
Establishment Registration, which requires establishments involved in the production and distribution of
medical devices intended for commercial distribution in the U.S. to register with the U.S. Food and Drug
Administration;
Medical Device Listing, which requires manufacturers to list the devices they have in commercial
distribution with the U.S. Food and Drug Administration;
Labeling regulations, which prohibit “misbranded” devices from entering the market, as well as prohibit the
promotion of products for unapproved or “off-label” uses and impose other restrictions on labeling; and
Medical Device Reporting regulations, which require that manufacturers report to the U.S. Food and Drug
Administration if their device may have caused or contributed to a death or serious injury or malfunctioned
in a way that would likely cause or contribute to a death or serious injury if it were to recur.
Failure to comply with applicable regulatory requirements can result in enforcement action by the U.S. Food and Drug
Administration, which may include one or more of the following sanctions:
●
●
●
●
●
●
●
Fines, injunctions, and civil penalties;
Mandatory recall or seizure of our products;
Administrative detention or banning of our products;
Operating restrictions, partial suspension or total shutdown of production;
Refusing our request for 510(k) clearance or pre-market approval of new product versions;
Revocation of 510(k) clearance or pre-market approvals previously granted; and
Criminal penalties.
15
Table of Contents
International Regulation
International sales of medical devices are subject to foreign government regulations, which vary substantially from country to
country. The time required to obtain approval by a foreign country may be longer or shorter than that required for U.S. Food and Drug
Administration approval, and the requirements may differ significantly.
The European Union has adopted legislation, in the form of directives to be implemented in each member state, concerning the
regulation of medical devices within the European Union. The directives include, among others, the Medical Device Directive that establishes
standards for regulating the design, manufacture, clinical trials, labeling, and vigilance reporting for medical devices. Our PURE EP system
may be affected by this legislation. Under the European Union Medical Device Directive, medical devices are classified into four classes, I,
IIa, IIb, and III, with class I being the lowest risk and class III being the highest risk. Under the Medical Device Directive, a competent
authority is nominated by the government of each member state to monitor and ensure compliance with the Medical Device Directive. The
competent authority of each member state then designates a notified body to oversee the conformity assessment procedures set forth in the
Medical Device Directive, whereby manufacturers demonstrate that their devices comply with the requirements of the Medical Device
Directive and are entitled to bear the CE mark. CE is an abbreviation for Conformité Européenne (or European Conformity) and the CE mark,
when placed on a product, indicates compliance with the requirements of the applicable directive. Medical devices properly bearing the CE
mark may be commercially distributed throughout the European Union. Failure to obtain the CE mark will preclude us from selling the PURE
EP System and related products in the European Union.
Employees
As of February 20, 2015, we had 8 full-time employees. Additionally, we use consultants as needed to perform various specialized
services. None of our employees are represented under a collective bargaining agreement.
ITEM 1A – RISK FACTORS
RISK FACTORS
There are numerous and varied risks, known and unknown, that may prevent us from achieving our goals. You should carefully
consider the risks described below and the other information included in this Annual Report on Form 10-K, including the consolidated
financial statements and related notes. If any of the following risks, or any other risks not described below, actually occur, it is likely that
our business, financial condition, and/or operating results could be materially adversely affected. The risks and uncertainties described
below include forward-looking statements and our actual results may differ from those discussed in these forward-looking statements.
Risks Related to Our Business and Industry
Because our condition as a going concern is in doubt, we will be forced to cease our business operations unless we can raise sufficient
funds to satisfy our working capital needs.
As shown in the accompanying financial statements during years ended December 31, 2014 and 2013, we incurred net losses
attributable to common stockholders of $8,773,399 and $10,101,846, respectively and used $1,997,072 in cash for operating activities for the
year ended December 31, 2014. As of February 12, 2015, we had cash on hand of approximately $1,405,800. These factors, among others,
raise substantial doubt that we will be able to continue as a going concern for a reasonable period of time.
Our existence is dependent upon management’s ability to develop profitable operations. Our management is devoting substantially
all of its efforts to developing its products and services and there can be no assurance that our efforts will be successful. There is no assurance
that can be given that management’s actions will result in our profitable operations or the resolution of our liquidity problems.
16
Table of Contents
Because we are an early development stage company with no products near commercialization, we expect to incur significant additional
operating losses.
We are an early development stage company and we expect to incur substantial additional operating expenses over the next several
years as our research, development, pre-clinical testing, regulatory approval and clinical trial activities increase. The amount of our future
losses and when, if ever, we will achieve profitability are uncertain. We have no products that have generated any commercial revenue and
do not expect to generate revenues from the commercial sale of our products in the near future, if ever. Our ability to generate revenue and
achieve profitability will depend on, among other things, the following:
●
●
●
●
successful completion of the preclinical and clinical development of our products;
obtaining necessary regulatory approvals from the U.S. Food and Drug Administration or other regulatory
authorities;
establishing manufacturing, sales, and marketing arrangements, either alone or with third parties; and
raising sufficient funds to finance our activities.
We might not succeed at all, or at any, of these undertakings. If we are unsuccessful at some or all of these undertakings, our
business, prospects, and results of operations may be materially adversely affected.
Our product candidates are at an early stage of development and may not be successfully developed or commercialized.
Our main product candidate, the PURE EP System, is in the early stage of development and will require substantial further capital
expenditures, development, testing, and regulatory clearances prior to commercialization, especially given that we have not yet completed pre-
clinical testing on this product. The development and regulatory approval process takes several years and it is not likely that the PURE EP
System, even if successfully developed and approved by the U.S. Food and Drug Administration, may not be commercially available for a
number of years. In addition, due to budgetary constraints, we recently have not been able to devote the level of resources that we desired to
our research and development efforts. The continued development of our product candidates is dependent upon our ability to obtain sufficient
financing. However, even if we are able to obtain the requisite financing to fund our development program, we cannot assure you that our
product candidates will be successfully developed or commercialized. Our failure to develop, manufacture or receive regulatory approval for
or successfully commercialize any of our product candidates could result in the failure of our business and a loss of all of your investment in
our company.
We expect to derive our revenue from sales of our PURE EP System and other products we may develop. If we fail to generate revenue
from these sources, our results of operations and the value of our business will be materially and adversely affected.
We expect our revenue to be generated from sales of our PURE EP System and other products we may develop. Future sales of these
products, if any, will be subject to, among other things, the receipt of regulatory approvals and commercial and market uncertainties that may
be outside our control. If we fail to generate our intended revenues from these products, our results of operations and the value of our business
and securities would be materially and adversely affected.
We may need to finance our future cash needs through public or private equity offerings, debt financings or corporate collaboration and
licensing arrangements. Any additional funds that we obtain may not be on terms favorable to us or our stockholders and may require us
to relinquish valuable rights.
Until and unless we receive approval from the U.S. Food and Drug Administration and other regulatory authorities for our products,
we will not generate revenues from our products. Therefore, for the foreseeable future, we will have to fund all of our operations and capital
expenditures from cash on hand, public or private equity offerings, debt financings, bank credit facilities or corporate collaboration and
licensing arrangements. We believe that our existing cash on hand will be sufficient to enable us to fund our projected operating requirements
for approximately the next five months. However, we may need to raise additional funds more quickly if one or more of our assumptions
prove to be incorrect or if we choose to expand our product development efforts more rapidly than we presently anticipate. We also may
decide to raise additional funds before we require them if we are presented with favorable terms for raising capital.
17
Table of Contents
If we seek to sell additional equity or debt securities, obtain a bank credit facility or enter into a corporate collaboration or licensing
arrangement, we may not obtain favorable terms for us and/or our stockholders or be able to raise any capital at all, all of which could result in
a material adverse effect on our business and results of operations. The sale of additional equity or debt securities, if convertible, could result
in dilution to our stockholders. The incurrence of indebtedness would result in increased fixed obligations and could also result in covenants
that would restrict our operations. Raising additional funds through collaboration or licensing arrangements with third parties may require us
to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or to grant licenses on
terms that may not be favorable to us or our stockholders. In addition, we could be forced to discontinue product development, reduce or
forego sales and marketing efforts and forego attractive business opportunities, all of which could have an adverse impact on our business and
results of operations.
We may be unable to develop our existing or future technology.
Our product, the PURE EP System, may not deliver the levels of accuracy and reliability needed to make it a successful product in
the market place. Additionally, the development of such accuracy and reliability may be indefinitely delayed or may never be achieved. In
the fourth quarter of 2013, the development of our PURE EP System product was delayed due to decisions made by our former chief
executive officer and president, who terminated most of our engineering team and sought to develop a different technology, as opposed to the
PURE EP System, with a different engineering team. After the resignation of our former chief executive officer and president from his
positions with us in November 2013, we decided to continue the development of our PURE EP System product, as opposed to the different
technology pursued by our former chief executive officer and president, and therefore re-hired our original engineering team. The change in
development strategy with respect to our products resulted in delays in the timing of the achievement of our anticipated milestones for our
PURE EP System product. While we do not believe delays will be caused by similar changes in the future, we may experience additional
delays in the development of our technology for other reasons, including failure to obtain necessary funding and failure to obtain regulatory
approvals. Failure to develop this or other technology could have an adverse material effect on our business, financial condition, results of
operations and future prospects.
The results of clinical studies may not support the usefulness of our technology.
Conducting clinical trials is a long, expensive and uncertain process that is subject to delays and failure at any stage. Clinical trials
can take months or years. The commencement or completion of any of our clinical trials may be delayed or halted for numerous reasons,
including:
●
●
●
●
●
●
●
the U.S. Food and Drug Administration may not approve a clinical trial protocol or a clinical trial, or may
place a clinical trial on hold;
subjects may not enroll in clinical trials at the rate we expect or we may not follow up on subjects at the rate
we expect;
subjects may experience events unrelated to our products;
third-party clinical investigators may not perform our clinical trials consistent with our anticipated schedule
or the clinical trial protocol and good clinical practices, or other third-party organizations may not perform
data collection and analysis in a timely or accurate manner;
interim results of any of our clinical trials may be inconclusive or negative;
regulatory inspections of our clinical trials may require us to undertake corrective action or suspend or
terminate the clinical trials if investigators find us not to be in compliance with regulatory requirements; or
governmental regulations or administrative actions may change and impose new requirements, particularly
with respect to reimbursement.
18
Table of Contents
Results of pre-clinical studies do not necessarily predict future clinical trial results and previous clinical trial results may not be
repeated in subsequent medical trials. We may experience delays, cost overruns and project terminations despite achieving promising results
in pre-clinical testing or early clinical testing. In addition, the data obtained from clinical trials may be inadequate to support approval or
clearance of a submission. The U.S. Food and Drug Administration may disagree with our interpretation of the data from our clinical trials, or
may find the clinical trial design, conduct or results inadequate to demonstrate the safety and effectiveness of the product candidate. The U.S.
Food and Drug Administration may also require us to conduct additional pre-clinical studies or clinical trials that could further delay approval
of our products. If we are unsuccessful in receiving U.S. Food and Drug Administration approval of a product, we would not be able to
commercialize the product in the U.S., which could seriously harm our business. Moreover, we face similar risks in other jurisdictions in
which we may sell or propose to sell our products.
The medical device industry is subject to stringent regulation and failure to obtain regulatory approval will prevent commercialization of
our products.
Medical devices are subject to extensive and rigorous regulation by the U.S. Food and Drug Administration pursuant to the Federal
Food, Drug, and Cosmetic Act, by comparable agencies in foreign countries and by other regulatory agencies and governing bodies. Under the
Federal Food, Drug, and Cosmetic Act and associated regulations, manufacturers of medical devices must comply with certain regulations that
cover the composition, labeling, testing, clinical study, manufacturing, packaging and distribution of medical devices. In addition, medical
devices must receive U.S. Food and Drug Administration clearance or approval before they can be commercially marketed in the U.S., and the
U.S. Food and Drug Administration may require testing and surveillance programs to monitor the effects of approved products that have been
commercialized and can prevent or limit further marketing of a product based on the results of these post-market evaluation programs.
The process of obtaining marketing clearance from the U.S. Food and Drug Administration for new products could take a significant
period of time, require the expenditure of substantial resources, involve rigorous pre-clinical and clinical testing, require changes to the
products and result in limitations on the indicated uses of the product. In addition, if we seek regulatory approval in non-U.S. markets, we will
be subject to further regulatory approvals, that will require additional costs and resources. There is no assurance that we will obtain necessary
regulatory approvals in a timely manner, or at all.
Our product, the PURE EP System, will need to receive 510(k) marketing clearance from the U.S. Food and Drug Administration in
order permit us to market this product in the U.S. In addition, if we intend to market our product for additional medical uses or indications, we
will need to submit additional 510(k) applications to the U.S. Food and Drug Administration that are supported by satisfactory clinical trial
results specifically for the additional indication. The results of our initial clinical trials may not provide sufficient evidence to allow the U.S.
Food and Drug Administration to grant us such additional marketing clearances and even additional trials requested by the U.S. Food and
Drug Administration may not result in our obtaining 510(k) marketing clearance for our product. The failure to obtain U.S. Food and Drug
Administration marketing clearance for the PURE EP System, any additional indications for the PURE EP System or any other of our future
products would have a material adverse effect on our business.
Even if regulatory approval is obtained, our products will be subject to extensive post-approval regulation.
Once a product is approved by the relevant regulatory body for our targeted commercialization market, numerous post-approval
requirements apply, including but not limited to requirements relating to manufacturing, labeling, packaging, advertising and record
keeping. Even if regulatory approval of a product is obtained, the approval may be subject to limitations on the uses for which the product
may be marketed, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product.
Any such post-approval requirement could reduce our revenues, increase our expenses and render the approved product candidate not
commercially viable. If we fail to comply with the regulatory requirements of the applicable regulatory authorities, or if previously unknown
problems with any approved commercial products, manufacturers or manufacturing processes are discovered, we could be subject to
administrative or judicially imposed sanctions or other negative consequences, including:
●
●
●
●
restrictions on our products, manufacturers or manufacturing processes;
warning letters and untitled letters;
civil penalties and criminal prosecutions and penalties;
fines;
19
Table of Contents
●
●
●
●
●
●
●
injunctions;
product seizures or detentions;
import or export bans or restrictions;
voluntary or mandatory product recalls and related publicity requirements;
suspension or withdrawal of regulatory approvals;
total or partial suspension of production; and
refusal to approve pending applications for marketing approval of new products or of supplements to
approved applications.
Regulations are constantly changing, and in the future our business may be subject to additional regulations that increase our compliance
costs.
We believe that we understand the current laws and regulations to which our products will be subject in the future. However, federal,
state and foreign laws and regulations relating to the sale of our products are subject to future changes, as are administrative interpretations of
regulatory agencies. If we fail to comply with such federal, state or foreign laws or regulations, we may fail to obtain regulatory approval for
our products and, if we have already obtained regulatory approval, we could be subject to enforcement actions, including injunctions
preventing us from conducting our business, withdrawal of clearances or approvals and civil and criminal penalties. In the event that federal,
state, and foreign laws and regulations change, we may need to incur additional costs to seek government approvals, in addition to the
clearance we intend to seek from the U.S. Food and Drug Administration in order to sell or market our products. If we are slow or unable to
adapt to changes in existing regulatory requirements or the promulgation of new regulatory requirements or policies, we or our licensees may
lose marketing approval for our products which will impact our ability to conduct business in the future.
The market for our technology and revenue generation avenues for our products may be slow to develop, if at all.
The market for our products may be slower to develop or smaller than estimated or it may be more difficult to build the market than
anticipated. The medical community may resist our products or be slower to accept them than we anticipate. Revenues from our products
may be delayed or costs may be higher than anticipated which may result in our need for additional funding. We anticipate that our principal
route to market will be through commercial distribution partners. These arrangements are generally non-exclusive and have no guaranteed
sales volumes or commitments. The partners may be slower to sell our products than anticipated. Any financial, operational or regulatory
risks that affect our partners could also affect the sales of our products. In the current economic environment, hospitals and clinical
purchasing budgets may exercise greater restraint with respect to purchases, which may result in purchasing decisions being delayed or
denied. If any of these situations were to occur this could have a material adverse effect on our business, financial condition, results of
operations and future prospects.
If we seek to market our products in foreign jurisdictions, we may need to obtain regulatory approval in these jurisdictions.
In order to market our products in the European Union and many other foreign jurisdictions, we may need to obtain separate
regulatory approvals and comply with numerous and varying regulatory requirements. Approval procedures vary among countries (except with
respect to the countries that are part of the European Economic Area) and can involve additional clinical testing. The time required to obtain
approval may differ from that required to obtain U.S. Food and Drug Administration approval. Should we decide to market our products
abroad, we may fail to obtain foreign regulatory approvals on a timely basis, if at all. Approval by the U.S. Food and Drug Administration
does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority, including obtaining CE
Mark approval, does not ensure approval by regulatory authorities in other foreign countries or by the U.S. Food and Drug Administration.
We may be unable to file for, and may not receive, necessary regulatory approvals to commercialize our products in any foreign market, which
could adversely affect our business prospects.
20
Table of Contents
If we fail to obtain an adequate level of reimbursement for our system by third-party payors, there may be no commercially viable markets
for our system or the markets may be much smaller than expected.
The availability and levels of reimbursement by governmental and other third-party payors significantly affect the market for our
system. Reimbursement by third-party payors in the U.S. typically is based on the device’s perceived benefit and whether it is deemed
medically reasonable and necessary. Reimbursement levels of third-party payors in the U.S. are also based on established payment formulas
that take into account part or all of the cost associated with these devices and the related procedures performed. We cannot assure you the
level of reimbursement we might obtain in the U.S., if any, for our system.
If we do not obtain adequate levels of reimbursement for our system by third-party payors in the U.S., which we believe is largest
potential market for our system, our financial condition, results of operations and prospects would be harmed.
Reimbursement and health care payment systems in international markets vary significantly by country, and include both
government-sponsored health care and private insurance. To obtain reimbursement or pricing approval in some countries, we may be required
to produce additional clinical data, which may involve one or more additional clinical trials, that compares the cost-effectiveness of our system
to other available therapies. We may not obtain international reimbursement or pricing approvals in a timely manner, if at all. Our failure to
receive international reimbursement or pricing approvals would negatively impact market acceptance of our system in the international
markets in which those approvals are sought.
We believe that future reimbursement may be subject to increased restrictions both in the U.S. and in international markets. Future
legislation, regulation or reimbursement policies of third-party payors may adversely affect the demand for the PURE EP System or any of
our other future products and limit our ability to sell the PURE EP System or any of our other future products on a profitable basis. In
addition, third-party payors continually attempt to contain or reduce the costs of health care by challenging the prices charged for health care
products and services. If reimbursement for our system is unavailable in any market or limited in scope or amount, or if pricing is set at
unsatisfactory levels, market acceptance of our system would be significantly impaired and our future revenues, if any, would be significantly
harmed.
The electrophysiology market is highly competitive.
There are a number of groups and organizations, such as healthcare, medical device and software companies in the electrophysiology
market that may develop a competitive offering to our products, especially given that we have not yet filed for patent protection for any of our
intellectual property. The largest companies in the electrophysiology market are GE, Johnson & Johnson, Boston Scientific, Siemens and St.
Jude Medical. All of these companies have significantly greater resources, experience and name recognition than we possess. There is no
assurance that they will not attempt to develop similar or superior products, that they will not be successful in developing such products or that
any products they may develop will not have a competitive advantage over our products. If we experience delayed regulatory approvals or
disputed clinical claims, we may not have a commercial or clinical advantage over competitors’ products that we believe we currently
possess. Should a superior offering come to market, this could have a material adverse effect on our business, financial condition, results of
operations and future prospects.
We rely on key officers, consultants and scientific and medical advisors, and their knowledge of our business and technical expertise
would be difficult to replace.
We are highly dependent on our officers, consultants and scientific and medical advisors because of their expertise and experience in
medical device development. We do not have “key person” life insurance policies for any of our officers. Our former chief executive officer
and president relieved most of our employees and consultants of their duties in October 2013 and, after the resignation of our former chief
executive officer and president in November 2013, we rehired such employees and consultants. Due to our funding constraints, we made
irregular payments to such employees and consultants until January 2014, at which time we compensated them in full for their accrued but
unpaid service. If we are unable to obtain additional funding, we will be unable to meet our current and future compensation obligations to
such employees and consultants. In light of the foregoing, we are at risk that one or more of our consultants or employees may leave our
company for other opportunities where there is no concern about such employers fulfilling their compensation obligations, or for other
reasons. The loss of the technical knowledge and management and industry expertise of any of our key personnel could result in delays in
product development, loss of customers and sales and diversion of management resources, which could adversely affect our results of
operations.
21
Table of Contents
We may fail to attract and retain qualified personnel.
We expect to rapidly expand our operations and grow our sales, research and development and administrative operations. This
expansion is expected to place a significant strain on our management and will require hiring a significant number of qualified
personnel. Accordingly, recruiting and retaining such personnel in the future will be critical to our success. There is intense competition from
other companies, research and academic institutions, government entities and other organizations for qualified personnel in the areas of our
activities. Many of these companies, institutions and organizations have greater resources than we do, along with more prestige associated
with their names. If we fail to identify, attract, retain and motivate these highly skilled personnel, we may be unable to continue our marketing
and development activities, and this could have a material adverse effect on our business, financial condition, results of operations and future
prospects.
If we do not effectively manage changes in our business, these changes could place a significant strain on our management and
operations.
Our ability to grow successfully requires an effective planning and management process. The expansion and growth of our business
could place a significant strain on our management systems, infrastructure and other resources. To manage our growth successfully, we must
continue to improve and expand our systems and infrastructure in a timely and efficient manner. Our controls, systems, procedures and
resources may not be adequate to support a changing and growing company. If our management fails to respond effectively to changes and
growth in our business, including acquisitions, there could be a material adverse effect on our business, financial condition, results of
operations and future prospects.
Our strategic business plan may not produce the intended growth in revenue and operating income.
Our strategies ultimately include making significant investments in sales and marketing programs to achieve revenue growth and
margin improvement targets. If we do not achieve the expected benefits from these investments or otherwise fail to execute on our strategic
initiatives, we may not achieve the growth improvement we are targeting and our results of operations may be adversely affected. We may
also fail to secure the capital necessary to make these investments, which will hinder our growth.
In addition, as part of our strategy for growth, we may make acquisitions and enter into strategic alliances such as joint ventures and
joint development agreements. However, we may not be able to identify suitable acquisition candidates, complete acquisitions or integrate
acquisitions successfully, and our strategic alliances may not prove to be successful. In this regard, acquisitions involve numerous risks,
including difficulties in the integration of the operations, technologies, services and products of the acquired companies and the diversion of
management’s attention from other business concerns. Although we will endeavor to evaluate the risks inherent in any particular transaction,
there can be no assurance that we will properly ascertain all such risks. In addition, acquisitions could result in the incurrence of substantial
additional indebtedness and other expenses or in potentially dilutive issuances of equity securities. There can be no assurance that difficulties
encountered with acquisitions will not have a material adverse effect on our business, financial condition and results of operations.
We currently have no sales, marketing or distribution operations and will need to expand our expertise in these areas.
We currently have no sales, marketing or distribution operations and, in connection with the expected commercialization of our
system, will need to expand our expertise in these areas. To increase internal sales, distribution and marketing expertise and be able to conduct
these operations, we would have to invest significant amounts of financial and management resources. In developing these functions
ourselves, we could face a number of risks, including:
●
●
●
we may not be able to attract and build an effective marketing or sales force;
the cost of establishing, training and providing regulatory oversight for a marketing or sales force may be
substantial; and
there are significant legal and regulatory risks in medical device marketing and sales that we have never
faced, and any failure to comply with applicable legal and regulatory requirements for sales, marketing and
distribution could result in an enforcement action by the U.S. Food and Drug Administration, European
regulators or other authorities that could jeopardize our ability to market the system or could subject us to
substantial liability.
22
Table of Contents
The liability of our directors and officers is limited.
The applicable provisions of the Delaware General Corporation Law and our Amended and Restated Certificate of Incorporation and
By-laws limit the liability of our directors to us and our stockholders for monetary damages for breaches of their fiduciary duties, with certain
exceptions, and for other specified acts or omissions of such persons. In addition, the applicable provisions of the Delaware General
Corporation Law and of our Amended and Restated Certificate of Incorporation and Bylaws provide for indemnification of such persons under
certain circumstances. In the event we are required to indemnify any of our directors or any other person, our financial strength may be
harmed.
Our product development program depends upon third-party researchers who are outside our control and whose negative performance
could materially hinder or delay our pre-clinical testing or clinical trials
We do not have the ability to conduct all aspects of pre-clinical testing or clinical trials ourselves. We depend upon independent
investigators and collaborators, such as commercial third-parties, government, universities and medical institutions, to conduct our preclinical
and clinical trials under agreements with us. These collaborators are not our employees and we cannot control the amount or timing of
resources that they devote to our programs. These investigators may not assign as great a priority to our programs or pursue them as diligently
as we would if we were undertaking such programs ourselves. The failure of any of these outside collaborators to perform in an acceptable
and timely manner in the future, including in accordance with any applicable regulatory requirements, such as good clinical and laboratory
practices, or pre-clinical testing or clinical trial protocols, could cause a delay or otherwise adversely affect our pre-clinical testing or clinical
trials, our success in obtaining regulatory approvals and, ultimately, the timely advancement of our development programs. In addition, these
collaborators may also have relationships with other commercial entities, some of whom may compete with us. If our collaborators assist our
competitors at our expense, our competitive position would be harmed.
Negative publicity or unfavorable media coverage could damage our reputation and harm our operations.
In the event that the marketplace perceives our products as not offering the benefits which we believe they offer, we may receive
negative publicity. This publicity may result in litigation and increased regulation and governmental review. If we were to receive such
negative publicity or unfavorable media attention, whether warranted or unwarranted, our ability to market our products would be adversely
affected. We may be required to change our products and services and become subject to increased regulatory burdens, and we may be
required to pay large judgments or fines and incur significant legal expenses. Any combination of these factors could further increase our cost
of doing business and adversely affect our financial position, results of operations and cash flows.
We may face risks associated with future litigation and claims.
In addition to the existing arbitration with our former chief executive officer and president, we may, in the future, be involved in one
or more lawsuits, claims or other proceedings. These suits could concern issues including contract disputes, employment actions, employee
benefits, taxes, environmental, health and safety, personal injury and product liability matters. Due to the uncertainties of litigation, we can
give no assurance that we will prevail on any claims made against us in any such lawsuit.
Also, we can give no assurance that any other lawsuits or claims brought in the future will not have an adverse effect on our financial
condition, liquidity or operating results.
Specifically, we believe we will be subject to product liability claims or product recalls, particularly in the event of false positive or
false negative reports, because we plan to develop and manufacture medical diagnostic products. We intend to obtain appropriate insurance
coverage once we reach a manufacturing stage. A product recall or a successful product liability claim or claims that exceed our planned
insurance coverage could have a material adverse effect on us. In addition, product liability insurance is expensive. In the future we may not
be able to obtain coverage on acceptable terms, if at all. Moreover, our insurance coverage may not adequately protect us from liability that
we incur in connection with clinical trials or sales of our products. In the event of an award against us during a time when we have no available
insurance or insufficient insurance, we may sustain significant losses of our operating capital. In addition, any products liability litigation,
regardless of outcome or strength of claims, may divert time and resources away from the day-to-day operation of our business and product
development efforts. Any of these outcomes could adversely impact our business and results of operations, as well as impair our reputation in
the medical and investment communities.
23
Table of Contents
Recent global economic trends could adversely affect our business, liquidity and financial results.
Recent global economic conditions, including disruption of financial markets, could adversely affect us, primarily through limiting
our access to capital and disrupting our potential clients’ businesses. In addition, continuation or worsening of general market conditions in
economies important to our businesses may adversely affect our potential customers’ level of spending and ability to obtain financing, leading
to us being unable to generate the levels of sales that we anticipate. Continued disruption of financial markets could have a material adverse
effect on our business, financial condition, results of operations and future prospects.
We may be subject, directly or indirectly, to U.S. federal and state health care fraud and abuse and false claims laws and regulations.
Prosecutions under such laws have increased in recent years and we may become subject to such litigation. If we are unable to, or have not
fully complied with such laws, we could face substantial penalties.
If we are successful in achieving regulatory approval to market our PURE EP System, our operations will be directly, or indirectly
through our customers and health care professionals, subject to various U.S. federal and state fraud and abuse laws, including, without
limitation, the federal Anti-Kickback Statute, federal False Claims Act, and federal Foreign Corrupt Practices Act. These laws may impact,
among other things, our proposed sales, and marketing and education programs.
The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing
remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good
or service, for which payment may be made under a federal health care program such as the Medicare and Medicaid programs. Several courts
have interpreted the statute’s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce
referrals of federal health care covered business, the statute has been violated. The Anti-Kickback Statute is broad and, despite a series of
narrow safe harbors, prohibits many arrangements and practices that are lawful in businesses outside of the health care industry. Penalties for
violations of the federal Anti-Kickback Statute include criminal penalties and civil and administrative sanctions such as fines, imprisonment
and possible exclusion from Medicare, Medicaid and other federal health care programs. An alleged violation of the Anti-Kickback Statute
may be used as a predicate offense to establish liability pursuant to other federal laws and regulations such as the federal False Claims Act.
Many states have also adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for health care
items or services reimbursed by any source, not only the Medicare and Medicaid programs.
The federal False Claims Act prohibits persons from knowingly filing, or causing to be filed, a false claim to, or the knowing use of
false statements to obtain payment from, the federal government. Suits filed under the False Claims Act, known as “qui tam” actions, can be
brought by any individual on behalf of the government and such individuals, commonly known as “relators” or “whistleblowers,” may share in
any amounts paid by the entity to the government in fines or settlement. The frequency of filing qui tam actions has increased significantly in
recent years, causing greater numbers of medical device and health care companies to have to defend a False Claim Act action. The federal
Patient Protection and Affordable Care Act includes provisions expanding the ability of certain relators to bring actions that would have been
previously dismissed under prior law. When an entity is determined to have violated the federal False Claims Act, it may be required to pay up
to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. The Deficit Reduction Act of
2005 encouraged states to enact or modify their state false claims act to be at least as effective as the federal False Claims Act by granting
states a portion of any federal Medicaid funds recovered through Medicaid-related actions. Most states have enacted state false claims laws,
and many of those states included laws including qui tam provisions. States have until March 31, 2013 to enact or amend their false claims
laws modeled after the federal False Claims Act for review and approval to receive a greater portion of any recovery.
The federal Patient Protection and Affordable Care Act includes provisions known as the Physician Payments Sunshine Act, which
requires manufacturers of drugs, biologics, devices and medical supplies covered under Medicare and Medicaid starting in 2012 to record any
transfers of value to physicians and teaching hospitals and to report this data beginning in 2013 to the Centers for Medicare and Medicaid
Services for subsequent public disclosure. Manufacturers must also disclose investment interests held by physicians and their family members.
Failure to submit the required information may result in civil monetary penalties of up to $1 million per year for knowing violations and may
result in liability under other federal laws or regulations. Similar reporting requirements have also been enacted on the state level in the U.S.,
and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions
with health care professionals. In addition, some states such as Massachusetts and Vermont impose an outright ban on certain gifts to
physicians. If we receive U.S. Food and Drug Administration clearance to market our system in the U.S., these laws could affect our
promotional activities by limiting the kinds of interactions we could have with hospitals, physicians or other potential purchasers or users of
our system. Both the disclosure laws and gift bans will impose administrative, cost and compliance burdens on us.
24
Table of Contents
We are unable to predict whether we could be subject to actions under any of these laws, or the impact of such actions. If we are
found to be in violation of any of the laws described above and other applicable state and federal fraud and abuse laws, we may be subject to
penalties, including civil and criminal penalties, damages, fines, or an administrative action of suspension or exclusion from government
health care reimbursement programs and the curtailment or restructuring of our operations.
In addition, to the extent we commence commercial operations overseas, we will be subject to the Foreign Corrupt Practices Act and
other countries’ anti-corruption/anti-bribery regimes, such as the U.K. Bribery Act. The Foreign Corrupt Practices Act prohibits improper
payments or offers of payments to foreign governments and their officials for the purpose of obtaining or retaining business. Safeguards we
implement to discourage improper payments or offers of payments by our employees, consultants, sales agents or distributors may be
ineffective, and violations of the Foreign Corrupt Practices Act and similar laws may result in severe criminal or civil sanctions, or other
liabilities or proceedings against us, any of which would likely harm our reputation, business, financial condition and results of operations.
Risks Related to Our Intellectual Property
If we do not obtain protection for our intellectual property rights, our competitors may be able to take advantage of our research and
development efforts to develop competing products.
We intend to rely on a combination of patents, trade secrets, and nondisclosure and non-competition agreements to protect our
proprietary intellectual property. We have filed two patent applications in the U.S. and plan to file additional patent applications in the U.S.
and in other countries, as we deem appropriate for our products. Our applications have and will include claims intended to provide market
exclusivity for certain commercial aspects of the products, including the methods of production, the methods of usage and the commercial
packaging of the products. However, we cannot predict:
●
●
●
●
the degree and range of protection any patents will afford us against competitors, including whether third
parties will find ways to invalidate or otherwise circumvent our patents;
if and when such patents will be issued, and, if granted, whether patents will be challenged and held invalid
or unenforceable;
whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent
applications; or
whether we will need to initiate litigation or administrative proceedings which may be costly regardless of
outcome.
Our success also depends upon the skills, knowledge and experience of our scientific and technical personnel, our consultants and
advisors as well as our licensors and contractors. To help protect our proprietary know-how and our inventions for which patents may be
unobtainable or difficult to obtain, we rely on trade secret protection and confidentiality agreements. To this end, it is our policy to require all
of our employees, consultants, advisors and contractors to enter into agreements which prohibit the disclosure of confidential information and,
where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our
business. These agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the
event of any unauthorized use or disclosure or the lawful development by others of such information. If any of our trade secrets, know-how
or other proprietary information is disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly
impaired and our business and competitive position would suffer.
Given the fact that we may pose a competitive threat, competitors, especially large and well-capitalized companies that own or control
patents relating to electrophysiology recording systems, may successfully challenge our patent applications, produce similar products or
products that do not infringe our patents, or produce products in countries where we have not applied for patent protection or that do not
respect our patents.
25
Table of Contents
If any of these events occurs, or we otherwise lose protection for our trade secrets or proprietary know-how, the value of our
intellectual property may be greatly reduced. Patent protection and other intellectual property protection are important to the success of our
business and prospects, and there is a substantial risk that such protections will prove inadequate.
If we infringe upon the rights of third parties, we could be prevented from selling products and forced to pay damages and defend against
litigation.
If our products, methods, processes and other technologies infringe the proprietary rights of other parties, we could incur substantial
costs and we may be required to:
●
●
●
●
●
●
obtain licenses, which may not be available on commercially reasonable terms, if at all;
abandon an infringing product candidate;
redesign our product candidates or processes to avoid infringement;
cease usage of the subject matter claimed in the patents held by others;
pay damages; and/or
defend litigation or administrative proceedings which may be costly regardless of outcome, and which could
result in a substantial diversion of our financial and management resources.
Any of these events could substantially harm our earnings, financial condition and operations.
Risks Related to our Common Stock
The public trading market for our common stock is volatile and may result in higher spreads in stock prices, which may limit the ability
of our investors to sell their Shares at a profit, if at all.
Our common stock trades in the over-the-counter market and is quoted on the Over-the-Counter Bulletin Board, or OTCBB, and in
the Over-the-Counter Markets on the OTCQB. The over-the-counter market for securities has historically experienced extreme price and
volume fluctuations during certain periods. These broad market fluctuations may adversely affect the market price of our common stock and
result in substantial losses to our investors. In addition, the spreads on stock traded through the over-the-counter market are generally
unregulated and higher than on national stock exchanges, which means that the difference between the price at which shares could be
purchased by investors in the over-the-counter market compared to the price at which they could be subsequently sold would be greater than
on these exchanges. Significant spreads between the bid and asked prices of the stock could continue during any period in which a sufficient
volume of trading is unavailable or if the stock is quoted by an insignificant number of market makers. Historically our trading volume has
been insufficient to significantly reduce this spread and we have had a limited number of market makers sufficient to affect this spread. These
higher spreads could adversely affect investors who purchase the shares at the higher price at which the shares are sold, but subsequently
sell the shares at the lower bid prices quoted by the brokers. Unless the bid price for the stock exceeds the price paid for the shares by the
investor, plus brokerage commissions or charges, the investor could lose money on the sale. For higher spreads such as those on over-the-
counter stocks, this is likely a much greater percentage of the price of the stock than for exchange listed stocks. There is no assurance that at
the time an investor in our common stock wishes to sell the shares, the bid price will have sufficiently increased to create a profit on the sale.
We do not know whether a market for our common stock will be sustained or what the market price of our common stock will be and as a
result it may be difficult for you to sell your shares of our common stock.
Although our common stock now trades on the OTCBB and OTCQB, an active trading market for our shares may not be sustained.
It may be difficult for our stockholders to sell their shares without depressing the market price for our shares or at all. As a result of these and
other factors, our stockholders may not be able to sell their shares. Further, an inactive market may also impair our ability to raise capital by
selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using
our shares of common stock as consideration. If an active market for our common stock does not develop or is not sustained, it may be
difficult for our stockholders to sell shares of our common stock.
26
Table of Contents
Our cash flows are unpredictable, and this may harm our financial condition or the market price for our common stock.
The amount and timing of cash flows from our licensing and enforcement activities are subject to uncertainties stemming primarily
from uncertainties regarding the rates of adoption of our patented technologies, the growth rates of our licensees, the outcome of enforcement
actions and certain other factors. As such, our income and cash flows may vary significantly from period to period, which could make our
business difficult to manage, adversely affect our business and operating results, cause our annual or quarterly results to fall below market
expectations and adversely affect the market price of our common stock.
The market price for our common stock may fluctuate significantly, which could result in substantial losses by our investors.
The market price of our common stock may fluctuate significantly in response to numerous factors, some of which are beyond our
control, such as:
· the outcomes of our current and potential future patent litigation;
· our ability to monetize our patents;
· changes in our industry;
· announcements of technological innovations, new products or product enhancements by us or others;
· announcements by us of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital
commitments;
· changes in earnings estimates or recommendations by security analysts, if our common stock is covered by analysts;
· investors’ general perception of us;
· future issuances of common stock;
· the addition or departure of key personnel;
· general market conditions, including the volatility of market prices for shares of technology companies, generally, and other
factors, including factors unrelated to our operating performance; and
· the other factors described in this “Risk Factors” section.
These factors and any corresponding price fluctuations may materially and adversely affect the market price of our common stock
and result in substantial losses by our investors.
Further, the stock market in general, and the market for technology companies in particular, has experienced extreme price and
volume fluctuations in the past. Continued market fluctuations could result in extreme volatility in the price of our common stock, which
could cause a decline in the value of our common stock.
Price volatility of our common stock might be worse if the trading volume of our common stock is low. In the past, following
periods of market volatility, stockholders have often instituted securities class action litigation. If we were involved in securities litigation, it
could have a substantial cost and divert resources and attention of management from our business, even if we are successful. Future sales of
our common stock could also reduce the market price of such stock.
Moreover, the liquidity of our common stock is limited, not only in terms of the number of shares that can be bought and sold at a
given price, but by delays in the timing of transactions and reduction in security analysts’ and the media’s coverage of us, if any. These
factors may result in lower prices for our common stock than might otherwise be obtained and could also result in a larger spread between
the bid and ask prices for our common stock. In addition, without a large float, our common stock is less liquid than the stock of companies
with broader public ownership and, as a result, the trading prices of our common stock may be more volatile. In the absence of an active
public trading market, an investor may be unable to liquidate its investment in our common stock. Trading of a relatively small volume of our
common stock may have a greater impact on the trading price of our stock than would be the case if our public float were larger. We cannot
predict the prices at which our common stock will trade in the future.
27
Table of Contents
Our common stock is a “penny stock,” which makes it more difficult for our investors to sell their shares.
Our common stock is subject to the “penny stock” rules adopted under Section 15(g) of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”). The penny stock rules generally apply to companies whose common stock is not listed on The NASDAQ
Stock Market or other national securities exchange and trades at less than $5.00 per share, other than companies that have had average
revenue of at least $6,000,000 for the last three years or that have tangible net worth of at least $5,000,000 ($2,000,000 if the company has
been operating for three or more years). These rules require, among other things, that brokers who trade penny stock to persons other than
“established customers” complete certain documentation, make suitability inquiries of investors and provide investors with certain
information concerning trading in the security, including a risk disclosure document and quote information under certain circumstances.
Many brokers have decided not to trade penny stocks because of the requirements of the penny stock rules and, as a result, the number of
broker-dealers willing to act as market makers in such securities is limited. If we remain subject to the penny stock rules for any significant
period, it could have an adverse effect on the market, if any, for our securities. If our securities are subject to the penny stock rules, investors
will find it more difficult to dispose of our securities.
Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to
decline.
If our stockholders sell substantial amounts of our common stock in the public market, it could create a circumstance commonly
referred to as an “overhang,” in anticipation of which the market price of our common stock could fall. The existence of an overhang,
whether or not sales have occurred or are occurring, also could make more difficult our ability to raise additional financing through the sale
of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.
Our stockholders may experience substantial dilution as a result of the conversion of outstanding convertible preferred stock or the
exercise of options and warrants to purchase shares of our common stock.
As of February 12, 2015, we have granted options to purchase 6,190,190 shares of common stock and have reserved 1,445,933 shares
of our common stock for issuance upon the exercise of options pursuant to our 2012 Equity Incentive Plan. In addition, as of February 12,
2015, we may be required to issue 1,774,018 shares of our common stock for issuance upon conversion or outstanding convertible preferred
stock and 6,342,839 shares of our common stock for issuance upon exercise of outstanding warrants.
The interests of our controlling stockholders may not coincide with yours and such controlling stockholder may make decisions with which
you may disagree.
As of February 12, 2015, two of our stockholders beneficially owned over 62.96% of our common stock. As a result, our controlling
stockholders control substantially all matters requiring stockholder approval, including the election of directors and approval of significant
corporate transactions. In addition, this concentration of ownership may delay or prevent a change in control of our company and make some
future transactions more difficult or impossible without the support of our controlling stockholders. The interests of our controlling
stockholders may not coincide with our interests or the interests of other stockholders.
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock
price and trading volume could decline.
The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish
about us or our business. We do not currently have research coverage by securities and industry analysts and you should not invest in our
common stock in anticipation that we will obtain such coverage. If we obtain securities or industry analyst coverage and if one or more of the
analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price would likely
decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease,
which could cause our stock price and trading volume to decline.
28
Table of Contents
We are an “emerging growth company” and we cannot be certain that the reduced disclosure requirements applicable to emerging growth
companies will make our common stock less attractive to investors.
The JOBS Act permits “emerging growth companies” like us, upon becoming a publicly-reporting company, to rely on some of the
reduced disclosure requirements that are already available to smaller reporting companies. As long as we qualify as an emerging growth
company or a smaller reporting company, we would be permitted to omit the auditor’s attestation on internal control over financial reporting
that would otherwise be required by the Sarbanes-Oxley Act, as described above, and are also exempt from the requirement to submit “say-on-
pay”, “say-on-pay frequency” and “say-on-parachute” votes to our stockholders and may avail ourselves of reduced executive compensation
disclosure that is already available to smaller reporting companies.
In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the exemption from
complying with new or revised accounting standards provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, as long as we
are an emerging growth company. An emerging growth company can therefore delay the adoption of certain accounting standards until those
standards would otherwise apply to private companies. We intend to take advantage of the benefits of this until we are no longer an emerging
growth company or until we affirmatively and irrevocably opt out of this exemption. Our financial statements may therefore not be
comparable to those of companies that comply with such new or revised accounting standards.
We will cease to be an emerging growth company at such time as described in the risk factor immediately above. Until such time,
however, we cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors
find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be
more volatile and could cause our stock price to decline.
Delaware law and our corporate charter and bylaws contain anti-takeover provisions that could delay or discourage takeover attempts that
stockholders may consider favorable.
Our board of directors is authorized to issue shares of preferred stock in one or more series and to fix the voting powers, preferences
and other rights and limitations of the preferred stock. Accordingly, we may issue shares of preferred stock with a preference over our
common stock with respect to dividends or distributions on liquidation or dissolution, or that may otherwise adversely affect the voting or
other rights of the holders of common stock. Issuances of preferred stock, depending upon the rights, preferences and designations of the
preferred stock, may have the effect of delaying, deterring or preventing a change of control, even if that change of control might benefit our
stockholders. In addition, we are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits a public
Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of
the transaction in which the person became an interested stockholder, unless (i) prior to the date of the transaction, the board of directors of
the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested
stockholder; (ii) the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction
commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also
officers and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially
whether shares held subject to the plan will be tendered in a tender or exchange offer; or (iii) on or subsequent to the date of the transaction,
the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent,
by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.
Section 203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may
discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above
the prevailing market price.
The terms of our Series C Preferred Stock prohibit us from paying dividends in the future. As a result, any return on investment may be
limited to the value of our common stock.
The terms of our Series C Preferred Stock prohibit us from paying dividends in the future on our common stock, absent consent from
the holders representing a super-majority of the outstanding shares of our Series C Preferred Stock and a certain investor. Because we will
likely not pay dividends, our common stock may be less valuable because a return on an investment in our common stock will only occur if
our stock price appreciates.
29
Table of Contents
Risks Related to our Series C Preferred Stock
Our Series C Preferred Stock contains covenants that could limit our financing options and liquidity position, which would limit our ability
to grow our business.
Covenants in the certificate of designation for our Series C Preferred Stock impose operating and financial restrictions on us. These
restrictions prohibit or limit our ability to, among other things:
●
●
●
●
●
incur additional indebtedness;
permit liens on assets;
repay, repurchase or otherwise acquire more than a de minimis number of shares of common stock, Series A
Preferred Stock or Series B Preferred Stock;
pay cash dividends to our stockholders; and
engage in transactions with affiliates.
These restrictions may limit our ability to obtain financing, withstand downturns in our business or take advantage of business
opportunities. Moreover, debt financing we may seek may contain terms that include more restrictive covenants, may require repayment on an
accelerated schedule or may impose other obligations that limit our ability to grow our business, acquire needed assets, or take other actions
we might otherwise consider appropriate or desirable.
In addition, the certificate of designation for our Series C Preferred Stock requires us to redeem shares of our Series C Preferred
Stock, at each holder’s option and for an amount greater than their stated value, upon the occurrence of certain events, including our being
subject to a judgment of greater than $100,000 or our initiation of bankruptcy proceedings. Pursuant to an amendment to the terms of our
Series C Preferred Stock, because we failed to complete a financing or series of related financings by February 12, 2014 that resulted in gross
proceeds to us of at least $3 million at a valuation of at least $30 million and because we failed to maintain the listing of our common stock on
a trading market for more than five trading days in any twelve month period after February 12, 2014, the conversion price of our Series C
Preferred Stock was reduced to $1.50 per share.
The holders of our Series C Preferred Stock are entitled to receive a dividend, which may be increased if we do not comply with certain
covenants, and are also entitled to receive a make-whole payment if the Series C Preferred Stock is converted into common stock prior to
February 12, 2016.
The holders of the Series C Preferred Stock are entitled to a 9% annual dividend on the $1,000 per share stated value of our Series C
Preferred Stock, which is payable in cash or, subject to the satisfaction of certain conditions, in pay-in-kind shares. The dividend may be
increased to a 18% annual dividend if we fail to comply with certain covenants, including our being subject to a judgment of greater than
$100,000 or our initiation of bankruptcy proceedings. In addition, if a holder of the Series C Preferred Stock converts its shares of Series C
Preferred Stock into shares of common stock any time prior to February 12, 2016, the holder will be deemed to have earned a make whole
amount equal to the amount that would have been due if such shares of Series C Preferred Stock had been outstanding until such date, which
may be paid in cash or pay-in-kind shares, depending upon the availability of funds to us to make such payments and the fulfillment of certain
conditions relating to our company and our common stock. As a result of the payment of dividends and the make whole amounts related to
our Series C Preferred Stock, we may be obligated to pay significant sums of money or issue significantly more shares of common stock than
our Series C Preferred Stock would otherwise be convertible into, which could negatively affect our operations or result in the dilution of the
holders of our common stock, respectively.
30
Table of Contents
Our Series C Preferred Stock and our warrants contain anti-dilution provisions that may result in the reduction of their conversion prices
or exercise prices in the future.
Our Series C Preferred Stock and our warrants contain anti-dilution provisions, which provisions require the lowering of the
conversion price or exercise price, as applicable, to the purchase price of future offerings. Furthermore, with respect to our warrants, if we
complete an offering below the exercise price of such warrants, the number of shares issuable under such warrants will be proportionately
increased such that the aggregate exercise price payable after taking into account the decrease in the exercise price, shall be equal to the
aggregate exercise price prior to such adjustment. If in the future we issue securities for less than the conversion or exercise price of our
Series C Preferred Stock and our warrants, respectively, we will be required to further reduce the relevant conversion or exercise prices, and
the number of shares underlying the warrants will be increased. We may find it more difficult to raise additional equity capital while our
Series C Preferred Stock and our warrants are outstanding. Although we do not intend to reduce the conversion or exercise prices of our
outstanding securities in the future, if we do so, the holders of our common stock may experience greater dilution upon the conversion or
exercise of our outstanding securities convertible or exercisable into our common stock.
ITEM 1B – UNRESOLVED STAFF COMMENTS
Not applicable.
ITEM 2 – PROPERTIES
We maintain our principal office at 12424 Wilshire Boulevard, Suite 745, Los Angeles, California. On May 31, 2014, the
Company extended its expiring three-year lease for office space in Los Angeles, California for one additional year, with monthly payments
of $6,530 beginning on September 1, 2014.
ITEM 3 – LEGAL PROCEEDINGS
From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business.
However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may
harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have, individually or in the
aggregate, a material adverse effect on our business, financial condition or operating results.
ITEM 4 – MINE SAFETY DISCLOSURES
Not applicable.
31
Table of Contents
PART II
ITEM 5 – MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER
PURCHASES OF EQUITY SECURITIES
Market for Common Stock
On October 29, 2014, our common stock commenced trading on OTCQB under the symbol “BSGM.” Prior to October 29, 2014,
there was no established public trading for our common stock. The following table sets forth, for the periods indicated, the high and low sales
prices per share of our common stock as reported by the OTCQB. The quotations reflect inter-dealer prices, without retail markup,
markdown, or commissions, and may not represent actual transactions:
First Quarter
Second Quarter
Third Quarter
Fourth Quarter
First Quarter
Second Quarter
Third Quarter
Fourth Quarter
Fiscal Year 2013
High
Low
$
$
$
$
-
-
-
-
$
$
$
$
Fiscal Year 2014
High
Low
$
$
$
$
-
-
-
3.50
$
$
$
$
-
-
-
-
-
-
-
2.56
Holders of Record
As of February 20, 2015, there were approximately 186 holders of record of our common stock.
Dividends
We have never paid cash dividends on our common stock and do not anticipate paying any cash dividends in the foreseeable future, but
intend to retain our capital resources for reinvestment in our business
ITEM 6 – SELECTED FINANCIAL DATA
Not applicable
ITEM 7 – MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Management's Discussion and Analysis of Financial Condition and Results of Operations includes a number of forward-
looking statements that reflect Management's current views with respect to future events and financial performance. You can identify these
statements by forward-looking words such as “may” “will,” “expect,” “anticipate,” “believe,” “estimate” and “continue,” or similar
words. Those statements include statements regarding the intent, belief or current expectations of us and members of its management team
as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from
those contemplated by such forward-looking statements as a result of certain factors, as more fully discussed in Item 1 of this report, entitled
“Business” under “Forward-Looking Statement” and Item 1A of this report, entitled “Risk Factors”.
Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed
with the Securities and Exchange Commission. Important factors known to us could cause actual results to differ materially from those in
forward-looking statements. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the
occurrence of unanticipated events or changes in the future operating results over time. We believe that its assumptions are based upon
reasonable data derived from and known about our business and operations and the business and operations of the Company. No assurances
are made that actual results of operations or the results of our future activities will not differ materially from its assumptions. Factors that
could cause differences include, but are not limited to, expected market demand for the Company’s services, fluctuations in pricing for
materials, and competition.
Our Business
We are a development stage medical device company that is developing a proprietary technology platform to minimize noise and
artifacts from cardiac recordings during electrophysiology studies and ablation. Our product under development, the PURE EP System, is a
surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram
and electrograms required during electrophysiology studies and ablation procedures.
We have not generated any revenue to date and consequently our operations are subject to all risks inherent in the establishment of a
new business enterprise.
32
Table of Contents
Critical Accounting Policies and Estimates
The following discussion and analysis of our financial condition and results of operations are based upon our financial statements,
which have been prepared in accordance with generally accepted accounting principles in the U.S. The preparation of financial statements in
accordance with generally accepted accounting principles in the U.S. requires us to make estimates and assumptions that affect the amounts
reported in our financial statements. The financial statements include estimates based on currently available information and our judgment as
to the outcome of future conditions and circumstances. Significant estimates in these financial statements include allowance for doubtful
accounts and accruals for inventory claims. Changes in the status of certain facts or circumstances could result in material changes to the
estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions.
Among the significant judgments made by management in the preparation of our financial statements are the following:
Research and Development.
We account for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research
and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred.
Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed
when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development
costs related to both present and future products are expensed in the period incurred.
Stock Based Compensation.
All stock-based payments to employees and to nonemployee directors for their services as directors consisted of grants of restricted
stock and stock options, which are measured at fair value on the grant date and recognized in the statements of operations as compensation
expense over the relevant vesting period. Restricted stock payments and stock-based payments to nonemployees are recognized as an expense
over the period of performance. Such payments are measured at fair value at the earlier of the date a performance commitment is reached or
the date performance is completed. In addition, for awards that vest immediately and are non-forfeitable, the measurement date is the date the
award is issued.
Because there is no viable market for our common stock in order to determine its fair value, we are required to estimate the fair value
to be utilized in the determining stock based compensation costs. In estimating the fair value, we consider recent sales of our common stock
or common stock equivalents to independent qualified investors, our placement agents’ assessments of the underlying common shares relating
to our sale of preferred stock and validation by independent fair value experts. Considerable judgment is necessary to estimate the fair
value. Accordingly, actual results could vary significantly from our estimates.
Income Taxes.
Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit
carryforwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts
measured at the current enacted tax rates. We record an estimated valuation allowance on our deferred income tax assets if it is not more
likely than not that these deferred income tax assets will be realized. We recognize a tax benefit from an uncertain tax position only if it is
more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.
The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than
50% likelihood of being realized upon ultimate settlement.
33
Table of Contents
Results of Operations
Twelve Months Ended December 31, 2014 Compared to Twelve Months Ended December 31, 2013
Revenues and Cost of Goods Sold. We had no revenues or cost of goods sold during the twelve months ended December 31, 2014 and
2013.
Research and Development Expenses. Research and development expenses for the twelve months ended December 31, 2014 were
$547,996, a decrease of $444,211, or 45%, from $992,207 for the twelve months ended December 31, 2013. This decrease is primarily due to a
reduction the costs paid to both personnel and research and development consulting services as we develop our proprietary technology
platform. Research and development expenses were comprised of $366,362 of personnel costs and $115,692 consulting services for the twelve
months ended December 31, 2014 as compared to $632,881 and $359,326 for the same period last year, respectively. This decrease is
primarily due to salary and fee reductions in both personnel and research and development consulting services expenses, including accounting
for payments to our scientists as personnel costs, as we develop our proprietary technology platform.
General and Administrative Expenses. General and administrative expenses for the twelve months ended December 31, 2014 were
$7,304,440, an increase of $2,557,242, or 49%, from $5,229,252 incurred in the twelve months ended December 31, 2013. This increase is
primarily due to increases in payroll related expenses and professional services and, to a lesser extent, due to increases in consulting fees and
travel, meals and entertainment costs.
Payroll related expenses increased to $5,938,442 in the twelve months ended December 31, 2014 from $3,465,680 for the twelve
months ended December 31, 2013, an increase of $2,472,762, or 71%. This increase is due to the value of the stock based compensation
increasing to $5,693,425 in 2014, as a result of the vesting of stock and stock options issued to board members, officers and employees, as
compared to $3,247,187 of stock based compensation in 2013.
Professional services for the twelve months ended December 31, 2014 totaled $585,472, an increase of $32,991, or 6%, over the
$552,481 recognized for the twelve months ended December 31, 2013. Of professional services, legal fees totaled $284,787 for the twelve
months ended December 31, 2014, a decrease of $24,406, or 8%, from $309,193 incurred for the twelve months ended December 31, 2013.
Accounting fees incurred in the twelve months ended December 31, 2012 amounted to $64,380, a decrease of $29,178, or 32%, from $93,558
incurred for the same period in 2013. The increase in professional fees was primarily related to an increase in legal requirements as we
continue to develop our operations, including legal fees associated with our capital raising transactions and the filing of our initial registration
statement.
Consulting fees totaled $246,754 for the twelve months ended December 31, 2014, a decrease of $608,902 or 71%, from $855,656
for the twelve months ended December 31, 2013. The consulting fees for the year ended December 31, 2013 included $800,823 in stock
based compensation for investment and finance consultants to assist in our fund raising and investor relations efforts to support our increased
efforts in market research and potential investor identification.
Travel, meals and entertainment costs for the twelve months ended December 31, 2014 were $125,923, an increase of $35,144, or
39%, from $90,779 incurred during the twelve months ended December 31, 2013. During 2014, more travel was required than in 2013. Rent
for the twelve months ended December 31, 2014 totaled $77,063, an increase of $3,058, or 4%, from $74,005 incurred during the same period
in 2013.
Depreciation Expense. Depreciation expense for the twelve months ended 2014 totaled $15,809, a decrease of $1,250, or 7%, over
the expense of $17,059 incurred during the same period in 2013, as a result of the aging of office computers and other equipment.
Interest Expense. Interest expense for the twelve months ended December 31, 2014 totaled $11,025, a decrease of $59,036 from of
$70,061 incurred during the twelve months ended December 31, 2013. For 2014, interest costs were comprised of finance costs and estimated
liquidated damages of $6,953. During the twelve months ended December 31, 2013, we accrued estimated liquidated damages of $48,668
relating to our registration rights obligations in connection to the issuance of our Series C preferred stock. In addition, other interest costs
were comprised primarily of bridge and related party notes issued in late 2012.
34
Table of Contents
Financing Costs. Financing costs for the year ended December 31, 2014 totaled $593,770, a decrease of $2,902,282 or 83% from
$3,496,052 incurred during the year ended December 31, 2013. Financing costs are primarily related to the fees paid related to the issuance of
our Series A and Series B Preferred Stock in 2011 and 2012 and a beneficial conversion feature in and the fees paid related to the issuance of
our Series C Preferred Stock issued in 2013. The beneficial conversion feature associated with the Series C Preferred Stock is comprised of
the allocated fair value of the conversion feature and the allocated fair value of warrants issued in connection with the sale of the Series C
Preferred Stock.
Preferred Stock Dividend. Our preferred stock dividend for the twelve months ended December 31, 2014 totaled $300,359, an
increase of $3,144, or 3% from $297,215 incurred during the twelve months ended December 31, 2013. Preferred stock dividends are related
to the issuance of our Series A, Series B and C Preferred Stock in 2011, 2012 and 2013.
Net Loss Available to Common Stockholders. Net loss Available to Common Stockholders for the twelve months ended December
31, 2014 was $8,773,399, compared to a net loss of $10,101,846 for the twelve months ended December 31, 2013, a decrease of $1,328,447
or 13%. The primary reasons for the decrease, as described above, is the reduction in financing costs net with the increase in stock based
compensation incurred in general and administrative expenses.
Liquidity and Capital Resources
Twelve Months Ended December 31, 2014 Compared to Twelve Months Ended December 31, 2013
As of December 31, 2014, we had a working capital deficit of $910,082, comprised of cash of $239,781 and prepaid expenses of
$75,537, which was offset by $554,026 of accounts payable and accrued expenses, stock based payable of $226,305 and accrued dividends
on preferred stock issuances of $445,069. For the twelve months ended December 31, 2014, we used $1,997,072 of cash in operating
activities. Cash provided by financing activities totaled $1,938,629, comprised of proceeds from the sale of our common stock of
$1,969,410, net with repayments of related party advances of $30,781. In the comparable period in 2013, $1,768,410 was raised from the
sale of our Series C Preferred stock, $299,974 was raised through the sale of our common stock, $13,741 through related party advances, net
with $30,000 repayments of related party loans. At December 31, 2014, we had cash of $239,781 compared to $302,187 at December 31,
2013. Our cash is held in bank deposit accounts. At December 31, 2014 and 2013, we had no convertible debentures outstanding.
Cash used in operations for the twelve months ended December 31, 2014 and 2013 was $1,997,072 and $1,762,459, respectively,
which represent cash outlays for research and development and general and administrative expenses in such periods. Increase in cash outlays
principally resulted from increased research and development and general and administrative expenses due to the continued development of
our operations.
Cash used in investing activities for the twelve months ended December 31, 2014 was $3,963, compared to $11,716 for the twelve
months ended December 31, 2013. During both the twelve months ended December 31, 2014 and the twelve months ended December 31,
2013, we purchased office furniture and computer equipment.
December 2014 Private Placement
On December 19, 2014, we entered into a unit purchase agreement with certain accredited investors, pursuant to which we issued and
sold, in multiple closings occurring on each of December 19, 2014, December 30, 2014, January 23, 2015 and February 10, 2015, an
aggregate of 24.256 units, which consisted of, in the aggregate, 970,240 shares of our common stock, “A” warrants to purchase 970,240
shares of our common stock at an exercise price of $2.50 and “B” warrants to purchase 485,120 shares of our common stock at an exercise
price of $3.75 per share, in exchange for aggregate gross proceeds of $2,425,600. As consideration for serving as our placement agent in
connection with the private placement, we issued to Laidlaw & Company (UK) Ltd. “B” warrants to purchase an aggregate of 226,760 shares
of common stock at an exercise price of $3.75 per share and paid cash fees equal to $291,072.
35
Table of Contents
In their report dated February 20, 2015, our independent registered public accounting firm stated at December 31, 2014, there is
substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is an issue raised due to our net
losses and negative cash flows from operations since inception and our expectation that these conditions will continue for the foreseeable
future. In addition, we will require additional financing to fund future operations. Further, we do not have any commercial products available
for sale and have not generated revenues to date, and there is no assurance that, if approval of our products is received, we will be able to
generate cash flow to fund operations. In addition, there can be no assurance that our research and development will be successfully completed
or that any product will be approved or commercially viable. Our ability to continue as a going concern is subject to our ability to obtain
necessary funding from outside sources, including obtaining additional funding from the sale of our securities, obtaining loans from various
financial institutions or being awarded grants from government agencies, where possible. Our continued net operating losses increase the
difficulty in meeting such goals and there can be no assurances that such methods will prove successful.
Our Series C Preferred Stock contains triggering events which would, among other things, require redemption (i) in cash, at the
greater of (a) 120% of the stated value of $1,000 or (b) the product of (I) the variable weighted average price of our common stock on the
trading day immediately preceding the date of the triggering event and (II) the stated value divided by the then conversion price or (ii) in
shares of our common stock, equal to a number of shares equal to the amount set forth in (i) above divided by 75%. The triggering events
include our being subject to a judgment of greater than $100,000 or our initiation of bankruptcy proceedings. If any of the triggering events
contained in our Series C Preferred Stock occur, the holders of our Series C Preferred Stock may demand redemption, an obligation we may
not have the ability to meet at the time of such demand. We will be required to pay interest on any amounts remaining unpaid after the
required redemption of our Series C Preferred Stock, at rate equal to the lesser of 18% per annum or the maximum rate permitted by
applicable law.
We expect to incur losses from operations for the near future. We expect to incur increasing research and development expenses,
including expenses related to clinical trials. We expect that our general and administrative expenses will increase in the future as we expand
our business development, add infrastructure and incur additional costs related to being a public company, including incremental audit fees,
investor relations programs and increased professional services.
Our future capital requirements will depend on a number of factors, including the progress of our research and development of
product candidates, the timing and outcome of regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining,
defending and enforcing patent claims and other intellectual property rights, the status of competitive products, the availability of financing
and our success in developing markets for our product candidates. We believe our existing cash will not be sufficient to fund our operating
expenses and capital equipment requirements. We anticipate we will need approximately $2 million in addition to our current cash on hand to
fund our operating expenses and capital equipment requirements for the next 12 months. We will have to raise additional funds to continue
our operations and, while we have been successful in doing so in the past, there can be no assurance that we will be able to do so in the future.
Our continuation as a going concern is dependent upon our ability to obtain necessary additional funds to continue operations and the
attainment of profitable operations.
Future financing may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms.
Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses or experience unexpected cash
requirements that would force us to seek alternative financing. Furthermore, if we issue additional equity or debt securities, existing holders of
our securities may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of
existing holders of our securities.
36
Table of Contents
If additional financing is not available or is not available on acceptable terms, we may be required to delay, reduce the scope of or
eliminate our research and development programs, reduce our commercialization efforts or obtain funds through arrangements with
collaborative partners or others that may require us to relinquish rights to certain product candidates that we might otherwise seek to develop
or commercialize independently.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements.
Transactions with Related Parties
The Company’s President and shareholders have advanced funds to the Company for working capital purposes since the Company’s inception
in February 2009. No formal repayment terms or arrangements exist and the Company is not accruing interest on these advances. The net
amount outstanding at December 31, 2014 and 2013 was $-0- and $30,781, respectively.
Accrued interest and expenses due related parties as of December 31, 2014 and 2013 was $40,293 and $123,089, respectively.
During 2014, one of the Company’s board of directors forgave an outstanding obligation of $87,500 for services. Accordingly, the Company
reclassified the liability to equity as donated capital.
During 2014, the Company issued 34,000 shares of its common stock for future services from a board member totaling $85,000
($2.50 per share), unrelated to his services as a board member. The fair value of the services is amortized over the service period. As of
December 31, 2014, the unamortized portion of $56,667 is included in prepaid expenses in the accompanying balance sheet.
During 2014, the Company issued 26,000 shares of its common stock in settlement of $65,000 debt to a board of directors member
($2.50 per share).
During 2013, in connection with the amendments of the Series C 9% Convertible Preferred stock, the Company issued to Company’s
president and a Director of the Company (Series C holders) an aggregate of 53,830 warrants to purchase the Company’s common stock at
$2.61 per share for five years. See Note 9 below.
The Company has informal compensation and consulting agreements with employees and outside contractors, certain of whom are
also Company stockholders. The Agreements are generally month to month. As of December 31, 2014 and 2013, total due under these
agreements and related expenses were $11,250 and $-0-, respectively.
Recent Accounting Pronouncements
There were various updates recently issued, most of which represented technical corrections to the accounting literature or application
to specific industries and are not expected to a have a material impact on the Company's consolidated financial position, results of operations
or cash flows.
ITEM 7A – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
37
Table of Contents
ITEM 8 – FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
BIOSIG TECHNOLOGIES, INC.
FINANCIAL STATEMENTS
TABLE OF CONTENTS
Report of Independent Registered Public Accounting Firm
Balance Sheets as of December 31, 2014 and 2013
Statements of Operations for the Years Ended December 31, 2014 and 2013
Statements of Changes in Stockholders’ Deficit for the Years Ended December 31, 2014 and 2013
Statements of Cash Flows for the Years Ended December 31, 2014 and 2013
Notes to Financial Statements
F-2
F-3
F-4
F-5
F-7
F-8
F-1
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
BioSig Technologies, Inc.
We have audited the accompanying balance sheet of BioSig Technologies. Inc. (“the Company”) as of December 31, 2014 and 2013, and the
related statements of operations, stockholders’ deficit, and cash flows for the years then ended. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in
the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial
reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe that our audit provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of BioSig Technologies,
Inc. as of December 31, 2014 and 2013, and the results of its operations and its cash flows for the years then ended in conformity with
accounting principles generally accepted in the United States of America.
The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2
to the financial statements, the Company has incurred losses from operations since its inception and has a net stockholders’ deficiency.
These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these
matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this
uncertainty.
February 20, 2015
New York, New York
/s/ Liggett, Vogt & Webb, P.A.
Liggett, Vogt & Webb, P.A.
F-2
Table of Contents
Current assets:
Cash
Prepaid expenses
Total current assets
Property and equipment, net
Other assets:
Deposits
Total assets
BIOSIG TECHNOLOGIES, INC.
BALANCE SHEETS
DECEMBER 31, 2014 AND 2013
ASSETS
2014
2013
$
239,781 $
75,537
315,318
302,187
-
302,187
13,020
24,866
25,000
25,000
$
353,338 $
352,053
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable and accrued expenses, including $40,293 and $92,308 to related parties as of
December 31, 2014 and 2013, respectively
Stock based payable
Advances, related party
Liability to placement agent
Redeemable Series A Preferred Stock, 184.4 shares issued and outstanding, liquidation preference
of $922,000, net of debt discount of $37,399 as of December 31, 2013
Redeemable Series B Preferred Stock, 177.5 shares issued and outstanding, liquidation preference
of $887,500, net of debt discount of $72,478 as of December 31, 2013
Dividends payable
Total current liabilities
$
554,026 $
226,305
-
-
819,330
-
30,781
52,800
-
884,601
-
445,069
1,225,400
815,022
414,967
3,017,501
Series C 9% Convertible Preferred stock, 2,711 and 2,781 shares issued and outstanding
liquidation preference of $2,711,000 and $2,781,000, net of debt discount of $-0- and $483,893,
respectively
2,711,000
2,297,107
Stockholders' deficit
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A,
600 shares of Series B and 4,200 shares of Series C Preferred Stock
Common stock, $0.001 par value, authorized 50,000,000 shares, 11,179,266 and 8,412,101 issued
and outstanding as of December 31, 2014 and 2013, respectively
Additional paid in capital
Accumulated deficit
Total stockholders' deficit
11,179
19,186,163
(22,780,404 )
(3,583,062 )
8,412
9,036,038
(14,007,005 )
(4,962,555 )
Total liabilities and stockholders' deficit
$
353,338 $
352,053
See the accompanying notes to the financial statements
F-3
BIOSIG TECHNOLOGIES, INC.
STATEMENTS OF OPERATIONS
Table of Contents
Operating expenses:
Research and development
General and administrative
Depreciation
Total operating expenses
Loss from operations
Other income (expense):
Interest income (expense)
Financing costs
Loss before income taxes
Income taxes (benefit)
Net loss
Preferred stock dividend
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS
Net loss per common share, basic and diluted
Year ended December 31,
2013
2014
$
$
547,996
7,304,440
15,809
7,868,245
992,207
5,229,252
17,059
6,238,518
(7,868,245)
(6,238,518)
(11,025)
(593,770)
(70,061)
(3,496,052)
(8,473,040)
(9,804,631)
-
-
(8,473,040)
(9,804,631)
(300,359)
(297,215)
(8,773,399) $
(10,101,846)
(0.91) $
(1.23)
$
$
Weighted average number of common shares outstanding, basic and diluted
9,650,275
8,187,648
See the accompanying notes to the financial statements
F-4
Table of Contents
Balance, December 31, 2012
Common stock issued for services
rendered
Common stock issued as payment for
accrued interest to note holders at $2.09
per share
Beneficial conversion feature in
connection with note payable
Beneficial conversion feature and
warrants issued in connection with the
Series C Preferred Stock
Fair value of warrants issued to Series C
investors for certificate of designation
amendment
Fair value of warrants issued for services
Common stock issued in settlement of
related party note and advances payable
Sale of common stock
Fair value of vested options
Preferred stock dividend
Net loss
Balance, December 31, 2013
BIOSIG TECHNOLOGIES, INC.
STATEMENT OF STOCKHOLDERS' DEFICIT
TWO YEARS ENDED DECEMBER 31, 2014
Common stock
Shares
Amount
Additional
Paid in
Capital
8,166,238
$
8,166
$
833,647
Accumulated
Deficit
(3,905,159) $
$
21,412
22
44,729
8,941
-
-
-
-
9
-
-
-
-
93,061
122,449
-
-
-
8,412,101
$
93
122
-
-
-
8,412
$
F-5
18,668
20,000
2,404,830
1,074,833
916,677
228,415
247,052
3,247,187
-
-
9,036,038
$
-
-
-
-
-
-
-
-
(297,215)
(9,804,631)
(14,007,005) $
Total
(3,063,346)
44,751
18,677
20,000
2,404,830
1,074,833
916,677
228,508
247,174
3,247,187
(297,215)
(9,804,631)
(4,962,555)
Table of Contents
Balance, December 31, 2013
Sale of common stock
Common stock issued for services
Common stock issued in settlement of
related party debt
Common stock issued upon conversion
of Series A preferred stock and accrued
dividends at $1.84 per share
Common stock issued upon conversion
of Series B preferred stock and accrued
dividends at $2.02 per share
Common stock issued upon conversion
of Series C preferred stock and accrued
dividends at $1.50 per share
Donated capital
Equity warrants issued to placement
agent for sale of common stock
Fair value of vested options
Preferred stock dividend
Net loss
Balance, December 31, 2014
BIOSIG TECHNOLOGIES, INC.
STATEMENT OF STOCKHOLDERS' DEFICIT
TWO YEARS ENDED DECEMBER 31, 2014
Common stock
Shares
Amount
Additional
Paid in
Capital
$
8,412,101
956,179
654,000
$
8,412
956
654
9,036,038
1,968,454
1,634,346
26,000
26
64,974
577,901
578
1,062,753
493,818
494
997,032
59,267
-
-
-
-
-
11,179,266
$
59
-
-
-
-
-
11,179
$
88,841
87,500
52,800
4,193,425
-
-
19,186,163
See the accompanying notes to the financial statements
F-6
Accumulated
Deficit
(14,007,005) $
$
-
-
-
-
-
-
-
-
-
(300,359)
(8,473,040)
(22,780,404) $
$
Total
(4,962,555)
1,969,410
1,635,000
65,000
1,063,331
997,526
88,900
87,500
52,800
4,193,425
(300,359)
(8,473,040)
(3,583,062)
Table of Contents
BIOSIG TECHNOLOGIES, INC.
STATEMENTS OF CASH FLOWS
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation
Amortization of debt discount
Stock based compensation
Fair value of warrants issued in connection with Series C preferred stock modifications
Fair value of warrants issued for services
Changes in operating assets and liabilities:
Prepaid expenses
Accounts payable
Stock based payable
Deferred rent payable
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment
Net cash used in investing activity
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from the sale of Series C preferred stock and warrants
Proceeds from sale of common stock
Payments of related party notes
Net repayments of related party advances
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of the period
Cash and cash equivalents, end of the period
Supplemental disclosures of cash flow information:
Cash paid during the period for interest
Cash paid during the period for income taxes
Non cash investing and financing activities:
Common stock issued upon conversion of Series A preferred stock and accrued dividends
Common stock issued upon conversion of Series B preferred stock and accrued dividends
Common stock issued upon conversion of Series C preferred stock and accrued dividends
Common stock options for future services, related party
Common stock options in settlement of accounts payable, related party
Related party donated capital
Common stock issued in settlement of related party note and advances payable
Common stock issued in settlement of accrued interest
Convertible bridge notes payable exchanged for preferred shares
See the accompanying notes to the financial statements
F-7
Year ended December 31,
2013
2014
$
(8,473,040 ) $
(9,804,631 )
15,809
593,770
5,743,425
-
-
8,715
(110,844 )
226,305
(1,212 )
(1,997,072 )
17,059
2,441,220
3,305,063
1,074,833
837,243
20,000
349,809
-
(3,055 )
(1,762,459 )
(3,963 )
(3,963 )
(11,716 )
(11,716 )
-
1,969,410
-
(30,781 )
1,938,629
1,768,410
299,974
(30,000 )
13,741
2,052,125
(62,406 )
277,950
302,187
239,781 $
24,237
302,187
- $
- $
-
-
1,063,331 $
997,526 $
88,900 $
85,000 $
65,000 $
87,500 $
- $
- $
- $
-
-
-
-
-
-
228,508
18,677
600,000
$
$
$
$
$
$
$
$
$
$
$
$
Table of Contents
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows.
Business and organization
BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and
subsequently re-incorporated in the state of Delaware in 2011. The Company and its efforts are principally devoted to improving the quality of
cardiac recordings obtained during ablation of atrial fibrillation (AF) and ventricular tachycardia (VT). The Company has not generated any
revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.
Revenue Recognition
The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-
10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists;
(2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria
(3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the
collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are
provided for in the same period the related sales are recorded.
Use of estimates
The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management
to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and disclosures of contingent assets and
liabilities at the date of the financial statements. Actual results could differ from those estimates. Significant estimates include the useful life
of fixed assets and assumptions used in the fair value of stock-based compensation.
Concentrations of Credit Risk
Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and
cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be
in excess of the FDIC insurance limit.
Prepaid Expenses
From time to time, the Company issues shares of its common stock for services to be performed. The fair value of the common stock is
determined at the date of the contract for services and is amortized ratably over the term of the contract. As of December 31, 2014 and 2013,
prepaid expenses relating to stock based payments were $56,667 and $-0-, respectively.
Property and Equipment
Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When
retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net
difference less any amount realized from disposition, is reflected in earnings.
F-8
Table of Contents
Long-Lived Assets
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
The Company follows Accounting Standards Codification 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a
“primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of
accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or
changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is
not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the
asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.
Fair Value of Financial Instruments
The Company’s short-term financial instruments, including cash, prepaid expenses and other assets, accounts payable and accrued expenses
and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on management’s estimates,
reasonably approximate their book value. The fair value of the Company’s convertible securities is based on management estimates and
reasonably approximates their book value.
Research and development costs
The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10,
Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred.
Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed
when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development
costs related to both present and future products are expensed in the period incurred. The Company incurred research and development
expenses of $547,996 and $992,207 for the years ended December 31, 2014 and 2013, respectively.
Net Income (loss) Per Common Share
The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-
10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding
during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all
potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.
The computation of basic and diluted loss per share as of December 31, 2014 and 2013 excludes potentially dilutive securities when their
inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.
Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:
Series A convertible preferred stock
Series B convertible preferred stock
Series C convertible preferred stock
Options to purchase common stock
Warrants to purchase common stock
Totals
F-9
2014
-
-
1,807,333
5,990,190
5,113,990
12,911,513
2013
501,089
451,726
1,330,627
2,990,977
2,717,258
7,991,667
Table of Contents
Income Taxes
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for
income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis
of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled.
Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests
that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce
the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the
provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from
income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or
non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences
that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences
are expected to reverse.
Stock Based Compensation
The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For
employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is
generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then
recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.
As of December 31, 2014, the Company had 5,990,190 options outstanding to purchase shares of common stock, of which 3,799,559 were
vested.
As of December 31, 2013, the Company had 2,990,977 options outstanding to purchase shares of common stock, of which 1,675,658 were
vested.
Registration Rights
The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20,
Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the
arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if
exists, to record or adjust the liability to current period operations. On June 23, 2014, the Company filed Form S-1/A became effective with
the Securities and Exchange Commission. As such, the Company determined that payments were due under its registration rights agreement
and therefore accrued $55,620 as interest expense for the liability under the registration rights agreements.
Recent Accounting Pronouncements
There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific
industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.
F-10
Table of Contents
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
NOTE 2 – GOING CONCERN MATTERS
The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the
satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements during the years ended
December 31, 2014 and 2013, the Company incurred net losses attributable to common stockholders of $8,773,399 and $10,101,846,
respectively and used $1,997,072 in cash for operating activities for the year ended December 31, 2014. These factors among others raise
substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time.
The Company's existence is dependent upon management's ability to develop profitable operations. The Company completed financing
subsequent to the date of these financial statements (See Note 16). However additional capital will be needed to continue developing its
products and services and there can be no assurance that the Company's efforts will be successful. There is no assurance that can be given that
management's actions will result in profitable operations or the resolution of its liquidity problems. The accompanying statements do not
include any adjustments that might result should the Company be unable to continue as a going concern.
NOTE 3 – RELATED PARTY TRANSACTIONS
The Company’s President and shareholders have advanced funds to the Company for working capital purposes since the Company’s inception
in February 2009. No formal repayment terms or arrangements exist and the Company is not accruing interest on these advances. The net
amount outstanding at December 31, 2014 and 2013 was $-0- and $30,781, respectively.
On December 31, 2013, as part of a private placement transaction of our common stock and warrants, (i) $228,000 of our outstanding
indebtedness that was due to a related party was converted into 93,061 shares of common stock and a warrant to purchase 46,531 shares of our
common stock; and (ii) we issued to a related party 122,448 shares of our common stock and a warrant to purchase 61,225 shares of our
common stock for a purchase price of $300,000
Accrued interest and expenses due related parties as of December 31, 2014 and 2013 was $40,293 and $123,089, respectively.
During 2014, one of the Company’s board of directors forgave an outstanding obligation of $87,500 for services. Accordingly, the Company
reclassified the liability to equity as donated capital.
During 2014, the Company issued 34,000 shares of its common stock for future services to a board member totaling $85,000 ($2.50 per
share), unrelated to his services as a board member. The fair value of the services is amortized over the service period. As of December 31,
2014, the unamortized portion of $56,667 is included in prepaid expenses in the accompanying balance sheet.
During 2014, the Company issued 26,000 shares of its common stock in settlement of $65,000 debt to a board of directors’ member ($2.50 per
share).
During 2013, in connection with the amendments of the Series C 9% Convertible Preferred stock, the Company issued to Company’s
president and a Director of the Company (Series C holders) an aggregate of 53,830 warrants to purchase the Company’s common stock at
$2.61 per share for five years. See Note 9 below.
The Company has informal compensation and consulting agreements with employees and outside contractors, certain of whom are also
Company stockholders. The Agreements are generally month to month. As of December 31, 2014 and 2013, total due under these agreements
and related expenses were $11,250 and $-0-, respectively.
On January 31, 2014, as part of a private placement transaction of our common stock and warrants, a related party purchased an aggregate of
24,490 shares of common stock and a warrant to purchase 12,246 shares of common stock for an aggregate purchase price of $60,000.
F-11
Table of Contents
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
NOTE 4 – PROPERTY AND EQUIPMENT
Property and equipment as of December 31, 2014 and 2013 is summarized as follows:
Computer equipment
Furniture and fixtures
Subtotal
Less accumulated depreciation
Property and equipment, net
2014
2013
$
$
$
54,900
7,803
62,703
(49,683)
$
13,020
50,937
7,803
58,740
(33,874)
24,866
Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When
retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net
difference less any amount realized from disposition, is reflected in earnings.
Depreciation expense was $15,809 and $17,059 at December 31, 2014 and 2013, respectively.
NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Accounts payable and accrued expenses at December 31, 2014 and 2013 consist of the following:
Accrued accounting and legal
Accrued reimbursements
Accrued consulting
Accrued research and development expenses
Accrued credit card obligations
Accrued payroll
Accrued liquidated damages
Accrued office and other
Accrued settlement related to arbitration
2014
2013
$
$
190,767
26,792
16,334
93,407
13,278
62,068
55,620
29,093
66,667
554,026
$
$
300,893
17,797
214,481
64,670
20,425
35,896
48,668
16,500
100,000
819,330
NOTE 6 – NOTES PAYABLE, RELATED PARTY
On November 21, 2012, the Company issued an unsecured promissory note for $218,000 to the Company’s President for previously advanced
funds with interest payable annually, in arrears, on each anniversary at the short term “Applicable Federal Rate” within the meaning of
Section 1274(d) of the Internal Revenue Code of 1986, as amended adjusted each anniversary date. The promissory note matures November
21, 2021 and may be prepaid, without premium or penalty, at any time.
In connection with the issuance of the unsecured promissory note, the Company’s President agreed not to receive payments (by voluntary
prepayment, acceleration, set-off or otherwise) associated with the unsecured promissory note absent the prior written consent of the
purchasers holding at least 67% interest of the preferred stock outstanding, which purchasers must include Alpha Capital Anstalt so long as
Alpha Capital Anstalt holds not less than $100,000 of preferred stock. On December 31, 2013, the Company converted the promissory note
and accrued interest to 93,061 shares of the Company’s common stock and 46,531 warrants to purchase the Company’s common stock at
$3.67 per share for five years.
F-12
Table of Contents
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
On December 6, 2012, the Company issued an unsecured promissory note for $30,000 to a company under the control of the Company’s
President for previously advanced funds, interest free and due the earlier of (i) the next financing of not less than $300,000; (ii) February 28,
2013 or (iii) occurrence of an event of default, as defined.
During year ended December 31, 2013, the Company paid off the promissory note in full.
NOTE 7 – CONVERTIBLE BRIDGE NOTES
In 2012, the Company issued an aggregate of $600,000 unsecured Senior Convertible Promissory Notes ($225,000 related party) with interest
due at maturity at 8% per annum and may be paid, at the Company’s discretion, in cash or the Company’s common stock. The Notes, together
with unpaid accrued interest, if any, is due upon written notice by the majority in interest of the holders on or after February 15, 2014 or (ii)
upon the occurrence of an event of default, as defined. The Notes may be prepaid in whole or in part prior to the maturity date at the
Company’s discretion.
The Convertible Bridge Notes and any accrued and unpaid interest automatically converts at the earlier of (i) (A) a completion of a
transaction whereby the Company merges or consolidates with another company that has its common stock approved for quotation on any
domestic national stock exchange and (B) the new entity thereafter issues and sells shares for no less than $3.0 million aggregate gross
proceeds or (ii) a qualified IPO. The Convertible Bridge Notes shall convert into the new securities issued at 95% of the purchase price of the
Conversion Securities offered to investors.
In connection with the issuance of the Senior Convertible Promissory Notes, the Company issued the right to purchase at any time, on or after
the Public Financing Closing Date,(as defined above) hereof until the fifth anniversary of the Public Financing Closing date, the number of
fully paid and nonassessable shares (the “Warrant Shares”) of the Company’s common stock equal to the quotient of (a) the Warrant
Coverage Amount (as defined below), divided by (b) the applicable Conversion Price of the Notes, at the per share exercise price (the
“Exercise Price”), which shall initially be, as of the Public Financing Closing Date, equal to the Initial Exercise Price (as defined below),
subject to further adjustments, as defined.
Initial Exercise Price” means one hundred twenty-five percent (125%) of the Conversion Price.
Warrant Coverage Amount ” shall be the amount obtained by multiplying (x) the Warrant Coverage Percentage by (y) the principal amount
outstanding (and not including any accrued and unpaid interest) of the Note, in connection with which this Warrant is concurrently issued.
“Warrant Coverage Percentage” shall be equal to fifty percent (50%) as defined in the Bridge Loan Agreement.
On February 6, 2013, the Convertible Bridge Notes and the above described contingent warrants previously issued as described above were
converted into 600 shares of Series C Convertible Preferred Stock and an aggregate of 287,082 warrants to purchase the Company’s common
stock at an exercise price of $2.09 per share for 5 years. On August 7, 2013, the Company issued an aggregate of 8,941 shares of its common
stock in settlement of accrued interest of $18,677.
NOTE 8 – REDEEMABLE PREFERRED STOCK
Series A Preferred Stock
In May 2011, the Board of Directors authorized the issuance of up to 200 shares of Series A Preferred Stock (the “Series A preferred stock”).
The Series A preferred stock is entitled to preference over holders of junior stock upon liquidation in the amount of $5,000 plus any accrued
and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 5% per annum of the Stated Value of $5,000
per share, payable quarterly beginning on August 31, 2011 and are cumulative. The holders of Series A preferred stock have no voting rights,
however without the affirmative vote of all the holders of then outstanding shares of the Series A preferred stock, the Company cannot, (a)
alter or change adversely the powers, preferences or rights given to the Series A preferred stock or alter or amend the Certificate of
Designation.
F-13
Table of Contents
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
The Series A preferred stock is mandatorily redeemable on December 31, 2014 (as modified) at a price equal to the Stated Value ($5,000) plus
an amount equal to all accumulated and unpaid dividends. If the Company fails to redeem at redemption, the unpaid redemption price will
accrue at 14% per annum until paid.
The Series A preferred stock is convertible (as amended), automatically, inclusive of any accrued and unpaid dividends, immediately into the
Company’s common stock upon the Company becoming subject to the reporting requirements under Section 13 or 15(d) of the Securities and
Exchange Act of 1934, as amended at conversion price of $1.84 per share.
On February 6, 2013, in connection with the amendment to the Series A preferred stock defining the conversion feature, the Company
reclassified the associated financing costs as a debt discount against the carrying value of the preferred stock.
As of December 31, 2013, 184.4 shares of Series A preferred stock were issued and outstanding with accrued dividends of $119,355 payable
on the Series A preferred stock.
On June 23, 2014, upon the effectiveness of the Company’s registration statement, the Company issued an aggregate of 577,901 shares of its
common stock in exchange for all the outstanding Series A preferred stock and accrued dividends of $141,331.
Series B Preferred Stock
On November 28, 2011, the Board of Directors authorized the issuance of up to 600 shares of Series B Preferred Stock (the “Series B
preferred stock”).
The Series B preferred stock is entitled to preference over holders of junior stock upon liquidation in the amount of $5,000 plus any accrued
and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 5% per annum of the Stated Value of $5,000
per share, payable quarterly beginning on December 31, 2011 and are cumulative. The holders of Series B preferred stock have no voting
rights, however without the affirmative vote of all the holders of then outstanding shares of the Series B preferred stock, the Company cannot
(a) alter or change adversely the powers, preferences or rights given to the Series A preferred stock or alter or amend the Certificate of
Designation.
The Series B preferred stock is mandatorily redeemable on December 31, 2014 at a price equal to the Stated Value ($5,000) plus an amount
equal to all accumulated and unpaid dividends. If the Company fails to redeem at redemption, the unpaid redemption price will accrue at
14% per annum until paid.
The Series B preferred stock is convertible (as amended), automatically, inclusive of any accrued and unpaid dividends, immediately into the
Company’s common stock upon the Company becoming subject to the reporting requirements under Section 13 or 15(d) of the Securities and
Exchange Act of 1934, as amended at conversion price of $2.02 per share.
On February 6, 2013, in connection with the amendment to the Series B preferred stock defining the conversion feature, the Company
reclassified the associated financing costs as a debt discount against the carrying value of the preferred stock.
As of December 31, 2013, 177.5 shares of Series B preferred stock were issued and outstanding. With accrued dividends of $88,872 payable
on the Series B preferred stock.
On June 23, 2014, upon the effectiveness of the Company’s registration statement, the Company issued an aggregate of 493,818 shares of its
common stock in exchange for all the outstanding Series B preferred stock and accrued dividends of $110,026.
F-14
Table of Contents
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
NOTE 9 – SERIES C 9% CONVERTIBLE PREFERRED STOCK
On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of Series C Convertible Preferred Stock (the “Series
C Convertible Preferred Stock”).
The Series C convertible preferred stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus
any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the Stated
Value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative. The holders of Series C preferred stock
have no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series C preferred stock, the
Company cannot (a) alter or change adversely the powers, preferences or rights given to the Series C preferred stock or alter or amend the
Certificate of Designation.
Each share of Series C preferred stock is convertible, at the holder’s option, inclusive of any accrued and unpaid dividends, at conversion price
of $1.50 (as reset).
If, at any time while the Series C preferred stock is outstanding, the Company sells or grants any option to purchase or sells or grants any right
to re-price, or otherwise disposes of or issues any common stock or common stock equivalents entitling any Person to acquire shares of
Common Stock at an effective price per share that is lower than the then conversion price (“Base Conversion Price”), then the conversion
price shall be reduced to equal the Base Conversion Price. Such adjustment shall be made whenever such Common Stock or Common Stock
Equivalents are issued. During the year ended December 31, 2014, the resets provisions as described above resulted in the conversion price
reset to $1.50.
The Series C preferred stock contains triggering events which would require redemption at (i) the greater of 120% of the stated value of
$1,000 or the product of the variable weighted average price of the Company’s common stock on the trading day immediately preceding the
date of the triggering event and the stated value divided by the then conversion price or (ii) either (a) redeem each Series C preferred share for
a redemption price, in shares of the Company’s common stock, equal to a number of shares equal to the (i) above divided by 75%. The
Company determined that certain of the defined triggering events were outside the Company’s control and therefore classified the Series C
preferred stock outside of equity.
In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the
Company’s common stock at $2.61 per share expiring five years from the initial exercise date. The warrant provides if, at any time while the
warrant is outstanding, the Company sells or grants any option to purchase or sells or grants any right to re-price, or otherwise disposes of or
issues any common stock or common stock equivalents entitling any person to acquire shares of common stock at an effective price per share
that is lower than the then conversion price (“base conversion price”), then the warrants outstanding will be subject anti-dilution provisions.
Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued. In addition, the warrants provides
for at any time after the six month anniversary of the initial exercise date, there is no effective registration statement registering, or no
current prospectus available for the resale of the warrant shares by the holder, then the warrant may only be exercised, in whole or in part, at
such time by means of a “cashless exercise” in which the holder shall be entitled to receive a number of Warrant Shares equal to defined
formula. During the year ended December 31, 2014, the resets provisions as described above resulted in an additional 984,674 warrants
issued with an exercise price reset to $1.50 all Series C warrants..
In accordance with ASC 470-20, the Company recognized an embedded beneficial conversion feature present in the Series C preferred stock
when it was issued. The Company allocated the net proceeds between the intrinsic value of the conversion option ($1,303,671) and the
warrants ($1,064,739) to additional paid-in capital. The aggregate debt discount, comprised of the relative intrinsic value the conversion
option ($1,303,671), relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590); total of $2,781,000, is amortized over
one year as interest expense, the date a possible redemption feature, outside of the Company’s control, would be available to the Series C
stockholders.
F-15
Table of Contents
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
The Company valued the warrants in accordance with ASC 470-20 using the Black-Scholes pricing model and the following assumptions:
contractual terms of 5 years, an average risk free interest rate of 0.39% to 1.40%, a dividend yield of 0%, and volatility of 123.41% to
125.33%.
During the month of February 2013, the holders of the Convertible Bridge Notes (See Note 7) converted into 600 shares of the Company’s
Series C 9% Convertible Preferred Stock.
During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company’s Series C 9%
Convertible Preferred Stock for net proceeds of $1,814,910.
During October 2014, the Company issued an aggregate of 59,267 shares of its commons stock in exchange for 70 shares of the Company’s
Series C 9% Convertible Preferred Stock and accrued dividends.
The Company determined that the anti-dilutive provisions embedded in the Series C 9% Convertible Preferred Stock and related issued
warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not
meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required. As of
December 31, 2014, the Company’ s common stock was thinly traded and there was no active trading market.
Series C preferred stock outstanding totaled 2,711 and 2,781 as of December 31, 2014 and 2013. As of December 31, 2014 and 2013, the
Company has accrued $445,069 and $206,740 dividends payable on the Series C preferred stock.
Registration Rights Agreement
The Company entered into a Registration Rights Agreement in connection with the sale and issuance of the Series C preferred stock. The
Company is required to file a registration statement registering for resale the (a) common stock issuable upon conversion in full of the
Preferred Stock (assuming on such date the shares of Preferred Stock are converted in full without regard to any conversion limitations
therein), (b) all shares of Common Stock issuable as dividends and “Make-Whole Payments” (as defined in the Certificate of Designation) on
the Preferred Stock assuming all dividend and Make-Whole Payments are made in shares of Common Stock and the Preferred Stock is held
for at least 3 years, (c) all warrant shares then issuable upon exercise of the Warrants (assuming on such date the warrants are exercised in full
without regard to any exercise limitations therein), (d) any additional shares of Common Stock issuable in connection with any anti-dilution
provisions in the Preferred Stock or the Warrants (in each case, without giving effect to any limitations on conversion set forth in the
Certificate of Designation or limitations on exercise set forth in the Warrants) and (e) any securities issued or then issuable upon any stock
split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. The Company is required to file a
registration statement and must be declared effective no later than 210 days from the date of termination of the sale the Series C preferred
stock.
The Company is required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under
the registration statement have been sold or are otherwise able to be sold. If the Company fails to comply with the registration statement
effective date requirements, the Company is required to pay the investors a fee equal to 0.25% of the Purchaser’s investment, for each 30-day
period of delay, subject to a maximum payment of 3% to each Purchaser.
On June 23 2014, the Company became effective and met its required filing requirement. The Company did not meet the effectiveness
obligation by November 22, 2013. As a result, the Company accrued $55,620 as interest expense for liquidating damages due under the
registration rights agreement.
F-16
Table of Contents
NOTE 10 – STOCKHOLDER EQUITY
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
There is not a viable market for the Company’s common stock to determine its fair value; therefore, management is required to estimate the
fair value to be utilized in the determining stock based compensation costs. In estimating the fair value, management considers recent sales of
its common stock to independent qualified investors, placement agents’ assessments of the underlying common shares relating to our sale of
preferred stock and validation by independent fair value experts. Considerable management judgment is necessary to estimate the fair
value. Accordingly, actual results could vary significantly from management’s estimates.
Preferred stock
The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of December 31, 2014 and 2013, the Company
has designated and issued 200 and 184.4 shares of Series A preferred stock, respectively, designated and issued 600 and 177.5 shares of Series
B preferred stock, respectively. See Note 8.
As of December 31, 2014 and 2013, the Company designated and issued 4,200 and 2,781 shares of Series C 9% convertible preferred stock,
respectively. See Note 9.
On June 23, 2014, the Company issued an aggregate of 577,901 and 493,818 shares of its common stock in exchange of all the issued and
outstanding Series A and Series B preferred stock.
During December 2014, the Company issued an aggregate of 59,267 shares of its commons stock in exchange for 70 shares of the
Company’s Series C 9% Convertible Preferred Stock and accrued dividends.
Common stock
The Company is authorized to issue 50,000,000 shares of $0.001 par value common stock. As of December 31, 2014 and 2013, the Company
has 11,179,266 and 8,412,101 shares issued and outstanding, respectively.
During the year ended December 31, 2013, the Company issued an aggregate of 21,412 shares of common stock for services rendered totaling
$44,751 ($2.09 per share).
During the year ended December 31, 2013, the Company issued an aggregate of 122,449 shares of common stock for cash rendered totaling
$247,174 ($2.45 per share).
During the year ended December 31, 2014, the Company issued 654,000 shares of its common stock (net of shares exchanged) under the
terms of its 2012 Equity Plan for services rendered totaling $1,635,000 ($2.50 per share).
During the year ended December 31, 2014, the Company issued 26,000 shares of its common stock in settlement of $65,000 related party debt
($2.50 per share).
During the year ended December 31, 2014, the Company entered into a securities purchase agreement with investors pursuant to which the
Company issued 956,179 shares of common stock and five-year warrants for aggregate net proceeds of $1,969,410.
Stock based payable
The Company is obligated to issue an aggregate of 417,500 shares of its common stock to consultants for past and future services. The
estimated liability as of December 31, 2014 of $226,305 ($2.50 per share) was determined based on services rendered in 2014.
F-17
Table of Contents
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
NOTE 11 – OPTIONS AND WARRANTS
There is not a viable market for the Company’s common stock to determine its fair value, therefore management is required to estimate the fair
value to be utilized in the determining stock based compensation costs. In estimating the fair value, management considers recent sales of its
common stock to independent qualified investors, placement agents’ assessments of the underlying common shares relating to our sale of
preferred stock and validation by independent fair value experts. Considerable management judgment is necessary to estimate the fair
value. Accordingly, actual results could vary significantly from management’s estimates
On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “2012 Plan) and terminated the Long-
Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 8,806,123,( as amended) shares of the
Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the
Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory
options. The Board of Directors of the Company determines the exercise price, vesting and expiration period of the grants under the Plan.
However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the
grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is
determined based on quoted market price or in absence of such quoted market price, by the Board of Directors in good faith.
Additionally, the vesting period of the grants under the Plan will be determined by the Committee, in its sole discretion, and expiration period
not more than ten years. The Company reserved 1,250,000 shares of its common stock for future issuance under the terms of the Plan.
During the year ended December 31, 2014, the Company granted an aggregate of 3,478,498 options and 654,000 stock grants (net of shares
exchanged) to officers, directors and key consultants.
A summary of the stock option activity and related information for the 2012 Plan for the year ended December 31, 2014 and 2013 is as
follows:
Weighted-
Average
Outstanding at January 1, 2013
Grants
Exercised
Canceled
Outstanding at December 31, 2013
Grants
Exercised
Canceled
Outstanding at December 31,2014
Vested and expected to vest at December 31, 2014
Exercisable at December 31, 2014
Weighted-
Average
Shares
1,298,927 $
1,692,050
Exercise Price
2.04
2.09
Remaining
Contractual
Term
Aggregate
Intrinsic Value
-
-
6.85
7.00
2,990,977 $
3,478,498 $
-
(479,285)
5,990,190 $
5,990,190 $
3,799,559 $
2.05
2.39
(2.00)
2.25
2.25
2.24
6.02 $
8.10 $
-
-
6.65 $
3,267,692
6.65 $
5.91 $
3,267,692
2,111,368
The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less
than the Company’s estimated market stock price of $2.80 as of December 31, 2014, which would have been received by the option holders
had those option holders exercised their options as of that date.
F-18
Table of Contents
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated
using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until
sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be
a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-
employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used
for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied
yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. The fair value of stock-
based payment awards during the years ended December 31, 2014 and 2014 was estimated using the Black-Scholes pricing model.
In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In
estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the
number of vested options as a percentage of total options outstanding.
If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future,
the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.
The Company estimated forfeitures related to option grants at a weighted average annual rate of 0% per year, as the Company does not yet
have adequate historical data, for options granted during the years ended December 31, 2014 and 2013.
During the year ended December 31, 2013, the Company granted an aggregate of 1,692,050 options to purchase the Company stock in
connection with the services rendered at the exercise price of $2.09 per share for a term of seven to ten years with 1,095,000 vesting
immediately, 145,833 vesting over three months, 30,000 vesting over nine months, 283,300 options vesting at ratably over one year and
137,917 vesting over two years.
The fair value of the granted options for year ended December 31, 2013 was determined using the Black Scholes option pricing model with
the following assumptions:
Dividend yield:
Volatility
Risk free rate:
Expected life:
Estimated fair value of the Company’s common stock
-0-%
110.70% to
115.03%
1.07% to 3.04%
7 to 10 years
$2.09
The following assumptions were used in determining the fair value of options during the year ended December 31, 2014:
Dividend yield:
Volatility
Risk free rate:
Expected life:
Estimated fair value of the Company’s common stock
-0-%
119.43% to
129.88%
0.48% to 2.53%
7 to 10 years
$2.21 to $2.50
In July 2014, the Company awarded 1,265,769 of stock options to Company’s Chief Executive Officer. The stock options have exercise
price of $2.21 per share, with 45,206 options vesting immediately and 497,267 options vesting quarterly over a two year period with the
remainder contingent on performance, and have an approximate fair value of $2,383,443 using the Black Scholes model.
F-19
Table of Contents
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
In September 2014, the Company awarded an aggregate of 880,000 of stock options to certain employees and key consultants. The stock
options have exercise price of $2.50 per share, with 605,000 vested immediately, 125,000 in one year and 150,000 over a two year period, and
have an approximate fair value of $1,753,616 using the Black Scholes model.
In September 2014, the Company canceled an aggregate of 479,285 previously issued, unvested (contingent) options issued in July 2012 at an
exercise price of $2.00 per share to a board member in exchange for issuance of 479,285 options at an exercise price of $2.50, vesting quarterly
over two years and expiring 7 years from the date of issuance. The greater of the approximate fair value of the options exchanged of $981,798
was determined using the Black Scholes option model.
In October 2014, the Company awarded an aggregate of 853,444 stock options to certain employees and a key consultant. The stock options
have an exercise price of $2.50 per share with 841,777 vested immediately and a remainder of 11,667 based on future performance
conditions, and have an approximate fair value of $1,339,151.
In October 2014, one of the Company’s board of directors exchanged 125,000 common shares issued in September 2014 for services and debt
repayment for 163,444 stock options. The stock options have an exercise price of $2.50, vesting immediately. The approximate fair value of
the exchange was determined to be the same.
The following table presents information related to stock options at December 31, 2014:
Options Outstanding
Options Exercisable
Exercise
Price
Number of
Options
$
1.01-2.00
2.01-2.50
819,642
5,170,548
5,990,190
Weighted
Average
Remaining Life
In Years
Exercisable
Number of
Options
4.7
7.0
6.7
526,642
3,272,917
3,799,559
The fair value of all options vesting during the year ended December 31, 2014 and 2013 of $4,193,425 and $3,247,187, respectively, was
charged to current period operations. Unrecognized compensation expense of $3,778,589 and $862,066 at December 31, 2014 and 2013,
respectively, will be expensed in future periods.
Warrants
The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which
were exercisable, at December 31, 2014:
Exercise
Price
Number
Outstanding
$
$
$
$
$
$
$
$
0.001
1.50
1.84
2.02
2.50
2.75
3.67
3.75
383,320
3,721,518
35,076
30,755
204,840
228,720
218,275
291,486
5,113,990
Expiration
Date
January 2020
February 2018 to September 2018
January 2020
January 2020
July 2015
August 2019 to September 2019
December 2018 to January 2019
April 2019 to March 2020
On January 13, 2013, the Company issued an aggregate of 65,831 warrants to purchase the Company stock in connection with the placement
services at the exercise prices of $1.84 (35,076 warrants) and $2.02 (30,775 warrants) per share for a term of five years exercisable
immediately.
F-20
Table of Contents
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
The fair value of the issued warrants were determined using the Black Scholes option pricing model with the following assumptions:
Dividend yield:
Volatility
Risk free rate:
Expected life:
Estimated fair value of the Company’s common stock
-0-%
123.30%
0.72%
5 years
2.09
$
The fair value of $115,854 was charged to operations ratably as financing costs through December 31, 2014.
During the year ended December 31, 2013, the Company issued an aggregate of 1,516,386 warrants to purchase the Company stock in
connection with the sale of the Series C 9% Convertible Preferred Stock at the exercise price of $2.61 per share for a term of five years
exercisable immediately.
During the months of July and September, 2013, the Company issued an aggregate of 622,414 warrants to purchase the Company’s stock to
holders of Series C preferred stock as an inducement to amend and waive certain defined provisions of the Series C preferred stock.
The fair value of the issued warrants were determined using the Black Scholes option pricing model with the following assumptions:
Dividend yield:
Volatility
Risk free rate:
Expected life:
Estimated fair value of the Company’s common stock
-0-%
125.33%
1.40%
5 years
2.09
$
During the year ended December 31, 2013, the fair value of $1,074,833 was charged to current period operations
On December 31, 2013, the Company issued an aggregate of 129,307 warrants to purchase the Company’s common stock at $3.67 per share
for five years in connection with the sale of the Company’s common stock.
On January 31, 2014, the Company issued an aggregate of 64,626 warrants to purchase the Company’s common stock at $3.67 per share for
five years in connection with the sale of the Company’s common stock.
In February 2014, as described in the terms of the warrants issued in connection with the sale of the Series C preferred stock, the Company
reset 2,138,800 previously issued warrants from a exercise price of $2.61 per share to $1.50. In addition, the Company was required to
increase the number of issued warrants to an aggregate total of 3,721,518 warrants.
In April 2014, the Company issued an aggregate of 137,856 warrants to purchase the Company’s common stock at $3.75 per share for five
years in connection with the sale of the Company’s common stock.
In August 2014, the Company issued an aggregate of 135,120 warrants to purchase the Company’s common stock at $2.75 per share for five
years in connection with the sale of the Company’s common stock.
In September 2014, the Company issued an aggregate of 93,600 warrants to purchase the Company’s common stock at $2.75 per share for five
years in connection with the sale of the Company’s common stock.
In December 2014, the Company issued an aggregate of 358,470 warrants to purchase the Company’s common stock in connection with the
sale of the Company’s common stock. Of the aggregate issued, 204,840 warrants are exercisable at $2.50 expiring six months from the date of
issuance and 153,630 warrants exercisable at $3.75 per share expiring March 31, 2020.
F-21
Table of Contents
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
A summary of the warrant activity for the years ended December 31, 2014 and 2013 is as follows:
Weighted-
Average
Outstanding at January 1, 2013
Grants
Exercised
Canceled
Outstanding at December 31, 2013
Grants
Exercised
Canceled
Outstanding at December 31,2014
Vested and expected to vest at December 31, 2014
Exercisable at December 31, 2014
Weighted-
Average
Shares
Exercise Price
- $
2,717,258
-
2.28
Remaining
Contractual
Term
Aggregate
Intrinsic Value
-
-
-
7.00
2,717,258 $
2,396,732 $
-
-
5,113,990 $
5,113,990 $
5,113,990 $
2.28
4.64
-
1.71
1.71
1.71
6.02 $
2.05 $
-
-
3.6 $
6,041,436
3.6 $
3.6 $
6,041,436
6,041,436
The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less
than the Company’s estimated market stock price of $2.80 as of December 31, 2014, which would have been received by the option holders
had those option holders exercised their options as of that date.
NOTE 12 – FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company follows the provisions of ASC 825-10. For financial assets and liabilities included within the scope of ASC 825-10, the
Company was required to adopt the provisions of ASC 825-10 prospectively as of the beginning of Fiscal 2009. The adoption of ASC 825-10
did not have a material impact on our consolidated financial position or results of operations.
The Company determined that the anti-dilutive provisions embedded in the Series C 9% Convertible Preferred Stock and related issued
warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not
meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required. As of
December 31, 2014, the Company’ s common stock was thinly traded and there was no active trading market.
The Company determined that there were no items required to be measured at fair value on a recurring basis in the consolidated financial
statements as of December 31, 2014 and 2013.
F-22
Table of Contents
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
NOTE 13 – COMMITMENTS AND CONTINGENCIES
Operating leases
On May 31, 2014, the Company extended its expiring three-year lease for office space in Los Angeles, California for one additional year, with
monthly payments of $6,530 beginning September 1, 2014.
Employment agreements
On July 14, 2014, the Company’s Board Of Directors (the “Board”) increased the size of the Board to eight members and appointed Gregory
D. Cash and Patrick J. Gallagher as members of the Board, effective as of July 15, 2014, to serve for a term expiring at the Company’s 2015
annual meeting of stockholders. In addition, the Board appointed Mr. Cash to serve as the Company’s president and chief executive officer.
In connection with the appointment of Mr. Cash, on July 15, 2014 (the “Effective Date”), the Company entered into an employment
agreement with Mr. Cash (the “Employment Agreement”). The Employment Agreement has an initial term of three years that expires on July
15, 2017. Under the Employment Agreement, Mr. Cash is entitled to an annual base salary of $275,000. Upon the Company closing an equity
or equity-linked financing with proceeds to the Company of at least $3.5 million (a “Qualified Financing”), Mr. Cash’s annual base salary will
automatically increase to $325,000 and he will receive (i) a one-time payment equal to the difference between the amount he would have
earned if his base salary was $325,000 and the amount he actually earned at his base salary of $275,000 for the time period from the Effective
Date until the closing of such Qualified Financing and (ii) a one-time cash bonus of $30,000. If the Company does not complete a Qualified
Financing within six months after the Effective Date, Mr. Cash’s annual base salary will nonetheless increase to $325,000 and he will receive
the same one-time payment unless the Company reasonably determines that the failure to complete such Qualified Financing was within the
reasonable control of Mr. Cash. Mr. Cash is also eligible to receive an annual bonus equal to at least 50% of the sum of his base salary and
one-time payment, based on the achievement of reasonable performance criteria to be determined by the Board in consultation with Mr. Cash
within 90 days of the Effective Date.
In accordance with the Employment Agreement, on July 15, 2014, the Company granted Mr. Cash an incentive stock option to purchase
1,265,769 shares of the Company’s common stock, made pursuant to an Incentive Stock Option Agreement. The option has an exercise price
of $2.21, which was the fair market value of the Company’s common stock on the date of grant, and a term that expires ten years from the
date of grant. The option will vest as follows (i) 542,473 shares of common stock will vest in eleven equal installments of 45,206 shares of
common stock and one final installment of 45,207 shares of common stock on a quarterly basis with the first installment vesting on the
Effective Date and subsequent installments vesting every three months thereafter; (ii) 180,824 shares of common stock will vest immediately
upon completion of a Qualified Financing; (iii) 180,824 shares of common stock will vest upon the listing of the Company’s common stock on
a recognized U.S. national securities exchange (i.e., NYSE, MKT LLC, The Nasdaq Stock Market LLC or the New York Stock Exchange);
(iv) 180,824 shares of common stock will vest upon the 510(k) clearance or any other type of clearance deemed necessary by the U.S. Food
and Drug Administration of the Company’s PURE (Precise Uninterrupted Real-time evaluations of Electrograms) EP technology platform;
and (v) 180,824 shares of common stock will vest upon the Company achieving a market capitalization of $150,000,000 and maintaining such
market capitalization for at least 90 consecutive calendar days.
Litigation
On January 7, 2014, David Drachman, the Company’s former chief executive officer and president, filed a statement of claim against the
Company with the American Arbitration Association with respect to his resignation from his positions with us in November 2013. Mr.
Drachman alleges, among other things, that (i) the Company misled him with respect to the status of our technology and required him to
perform capital raising duties that had not been previously agreed upon, (ii) he resigned from his positions with us for good reason, as such
term was defined in his employment agreement with the Company, and (iii) he, in his individual capacity, has full rights to the ownership and
control of a patent application describing a combined ablation and recording unit directed at the use of electrocardiography sensing for control
of radiofrequency renal denervation that we filed with the U.S. Patent and Trademark Office during the time Mr. Drachman served in his
positions with the Company.
F-23
Table of Contents
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
During the year ended December 31, 2014, the Company settled the above claim for $100,000 with payments over six months. As of
December 31, 2014, $66,667 was outstanding.
The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although
occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a
material adverse effect on its financial position, results of operations or liquidity. There was no outstanding litigation as of December 31,
2014.
NOTE 14 – INCOME TAXES
At December 31, 2014, the Company has available for federal income tax purposes a net operating loss carry forward of approximately
$6,800,000, expiring in the year 2034, that may be used to offset future taxable income. The Company has provided a valuation reserve
against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the
Company; it is more likely than not that the benefits will not be realized. Due to possible significant changes in the Company's ownership,
the future use of its existing net operating losses may be limited. All or portion of the remaining valuation allowance may be reduced in
future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits. During the year ended December 31,
2014, the Company has increased the valuation allowance from $1,400,000 to $2,300,000.
We have adopted the provisions of ASC 740-10-25, which provides recognition criteria and a related measurement model for uncertain tax
positions taken or expected to be taken in income tax returns. ASC 740-10-25 requires that a position taken or expected to be taken in a tax
return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax
authorities. Tax position that meet the more likely than not threshold are then measured using a probability weighted approach recognizing
the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company had no tax
positions relating to open income tax returns that were considered to be uncertain.
The Company is required to file income tax returns in the U.S. Federal jurisdiction and in California. The Company is no longer subject to
income tax examinations by tax authorities for tax years ending before December 31, 2010.
The effective rate differs from the statutory rate of 34% for due to the following:
Statutory rate on pre-tax book loss
Stock based compensation
Financing costs
Valuation allowance
2014
2013
(34.00)%
23.0%
2.4%
8.6%
0.00%
(34.00)%
11.70%
2.40%
19.90%
0.00%
The Company’s deferred taxes as of December 31, 2014 and 2013 consist of the following:
Non-Current deferred tax asset:
Net operating loss carry-forwards
Valuation allowance
Net non-current deferred tax asset
2014
2013
$
$
2,300,000 $
(2,300,000)
- $
1,400,000
(1,400,000)
-
F-24
Table of Contents
NOTE 15 – SUBSEQUENT EVENTS
Common stock:
BIOSIG TECHNOLOGIES INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2014
On January 13, 2015, the Company issued 42,334 shares of its Common stock upon conversion of 50 shares of Series C Preferred stock and
accrued dividends.
In January, 2015, the Company issued an aggregate of 302,500 shares of its common stock to consultants for services . See Note 10.
January 2015 Private Placement
On January 23, 2015, the Company entered into a securities purchase agreement with investors, pursuant to which we issued 365,200 shares of
the Company’s our common stock, and "A" warrants expiring July 31, 2015 to purchase 365,200 shares of our common stock for aggregate
cash proceeds of $913,000, and "B" warrants expiring March 21, 2020 to purchase 182,600 shares of our common stock for aggregate net cash
proceeds of $917,480. In connection with the private placement, the Company issued 91,300 warrants to purchase our stock in connection
with the placement services at the exercise price of $3.75 per share expiring March 21, 2020 for investment banking services.
February 2015 Private Placement
On February 10, 2015, the Company entered into a securities purchase agreement with investors, pursuant to which we issued 337,000 shares
of the Company’s common stock, and "A" warrants expiring July 31, 2015 to purchase 337,000 shares of our common stock for aggregate
cash proceeds of $842,500, and "B" warrants expiring March 21, 2020 to purchase 168,500 shares of our common stock for aggregate net cash
proceeds of $731,400. In connection with the private placement, the Company issued 84,250 warrants to purchase our stock in connection
with the placement services at the exercise price of $3.75 per share expiring March 21, 2020 for investment banking services.
F-25
Table of Contents
I T E M 9 – CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURES
None.
ITEM 9A – CONTROLS AND PROCEDURES
(a) Evaluation of disclosure controls and procedures.
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of
our disclosure controls and procedures pursuant to Rules 13a-15 (e) and 15d-15(e) of the Exchange Act as of December 31, 2014, and of the
period covered by this Annual Report on Form 10-K. In designing and evaluating the disclosure controls and procedures, management
recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving
the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource
constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to
their costs.
Based on management’s evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31,
2014, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance
that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and
reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our
management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required
disclosure.
(b) Changes in internal control over financial reporting.
There were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2014
that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
(c) Management’s report on internal control over financial reporting.
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in
Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Management conducted an evaluation of the effectiveness of our internal control over
financial reporting based on the framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission. Based on this evaluation, management concluded that our internal control over financial
reporting was effective as of December 31, 2014.
This annual report does not include an attestation report by Liggett, Vogt & Webb, P.A., our independent registered public
accounting firm regarding internal control over financial reporting. As a smaller reporting company, our management's report was not subject
to attestation by our registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit us to provide
only management's report in this annual report.
ITEM 9B – OTHER INFORMATION
None.
38
Table of Contents
PART III
ITEM 10 – DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The following table sets forth information regarding our executive officers and the members of our board of directors.
Name
Kenneth L. Londoner
Gregory D. Cash
Steve Chaussy
Asher Holzer, Ph.D.
Roy T. Tanaka
Jonathan Steinhouse
Patrick J. Gallagher
Seth H. Z. Fischer
Jeffrey F. O’Donnell, Sr.
Age
47
57
60
65
66
47
50
58
55
Position with the Company
Executive Chairman and Director
President and Chief Executive Officer, Director
Chief Financial Officer
Chief Scientific Advisor and Director
Director
Director
Director
Director
Director
Directors are elected annually and hold office until the next annual meeting of the stockholders of the Company and until their
successors are elected. Officers are elected annually and serve at the discretion of the Board of Directors.
Kenneth L. Londoner. Mr. Londoner has served as our director since February 2009 and as our executive chairman since November
2013. He previously served as our chairman and chief executive officer from February 2009 to September 2013. Mr. Londoner has served as
the managing partner of Endicott Management Partners, LLC, a firm dedicated to assisting emerging growth companies in their corporate
development, since February 2010.From April 2007 to October 2009, he served as executive vice president – corporate business development
and senior director of business development and, from November 2009 to December 2010, he served as a consultant to NewCardio, Inc., a
medical device designer and developer. Mr. Londoner has also served as a director of chatAND Inc. since January 2012. Mr. Londoner is a
co-founder and board member of Safe Ports Holdings, Charleston, South Carolina. Mr. Londoner also served as a director of MedClean
Technologies, Inc. from November 2008 to September 2010. Mr. Londoner was an investment officer and co-manager of the Seligman
Growth Fund, Seligman Capital Fund, and approximately $2 billion of pension assets at J & W Seligman & Co, Inc. in New York from 1991
to 1997. Mr. Londoner graduated from Lafayette College in 1989 with a degree in economics and finance and received his MBA from New
York University’s Leonard N. Stern School of Business in 1994.We believe that Mr. Londoner’s extensive experience in financial and venture
capital matters, as well as his intimate knowledge of our company as its co-founder make him an asset to our board of directors.
Gregory D. Cash. Mr. Cash served as the president, chief executive officer and founder of Argent International LLC, a life sciences
consulting firm, from July 2011 until July 2014. Mr. Cash is currently a member of the board of directors for Acuity Medical International,
Inc. From September 2012 until February 2013, he was also president and chief executive officer of NeuroTherm, Inc., a multinational
company in the interventional pain field. Until June] 2011, Mr. Cash served as president, chief executive officer and director of HeartSine
Technologies, Inc., a start-up company in the automated external defibrillator market. Prior to joining HeartSine Technologies in December
2006, he was President, Vascular Therapy and New Business for Sorin Group based in Milan, Italy and also Senior Vice President, Strategic
Alliances based in Denver, Colorado. From 2002 to 2004, Mr. Cash was the president, chief executive officer and a director of Vasomedical,
Inc., a NASDAQ traded public company. Prior to 2002, he was corporate vice president at Datascope Corporation and president of its wholly
owned subsidiary, InterVascular, Inc., president and chief operating officer of Eminent Technology Partners, Inc. and chief executive officer of
its subsidiary, Eminent Research Systems, vice president and general manager of vascular therapies for the U.S. Surgical Corporation and
spent five years at Boston Scientific Corporation in numerous roles, including vice president of cardiology sales and marketing in Europe. Mr.
Cash began his career at Medtronic, Inc., where he served fourteen years in increasingly senior sales and marketing positions. He currently
serves on a number of advisory boards, including the Concordia Language Villages National Board, the University of Minnesota Office for
Technology Commercialization as well as the French American Chamber of Commerce of Minneapolis/St. Paul. Mr. Cash holds a B.A. in
International Marketing and Business Administration from the College of St. Thomas in St. Paul, Minnesota.
39
Table of Contents
Steve Chaussy. Mr. Chaussy has served as our chief financial officer on a part time basis since May 2011. Since 2005, Mr. Chaussy
has been the sole proprietor of Anna & Co., Inc., a consulting company that offers services to small publicly traded companies. Anna & Co.,
Inc. provides general financial and accounting services, with a special emphasis towards SEC reporting and compliance, to companies that lack
sufficient resources to hire full-time employees to provide such services. From 2001 to 2005, Mr. Chaussy provided services as both a chief
financial officer and as a consultant to small publicly traded companies. Prior to 2001, Mr. Chaussy served as chief financial officer for a large
private distribution and wholesaling company, where he gained international experience. Mr. Chaussy is a graduate of Virginia Polytechnic
Institute and State University and is a licensed certified public accountant in Virginia, California and Florida.
Asher Holzer, Ph.D. Dr. Holzer has served as our chief scientific officer and our director since September 2012. Dr. Holzer serves
as a director of InspireMD, Inc., an Israeli-based developer of a new stent platform, and served as that company’s president from March 2011
until June 2012 and chairman from March 2011 until November 2011. In addition, Dr. Holzer co-founded InspireMD Ltd., the predecessor
and later wholly-owned subsidiary of InspireMD, Inc., and served as its president and chairman of the board from April 2007 until June 2012.
Previously, Dr. Holzer founded Adar Medical Ltd., an investment firm specializing in medical device startups, and served as its chief
executive officer from 2002 through 2004. Dr. Holzer currently serves on the board of directors of Adar Medical Ltd., O.S.H.-IL The Israeli
Society of Occupational Safety and Health Ltd., Theracoat Ltd., 2to3D Ltd., and S.P. Market Windows Cyprus. Dr. Holzer earned his Ph.D. in
Applied Physics from the Hebrew University. Dr. Holzer is also an inventor and holder of numerous patents. Dr. Holzer brings to the board
his more than 25 years of experience in advanced medical devices, as well as expertise covering a wide range of activities, including product
development, clinical studies, regulatory affairs, market introduction and the financial aspects of the advance medical device business.
Roy T. Tanaka . Mr. Tanaka has served as our director since July 2012. From 2004 until his retirement in September 2008, Mr.
Tanaka served as the worldwide president of Biosense Webster, Inc., a Johnson & Johnson company, a market and technology leader in the
field of electrophysiology. He joined Biosense Webster, Inc. as its U.S. president in 1997. Previously he held a variety of senior management
positions at Sorin Biomedical, Inc., including president and chief executive officer, and leadership roles at CooperVision Surgical and Shiley, a
division of Pfizer, Inc. He currently serves on the boards of directors of Coherex Medical, Inc., Advanced Cardiac Therapeutics Inc., a
company using electrophysiology to develop technology to measure the temperature in a lesion during cardiac ablation procedures, and
VytronUS Inc. In addition, Mr. Tanaka served as a director of Volcano Corporation until May 2014 and Tomo Therapy until its acquisition in
June 2011. Mr. Tanaka brings broad experience in executive leadership in the medical device field. His operational expertise and knowledge
of the regulatory environment, both in the U.S. and globally, also bring a valuable perspective.
Jonathan Steinhouse. Mr. Steinhouse has served as our director since February 2011. Since 2012, Mr. Steinhouse has served as vice
president of sales for Sandlot Solutions in Philadelphia, PA, a health information exchange and analytics software company. From 2008 to
2011, he served as director of healthcare for Oracle Corporation in Philadelphia, PA, where he was responsible for overall sales (acquiring
new, maintaining revenue and growing existing accounts) for direct and the channel sales to hospitals. From 2005 to 2008, he was regional
manager of Concerro Incorporated, where he was responsible for new “software as a service” to increase utilization of internal employee
resources. Mr. Steinhouse brings to the board the experience of a senior sales executive with over 23 years of experience in healthcare
industry.
Patrick J. Gallagher. Mr. Gallagher, MBA, CFA, is an accomplished capital markets executive, advisor, and investor with a
distinguished record of success in both the public and private markets. He has nearly 20 years of experience on Wall Street and extensive
expertise in alternative investments, capital markets, and marketing. Mr. Gallagher serves as a strategic consultant for Kinex
Pharmaceuticals, LLC, a biotechnology firm focused on next-generation therapies in oncology and immunology and was the vice president
of business development and investor relations from September 2012 to October 2013. In November 2010, he was appointed by broker
Concept Capital, a division of Sanders Morris Harris, as a Managing Director and the head of institutional sales. In 2001, Mr. Gallagher co-
founded BDR Research Group, LLC, an independent sell-side research firm specializing in healthcare investing, financing and operations,
and served as its chief executive officer until November 2010. Prior to 2001, he held various sales positions at investment and research firms
Kidder Peabody, PaineWebber and New Vernon Associates. Mr. Gallagher is a CFA charter holder, received his MBA from Pennsylvania
State University and holds a B.S. degree in finance from the University of Vermont.
40
Table of Contents
Seth H. Z. Fischer . Mr. Fischer has served as our director since May 2013. Since September 2013, Mr. Fischer has served as the
chief executive officer and director of Vivus, Inc., a biopharmaceutical company focusing on the treatment of obesity, sleep apnea, diabetes
and sexual health. Prior to that, Mr. Fischer served in positions of increasing responsibility with Johnson & Johnson until 2012. Most recently
Mr. Fischer served as Company Group Chairman Johnson & Johnson, Worldwide Franchise Chairman Cordis Corporation from 2008 to 2012,
which included responsibility for Cordis and Biosense Webster Inc., a market and technology leader in the field of electrophysiology.
Previously, he served as Company Group Chairman North America Pharmaceuticals from 2004 to 2007. In this position he had responsibilities
for Ortho-McNeil Pharmaceuticals, Janssen and Scios. Mr. Fischer was a former member of the board of directors of Trius Therapeutics, Inc.
which was acquired by Cubist Pharmaceuticals, now a wholly owned subsidiary of Merck & Co., Inc. We believe that Mr. Fischer’s extensive
executive experience in a major health care company and his specific experience in launching and growing new pharmaceutical products make
him an ideal candidate for our board.
Jeffrey F. O’Donnell, Sr. Mr. O’Donnell was appointed as a director and chairman of the compensation committee in February 2015;
he had previously served as a director of the Company from October 2011 until February 2014. Mr. O’Donnell has extensive experience in the
Healthcare industry, merging a solid, traditional corporate background with emerging growth experience. In July, 2014, Mr. O’Donnell was
named CEO of Trice Medical, Inc., a company he was Chairman of the Board since its founding in December, 2011. Trice is a medical device
start-up developing and commercializing a camera enabled needle for orthopedic diagnostic procedures. In 2008, Mr. O'Donnell started
Embrella Cardiovascular, a medical device startup company which was sold in 2011 to Edwards Lifesciences (EW). Prior to Embrella
Cardiovascular, Mr. O'Donnell served as President and CEO of PhotoMedex (PHMD) from 1999 to 2009. He was the President and CEO of
Radiance Medical Systems (originally Cardiovascular Dynamics) from 1997 to 1999 after serving as its Vice President of Sales and Marketing
from 1995 to 1997. From 1994 to 1995 Mr. O'Donnell held the position of President and CEO of Kensey Nash Corporation (KNSY).
Additionally, he has held several senior sales and marketing management positions at Boston Scientific Corporation, Guidant Corporation and
Johnson & Johnson's Orthopedic Division. In 2005, Mr. O'Donnell was named Life Sciences CEO of the year by Price Waterhouse Coopers.
In 2011, Mr. O'Donnell was named the Greater Philadelphia Emerging Entrepreneur Of The Year by Ernst & Young. Mr. O'Donnell is a
previous director for Cardiac Science (7 yrs) and Endologix (12 yrs). Mr. O’Donnell is also Chairman of the Board of Mela Sciences (MELA).
Family Relationships
There are no family relationships among any of our officers or executive officers.
Section 16(a) Beneficial Ownership Reporting Compliance
We do not have a class of equity securities registered pursuant to Section 12 of the Exchange Act. Accordingly, our directors, officers and
persons who own more than ten percent of our common stock are not required to file with the Securities and Exchange Commission initial
reports of ownership or reports of changes in ownership of our common stock.
Independent Directors
Our board of directors has determined that each of Roy T. Tanaka, Jonathan Steinhouse, Patrick J. Gallagher, Seth H. Z. Fischer, and
Jeffrey F. O’Donnell, Sr. is independent within the meaning of applicable listing rules of the Section 803A(2) of the NYSE MKT Rules and
the rules and regulations promulgated by the Securities and Exchange Commission.
Committees of the Board of Directors
We expect our board of directors, in the future, to appoint an audit committee, nominating committee and compensation committee
and to adopt charters relative to each such committee. We intend to appoint such persons to committees of the board of directors as are
expected to be required to meet the corporate governance requirements imposed by a national securities exchange, although we are not
required to comply with such requirements until we elect to seek a listing on a national securities exchange. In addition, we intend that at
least one of our directors who serves on our audit committee will qualify as an “audit committee financial expert,” within the meaning of
Item 407(d)(5) of Regulation S-K, as promulgated by the Securities and Exchange Commission. We do not currently have an “audit
committee financial expert” since we currently do not have an audit committee in place.
Code of Ethics
We intend to adopt a code of ethics that applies to our officers, directors and employees, including our principal executive officer and
principal accounting officer, but have not done so to date due to our relatively small size. We intend to adopt a written code of ethics in the
near future.
41
Table of Contents
ITEM 11 – EXECUTIVE COMPENSATION
Summary Compensation Table
The following table provides certain summary information concerning compensation awarded to, earned by or paid to (i) Gregory
Cash, our chief executive officer and (ii) Kenneth Londoner, our executive chairman and member of our board and (iii) Steven Chaussy, our
chief financial officer for fiscal years 2014 and 2013.
Name and principal position
Kenneth L. Londoner, Executive Chairman and Director
Gregory D. Cash, President, Chief Executive Officer and
Director
Steven Chaussy, Chief Financial Officer
Year
2014
2013
2014
2013
2014
2013
Salary
($)
Stock Awards
($) (1)
Total
($)
206,913
211,500
1,000,000 (1)
458,400 (2)
1,206,913
669,900
103,126
-
49,500
40,250
2,383,443 (3)
-
500,000 (4)
58,149 (5)
2,486,569
-
549,500
98,399
(1) Represents a common stock award of 400,000 shares granted on September 1, 2014.
(2) Represents a stock option granted January 16, 2013 for the purchase of 250,000 shares of common stock, exercisable immediately,
at an exercise price of $2.09 per share and termination date of January 16, 2020
(3) Represents a stock option granted July 15, 2014 for the purchase of 1,265,769 shares of common stock, 135,618 exercisable
immediately, 406,855 exercisable over two years vesting on a quarterly basis and remainder contingent on performance at $2.21
per share and termination date of July 15, 2024.
(4) Represents a common stock award of 200,000 shares granted on September 1, 2014.
(5) Represents a stock option granted January 16, 2013 for the purchase of 30,000 shares of common stock, exercisable immediately,
at an exercise price of $2.09 per share and termination date of January 16, 2020.
(9) Dr. Drakulic was terminated as our chief technology officer in October 2013, at which time he resigned as a member of our board
of directors. Dr. Drakulic returned to us in November 2013 as a consultant.
42
Table of Contents
Number of
securities to
be issued
upon
exercise of
outstanding
options
(a)
Weighted-
average
exercise
price of
outstanding
options
(b)
Securities remaining
available for future
issuance under equity
compensation plans
(excluding securities
reflected in column (a))
(c)
7,360,190 $
-
7,360,190
2.25
-
2.25
1,445,933
-
1,445,933
Plan category
Equity compensation plans approved by
security holders
Equity compensation plans not
approved by security holders
Total
Agreements with Executive Officers and Change-In-Control Arrangements
Kenneth L. Londoner
We entered into an employment agreement with Kenneth Londoner on March 1, 2013. The employment agreement terminates on
March 1, 2015, after which Mr. Londoner’s employment will be on at-will basis. Mr. Londoner’s annual base salary is $225,000, which will
be paid entirely as salary. Mr. Londoner will also be eligible for annual discretionary bonuses and equity-based incentives, as our board may
determine. Mr. Londoner is subject to non-competition and non-solicitation obligations, whereby, for a period lasting until one year after the
termination of his employment with us, Mr. Londoner is not permitted to, directly or indirectly, (i) in any state in the U.S. or country that we
conduct business and for which Mr. Londoner had responsibility, work for, invest in, provide financing to or establish a business that
competes with our business, other than an exception that permits limited investment in publicly-traded competitors, (ii) solicit business from
or do business with any customer, client, manufacturer or vendor with whom we did business or who we solicited within the preceding two
years, and (iii) solicit, engage or hire any person employed by or who served as a consultant to us within the preceding twelve months. In
September 2013, Mr. Londoner resigned as our chief executive officer, but remained with us in an executive role. In November 2013, Mr.
Londoner became our executive chairman. During this time, Mr. Londoner was and will continue to be, compensated pursuant to his
employment agreement for his contributions with respect to corporate finance, investor relations, and business development.
Prior to entering into his employment agreement, Mr. Londoner was an at-will employee.
Gregory D. Cash
On July 15, 2014, we entered into an employment agreement with Gregory Cash., The employment agreement has an initial term
of three years that expires on July 15, 2017. Under the employment agreement, Mr. Cash is entitled to an annual base salary of $275,000.
Upon the Company closing an equity or equity-linked financing with proceeds to the Company of at least $3.5 million (a “Qualified
Financing”), Mr. Cash’s annual base salary will automatically increase to $325,000 and he will receive (i) a one-time payment equal to the
difference between the amount he would have earned if his base salary was $325,000 and the amount he actually earned at his base salary
of $275,000 for the time period from the Effective Date until the closing of such Qualified Financing and (ii) a one-time cash bonus of
$30,000. If the Company does not complete a Qualified Financing within six months after the Effective Date, Mr. Cash’s annual base
salary will nonetheless increase to $325,000 and he will receive the same one-time payment unless the Company reasonably determines
that the failure to complete such Qualified Financing was within the reasonable control of Mr. Cash. Mr. Cash is also eligible to receive an
annual bonus equal to at least 50% of the sum of his base salary and one-time payment, based on the achievement of reasonable
performance criteria to be determined by the Board in consultation with Mr. Cash within 90 days of the Effective Date.
In accordance with Mr. Cash’s employment agreement, on July 15, 2014, the Company granted Mr. Cash an incentive stock
option to purchase 1,265,769 shares of the Company’s common stock, made pursuant to an Incentive Stock Option Agreement. The option
has an exercise price of $2.21, which was the fair market value of the Company’s common stock on the date of grant, and a term that
expires ten years from the date of grant. The option will vest as follows (i) 542,473 shares of common stock will vest in eleven equal
installments of 45,206 shares of common stock and one final installment of 45,207 shares of common stock on a quarterly basis with the
first installment vesting on the Effective Date and subsequent installments vesting every three months thereafter; (ii) 180,824 shares of
common stock will vest immediately upon completion of a Qualified Financing; (iii) 180,824 shares of common stock will vest upon the
listing of the Company’s common stock on a recognized U.S. national securities exchange (i.e., NYSE, MKT LLC, The Nasdaq Stock
Market LLC or the New York Stock Exchange); (iv) 180,824 shares of common stock will vest upon the 510(k) clearance or any other type
of clearance deemed necessary by the U.S. Food and Drug Administration of the Company’s PURE (Precise Uninterrupted Real-time
evaluations of Electrograms) EP technology platform; and (v) 180,824 shares of common stock will vest upon the Company achieving a
market capitalization of $150,000,000 and maintaining such market capitalization for at least 90 consecutive calendar days.
43
Table of Contents
Outstanding Equity Awards at Fiscal Year End
The following table sets forth information regarding equity awards that have been previously awarded to each of the named
executive officers and which remained outstanding as of December 31, 2014.
Number of
Securities
underlying
Unexercised
Options (#)
Exercisable
Number of
Securities
underlying
Unexercised
Options (#)
Unexercisable
90,412
1,175,357
250,000
30,000
30,000
-
-
-
Name
Gregory
D. Cash
Kenneth
Londoner
Steven
Chaussy
BioSig Technologies, Inc. 2011 Long-Term Incentive Plan
Option
Exercise
Price ($/Sh)
Option Expiration Date
$
$
$
$
2.21
2.09
2.09
2.00
7/15/2024
1/16/2020
1/16/2020
6/11/2023
On October 19, 2011, our board of directors and stockholders adopted and approved the BioSig Technologies, Inc. 2011 Long-Term
Incentive Plan. Under the BioSig Technologies, Inc. 2011 Long-Term Incentive Plan, we reserved 1,500,000 shares of our common stock as
awards to our employees, consultants, and service providers.
The purpose of the BioSig Technologies, Inc. 2011 Long-Term Incentive Plan was to provide an incentive to attract and retain
employees, officers, consultants, directors, and service providers whose services are considered valuable, to encourage a sense of
proprietorship and to stimulate an active interest of such persons in our development and financial success. The BioSig Technologies, Inc.
2011 Long-Term Incentive Plan was administered by our board of directors. On October 19, 2012, our board of directors elected to terminate
the BioSig Technologies, Inc. 2011 Long Term Incentive Plan. We did not grant options to purchase common stock under the BioSig
Technologies, Inc. 2011 Long-Term Incentive Plan to any of our named executive officers:
BioSig Technologies, Inc. 2012 Equity Incentive Plan
On October 19, 2012, our board of directors adopted the BioSig Technologies, Inc. 2012 Equity Incentive Plan, which provides for
the grant of stock options, stock appreciation rights, restricted stock and restricted stock units to employees, directors and consultants, to be
granted from time to time as determined by our board of directors or its designees. In addition, 1,500,000 shares under the BioSig
Technologies, Inc. 2011 Long Term Incentive Plan that were not subject to outstanding stock options or similar awards were rolled into the
BioSig Technologies, Inc. 2012 Equity Incentive Plan. An aggregate of 8,806,123 shares of common stock are reserved for issuance under
the BioSig Technologies, Inc. 2012 Equity Incentive Plan. As of February 12, 2015, the number of options and restricted stock awards
granted the under the BioSig Technologies, Inc. 2012 Equity Incentive Plan are 7,360,190.
44
Table of Contents
Director Compensation
The following table sets forth summary information concerning the total compensation paid to our non-employee directors during
the fiscal year ended December 31, 2014 for services to our company.
Name
Asher Holzer, Ph.D.
Roy T. Tanaka
Jonathan Steinhouse
Seth H. Z. Fischer
Patrick J. Gallagher
Total:
Fees Earned
or Paid in
Cash ($)
$
$
$
$
$
$
Option
Awards ($)
-
-
-
-
-
$
$
$
$
$
$
145,063 (1)
241,772 (2)
338,481 (3)
904,069 (4)
307,269 (5)
1,936,654
$
$
$
$
$
$
Total ($)
145,063
241,772
338,481
904,069
307,269
1,936,654
(1) Represents a stock option granted September 1, 2014 for the purchase of 75,000 shares of common stock, exercisable immediately,
at an exercise price of $2.50 per share and termination date of September 1, 2021.
(2) Represents a stock option granted September 1, 2014 for the purchase of 125,000 shares of common stock, exercisable immediately,
at an exercise price of $2.50 per share and termination date of September 1, 2021.
(3) Represents a stock option granted September 1, 2014 for the purchase of 175,000 shares of common stock, exercisable immediately,
at an exercise price of $2.50 per share and termination date of September 1, 2021.
(4) Represents a stock option granted on September 1, 2014 for the purchase of 150,000 shares of common stock of which 50% vested
on the date of the grant and 50% vest on the first anniversary, at an exercise price of $2.50 per share and termination date of
September 1, 2021; and a stock option granted on October 14, 2014 for 163,444 shares of common stock, exercisable immediately,
at an exercise price of $2.50 per share and termination date of October 14, 2021.
(5) Represents a stock option granted September 1, 2014 for the purchase of 150,000 shares of common stock, vesting over two years
with 50% vesting on the first anniversary and remaining 50% vest monthly over a year period, at an exercise price of $2.50 per
share and termination date of September 1, 2021.
ITEM 12 – SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS
Equity Compensation Plan Information
The following table provides certain information as of December 31, 2014 with respect to our equity compensation plans under which our
equity securities are authorized for issuance:
Number of
securities to
be issued
upon
exercise of
outstanding
options
(a)
7,360,190 $
-
7,360,190
Weighted-
average
exercise
price of
outstanding
options
(b)
Securities remaining
available for future
issuance under equity
compensation plans
(excluding securities
reflected in column (a))
(c)
2.25
-
2.25
1,445,933
-
1,445,933
Equity compensation plans approved by security holders
Equity compensation plans not approved by security holders
Plan category
Total
Security Ownership of Certain Beneficial Owners and Management
The following table sets forth certain information regarding beneficial ownership of our common stock as of February 20, 2015:
· by each person who is known by us to beneficially own more than 5% of our common stock;
· by each of our named executive officers and directors; and
· by all of our named executive officers and directors as a group.
The percentages of common stock beneficially owned are reported on the basis of regulations of the Securities and Exchange
Commission governing the determination of beneficial ownership of securities. Under the rules of the Securities and Exchange Commission,
a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or to
direct the voting of the security, or investment power, which includes the power to dispose of or to direct the disposition of the
security. With respect to the Series C Preferred Stock and warrants held by the beneficial owners listed below, there exist contractual
provisions limiting conversion and exercise to the extent such conversion or exercise would cause such beneficial owner, together with its
affiliates or members of a “group,” to beneficially own a number of shares of common stock which would exceed from 4.99% to 9.99% of
our then outstanding shares of common stock following such conversion or exercise.
45
Table of Contents
The shares and percentage ownership of our outstanding shares indicated in the table below do not give effect to these
limitations. Except as indicated in the footnotes to this table, to our knowledge and subject to community property laws where applicable,
each beneficial owner named in the table below has sole voting and sole investment power with respect to all shares beneficially owned and
each person’s address is c/o BioSig Technologies, Inc., 12424 Wilshire Boulevard, Suite 745, Los Angeles, California 90025.
Name of Beneficial Owner
5% Owners
Miko Consulting Group, Inc. (3)
Alpha Capital Anstalt (4)
Officers and Directors
Kenneth L. Londoner
Asher Holzer, Ph.D.
Gregory D. Cash
Roy T. Tanaka
Jonathan Steinhouse
Seth H. Z. Fischer
Patrick J. Gallagher
Jeffrey F. O’Donnell, Sr.
Steve Chaussy
Number of
Shares
Beneficially
Owned(1)
Percentage of
Common
Stock Owned
(1)(2)
3,392,474
1,808,396(5)
27.75%
13.41%
4,544,314(6)
35.21%
297,000(7)
135,618(8)
544,375(9)
436,133(10)
425,944(11)
-
183,300(12)
293,362(13)
2.38 %
1.10%
4.26%
3.50%
3.37%
*%
1.48%
2.92%
All directors and executive officers as a group (9 persons)
6,676,746
54.22%
* Less than 1%
(1) Shares of common stock beneficially owned and the respective percentages of beneficial ownership of common stock assume the
exercise of all options and other securities convertible into common stock beneficially owned by such person or entity currently
exercisable or exercisable within 60 days of February 12, 2015, except as otherwise noted. Shares issuable pursuant to the exercise of
stock options and other securities convertible into common stock exercisable within 60 days are deemed outstanding and held by the
holder of such options or other securities for computing the percentage of outstanding common stock beneficially owned by such
person, but are not deemed outstanding for computing the percentage of outstanding common stock beneficially owned by any other
person.
(2) These percentages have been calculated based on 12,226,300 shares of common stock outstanding as of February 12, 2015.
(3) Lora Mikolaitis has sole voting and dispositive power over the securities held for the account of this stockholder.
(4) The address for Alpha Capital Anstalt is Pradafant 7, 9490 Furstentums, Vaduz, Lichtenstein. Konrad Ackermann has sole voting and
dispositive power over the securities held for the account of this stockholder.
46
Table of Contents
(5) Comprised of (i) 550,001 shares of common stock, (ii) shares of Series C Preferred Stock that are convertible into 416,667 shares of
common stock, and (iii) warrants to purchase 841,728 shares of common stock. With respect to the Series C Preferred Stock and
warrants, there exist contractual provisions limiting conversion and exercise to the extent such conversion or exercise would cause
Alpha Capital Anstalt, together with its affiliates or members of a “group,” to beneficially own a number of shares of common stock
which would exceed from 4.99% to 9.99% of our then outstanding shares of common stock following such conversion or exercise. The
shares and percentage ownership of our outstanding shares indicated in the table do not give effect to these limitations.
(6) Comprised of (i) 529,711 shares of common stock directly held by Mr. Londoner, (ii) 3,334,974 shares of common stock are held by
Endicott Management Partners, LLC, an entity for which Mr. Londoner is deemed the beneficial owner, (iii) shares of Series C
Preferred Stock that are convertible into 133,334 shares of common stock, (iv) warrants to purchase 296,295 shares of common stock,
and (v) options to purchase 250,000 shares of common stock that are currently exercisable.
(7) Consists of (i) 60,000 shares of common stock, (ii) options to purchase 237,000 shares of common stock that are currently exercisable
or exercisable within 60 days of February 12, 2015.
(8) Comprised of options to purchase 135,618 shares of common stock that are currently exercisable or exercisable within 60 days of
February 12, 2015.
(9) Comprised of options to purchase 544,375 shares of common stock that are currently exercisable or exercisable within 60 days of
February 12, 2015.
(10) Comprised of (i) 215,665 shares of common stock, (ii) options to purchase 175,000 shares of common stock that are currently
exercisable., and (iii) warrants to purchase 45,468 shares of common stock.
(11) Consists of options to purchase 425,944 shares of common stock that are currently exercisable or exercisable within 60 days of
February 12, 2015.
(12) Consists of (i) 87,500 shares of common stock, (ii) options to purchase 95,800 shares of common stock that are currently exercisable.
(13) Consists of (i) 233,362 shares of common stock, (ii) options to purchase 60,000 shares of common stock that are currently exercisable.
ITEM 13 – CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
We entered into an employment agreement with Budimir S. Drakulic, Ph.D. on March 1, 2013. The employment agreement
terminated in October 2013, when Dr. Drakulic’s employment with us was terminated. Pursuant to the employment agreement, Dr.
Drakulic’s annual base salary was $225,000, which was paid partially as salary and partially as consulting fees. Dr. Drakulic was also
eligible for annual discretionary bonuses and equity-based incentives, as our board may have determined. Dr. Drakulic is subject to non-
competition and non-solicitation obligations, whereby, for a period lasting until one year after the termination of such executive officer’s
employment with us, such executive officer is not permitted to, directly or indirectly, (i) in any state in the U.S. or country that we conduct
business and for which such executive officer had responsibility, work for, invest in, provide financing to or establish a business that
competes with our business, other than an exception that permits limited investment in publicly-traded competitors, (ii) solicit business
from or do business with any customer, client, manufacturer or vendor with whom we did business or who we solicited within the
preceding two years, and (iii) solicit, engage or hire any person employed by or who served as a consultant to us within the preceding
twelve months. In November 2013, Dr. Drakulic returned to us as a consultant without an employment agreement.
On December 10, 2010, we entered into a two year consulting agreement with Jonathan Steinhouse, a member of our board of
directors, for certain consulting services in exchange for 43,750 shares of common stock valued at $35,000.
On May 15, 2011, we issued to each of an entity wholly-owned by Mr. Londoner and Miko Consulting Group, Inc., an entity jointly
controlled by Dr. Drakulic and Ms. Mikolaitis, 1,700,000 shares of common stock issued at par value for services rendered as our founders in
2009.
On August 1, 2012, we entered into a consulting agreement with Asher Holzer, Ph.D., a member of our board of directors. Pursuant
to the consulting agreement, Dr. Holzer was to serve as our chief scientific officer and assist in the development of our technology and our
PURE EP System, in exchange for monthly payments of $10,000. We have paid Dr. Holzer an initial payment of $7,500 pursuant to the
consulting agreement. In the first quarter of 2014, we agreed to an oral amendment to our consulting agreement with Dr. Holzer, which
resulted in Dr. Holzer agreeing to receive (i) a payment of $65,000, which will be paid by us upon our closing of a capital raising transaction
that results in proceeds to us of at least $5 million, and (ii) a future option grant to purchase 125,000 shares of our common stock, in exchange
for acknowledging that no other payments are due by us to Dr. Holzer pursuant to the consulting agreement.
47
Table of Contents
On November 21, 2012, we issued an unsecured promissory note for $218,000 to Kenneth L. Londoner, our then chairman and chief
executive officer, for previously advanced funds with interest payable annually, in arrears, on each anniversary at the short term “Applicable
Federal Rate” within the meaning of Section 1274(d) of the Internal Revenue Code of 1986, as amended, which was 0.22% in November
2012, and which will be adjusted each anniversary date. The promissory note matures November 21, 2021 and may be prepaid, without
premium or penalty, at any time. In connection with the private placement of our Series C Preferred Stock and warrants, on February 6, 2013,
Mr. Londoner agreed not to receive payments (by voluntary prepayment, acceleration, set-off or otherwise) associated with the unsecured
promissory note absent the prior written consent of the purchasers holding at least 67% interest of our Series C Preferred Stock outstanding,
which purchasers must include Alpha Capital Anstalt so long as Alpha Capital Anstalt holds not less than $100,000 of our Series C Preferred
Stock. As of June 30, 2013, aggregate interest of $277.19 has accrued on this unsecured promissory note. The unsecured promissory note
was converted into our equity securities, pursuant to a private placement transaction on December 31, 2013, as described below.
On December 6, 2012, we issued an unsecured promissory note for $30,000 to a company under the control of Mr. Londoner for
previously advanced funds, interest free and due the earlier of (i) the next financing of not less than $300,000; (ii) February 28, 2013 or (iii)
occurrence of an event of default, as defined. The promissory note has been paid in full.
In the fourth quarter of 2012, we sold $600,000 principal amount of certain bridge notes and related warrants in a private placement
to selected accredited investors. These bridge notes and related warrants were converted into shares of our Series C Preferred Stock and
warrants on February 6, 2013. Kenneth L. Londoner, our then chairman and chief executive officer, purchased $200,000 principal amount of
notes, which were converted into 200 shares of Series C Preferred Stock and a warrant to purchase 95,694 shares of our common stock, and
Jonathan Steinhouse; a member of our board of directors, purchased $25,000 principal amount of notes, which were converted into 25 shares
of Series C Preferred Stock and a warrant to purchase 11,962 shares of our common stock. We also issued to Mr. Londoner and Mr.
Steinhouse, in lieu of cash payments on the interest accrued on their respective bridge notes, 2,579 and 383 shares of common stock,
respectively. The terms of the Series C Preferred Stock were amended on March 27, 2014 to provide for a decrease of the conversion price of
the Series C Preferred Stock from $2.09 per share to $1.50 per share. As a result of the amendment, the full-ratchet anti-dilution protection
provision of the related warrants decreased the exercise price of the warrants from $2.61 per share to $1.50 per share and increased the number
of shares issuable under each warrant was increased such that the aggregate exercise price payable under such warrant, after taking into
account the decrease in the exercise price, is equal to the aggregate exercise price prior to such adjustment. As such, the number of shares of
common stock issuable upon exercise of the warrants increased to 166,508 shares for Mr. Londoner and 20,814 shares for Mr. Steinhouse. In
addition, in connection w0ith amendments to the terms of the Series C Preferred Stock, we issued to (i) Mr. Londoner warrants to purchase an
aggregate of 83,256 shares of common stock and (ii) Mr. Steinhouse warrants to purchase an aggregate of 10,408 shares of common stock,
which such figures reflecting the triggering of the full-ratchet anti-dilution protection provision of the warrants.
From 2010 to 2013, Mr. Londoner made four different advances of funds to us in the aggregate amount of $22,000, of which $12,000
has been repaid. In the first quarter of 2013, Mr. Steinhouse made an advance of funds to us in the amount of $20,000, which has been repaid
in full. These advances were interest-free and not made on condition of any specific terms. The remaining $10,000 owed to Mr. Londoner
was converted into our equity securities, pursuant to a private placement transaction on December 31, 2013, as described below.
On February 12, 2013, as part of a private placement transaction, we issued to Alpha Capital Anstalt 625 shares of Series C Preferred
Stock and a warrant to purchase 520,335 shares of our common stock for a purchase price of $625,000. In addition, in connection with
amendments to the terms of the Series C Preferred Stock, we issued to Alpha Capital Anstalt warrants to purchase an aggregate of 260,168
shares of common stock. The number of shares of common stock issuable upon exercise of the warrants reflect the triggering of the full-
ratchet anti-dilution protection provision of the warrants.
On May 2, 2013, we entered into an indemnity agreement with Seth H. Z. Fischer in connection with our appointment of Mr. Fischer
to our board of directors. Pursuant to the indemnity agreement, we agreed to indemnify Mr. Fischer for all costs and losses relating to
proceedings arising out of his service on our board of directors, to the fullest extent permitted by applicable law, subject to certain exceptions,
including, but limited to, a final adjudication that Mr. Fischer’s conduct was in bad faith, knowingly fraudulent or deliberately dishonest or
constituted willful misconduct, or a final adjudication that established Mr. Fischer breached his duty of loyalty to us or that his conduct
resulted in illegal personal profits. In addition, we agreed to advance Mr. Fischer expenses when properly requested and we will be entitled to
assume the defense of Mr. Fischer if he requests payment of expenses under the indemnity agreement.
48
Table of Contents
In the fourth quarter of 2013, Steve Chaussy, our chief financial officer, made three different advances of funds to us in the aggregate
amount of $21,545, which was repaid in 2014. Also in the fourth quarter of 2013, Mr. Steinhouse made an advance of funds to us in the
amount of $6,000, which was repaid in 2014. In addition, in the fourth quarter of 2013, Lora Mikolaitis, who controls Miko Consulting
Group, Inc. made an advance of funds to us in the amount of approximately $2,700. These advances were interest-free and not made on
condition of any specific terms. Each of these advances was repaid in full in the first quarter of 2014.
On December 31, 2013, as part of a private placement transaction of our common stock and warrants, (i) $228,000 of our outstanding
indebtedness that was due to Mr. Londoner was converted into 93,061 shares of common stock and a warrant to purchase 46,531 shares of our
common stock; and (ii) we issued to Alpha Capital Anstalt 122,448 shares of our common stock and a warrant to purchase 61,225 shares of
our common stock for a purchase price of $300,000.
On January 31, 2014, as part of a private placement transaction of our common stock and warrants, Mr. Steinhouse purchased an
aggregate of 24,490 shares of common stock and a warrant to purchase 12,246 shares of common stock for an aggregate purchase price of
$60,000.
On March 5, 2014, Mr. Steinhouse made an advance of funds to us in the aggregate amount of $10,000, which was repaid in full on
April 3, 2014. The advance was interest-free and not made on condition of any specific terms.
On September 1, 2014, we entered into a letter agreement and release with Dr. Holzer, a member of the Company’s board of
directors, pursuant to which Dr. Holzer agreed to cancel, extinguish and terminate all amounts due or owed by the Company for services
performed by Dr. Holzer pursuant to that certain consulting agreement, dated as of August 1, 2012, as amended. In connection with the
cancellation of all payment obligations and in exchange for Dr. Holzer waiving and releasing the Company from all possible claims related to
such obligations under the consulting agreement, Dr. Holzer received 26,000 shares of our common stock. Dr. Holzer also agreed to provide
one additional year of consulting services to the Company in exchange for 34,000 shares of common stock.
On November 3, 2014, we entered into a settlement and mutual release agreement with Mr. Drachman, our former chief executive
officer and president. Pursuant to the terms of the settlement agreement, in exchange for Mr. Drachman waiving and releasing us from any
and all claims he may have had against us, we agreed to pay Mr. Drachman an aggregate settlement amount of $100,000.
Director Independence
Our board of directors has determined that each of Roy T. Tanaka, Jonathan Steinhouse, Patrick J. Gallagher, Seth H. Z. Fischer, and
Jeffrey F. O’Donnell, Sr. would be considered independent within the meaning of applicable listing rules of the Section 803A(2) of the
NYSE MKT Rules and the rules and regulations promulgated by the Securities and Exchange Commission.
ITEM 14 – PRINCIPAL ACCOUNTING FEES AND SERVICES
Audit Fees. The aggregate fees billed by our independent registered public accounting firm, for professional services rendered for the
audit of our annual financial statements for the years ended December 31, 2014 and 2013, including review of our interim financial statements
were $54,000 and $12,500, respectively.
Audit Related Fees. We incurred fees to our independent registered public accounting firm of $-0- and $-0- for audit related fees
during the fiscal years ended December 31, 2014 and 2013, respectively, which related to filings with the SEC.
Tax and Other Fees. We incurred fees to our independent registered public accounting firm of $3,500 and $0 for tax and fees during
the fiscal years ended December 31, 2014 and 2013.
The Board of Directors pre-approves all auditing services and all permitted non-auditing services (including the fees and terms
thereof) to be performed by our independent registered public accounting firm.
49
Table of Contents
PART IV
ITEM 15 – EXHIBITS, FINANCIAL STATEMENT SCHEDULES
The following documents are filed as part of this report:
(1) Financial Statements
The following financial statements are included herein:
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of December 31, 2014 and 2013
Consolidated Statements of Operations for the years ended December 31, 2014 and 2013
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2014 and 2013
Consolidated Statements of Cash Flows for the years ended December 31, 2014 and 2013
Notes to Consolidated Financial Statements
(2) Financial Statement Schedules
None.
(3) Exhibits
See Index to Exhibits.
31.01
31.02
32.01
Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002.
101 INS
XBRL Instance Document
101 SCH
XBRL Taxonomy Extension Schema Document
101 CAL
XBRL Taxonomy Calculation Linkbase Document
101 LAB
XBRL Taxonomy Labels Linkbase Document
101 PRE
XBRL Taxonomy Presentation Linkbase Document
101 DEF
XBRL Taxonomy Extension Definition Linkbase Document
50
Table of Contents
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date: February 20, 2015
Date: February 20, 2015
BIOSIG TECHNOLOGIES, INC.
By:
By:
/s/ GREGORY D. CASH
Gregory D. Cash
Chief Executive Officer (Principal Executive Officer)
/s/ STEVEN CHAUSSY
Steven Chaussy
Chief Financial Officer (Principal Financial Officer
and Principal Accounting Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of
the registrant and in the capacities and on the dates indicated.
Name
Position
Date
/s/ KENNETH L. LONDONER
Kenneth L. Londoner
/s/ ASHER HOLZER
Asher Holzer
/s/ JONATHAN STEINHOUSE
Jonathan Steinhouse
/s/ PATRICK J. GALLAGHER
Patrick J. Gallagher
/s/ ROY T. TANAKA
Roy T. Tanaka
/s/ SETH H. Z. FISCHER
Seth H. Z. Fischer
/s/ JEFFREY F. O’DONNELL, SR.
Jeffrey F. O’Donnell, Sr.
Executive Chairman, Director
February 20, 2015
Director
Director
Director
Director
Director
Director
51
February 20, 2015
February 20, 2015
February 20, 2015
February 20, 2015
February 20, 2015
February 20, 2015
Table of Contents
Exhibit No.
Description
Index to Exhibits
3.1
3.2
3.3
3.4
3.5
3.6
3.7
10.1
10.2
10.3
10.4
10.5
10.6
10.7
10.8
Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1
to the Form S-1 filed on July 22, 2013)
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc.
(incorporated by reference to Exhibit 3.2 to the Form S-1 filed on July 22, 2013)
Certificate of Second Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc.
(incorporated by reference to Exhibit 3.3 to the Form S-1 filed on July 22, 2013)
Certificate of Third Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc.
(incorporated by reference to Exhibit 3.5 to the Form S-1/A filed on January 21, 2014)
Certificate of Fourth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc.
(incorporated by reference to Exhibit 3.6 to the Form S-1/A filed on March 28, 2014)
Certificate of Fifth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc.
(incorporated by reference to Exhibit 3.1 to the Form 8-K filed on August 21, 2014)
Bylaws of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.4 to the Form S-1 filed on July 22, 2013)
BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form S-1 filed on
July 22, 2013)
Form of Stock Option Agreement under the 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the
Form S-1 filed on July 22, 2013)
Securities Purchase Agreement, dated September 19, 2011, by and between BioSig Technologies, Inc. and certain
purchasers set forth therein (incorporated by reference to Exhibit 10.3 to the Form S-1 filed on July 22, 2013)
Securities Purchase Agreement, dated December 27, 2011, by and between BioSig Technologies, Inc. and certain
purchasers set forth therein (incorporated by reference to Exhibit 10.4 to the Form S-1 filed on July 22, 2013)
Securities Purchase Agreement, dated February 6, 2013, by and between BioSig Technologies, Inc. and certain purchasers
set forth therein (incorporated by reference to Exhibit 10.5 to the Form S-1 filed on July 22, 2013)
Registration Rights Agreement, dated February 6, 2013, by and between BioSig Technologies, Inc. and certain purchasers
set forth therein (incorporated by reference to Exhibit 10.6 to the Form S-1 filed on July 22, 2013)
Form of Warrant used in connection with February 6, 2013 private placement (incorporated by reference to Exhibit 10.7 to
the Form S-1 filed on July 22, 2013)
Amendment Agreement No. 1 to Securities Purchase Agreement and Registration Rights Agreement, dated February 25,
2013, by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to
Exhibit 10.8 to the Form S-1 filed on July 22, 2013)
10.9
Amendment Agreement No. 2 to Securities Purchase Agreement, dated April 12, 2013, by and between BioSig
10.10
Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.9 to the Form S-1 filed
on July 22, 2013)
Amendment Agreement No. 3 to Securities Purchase Agreement and Registration Rights Agreement, dated June 25, 2013,
by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit
10.10 to the Form S-1 filed on July 22, 2013)
52
Table of Contents
10.11
10.12
10.13
10.14
10.15
10.16
10.17
10.18
10.19
10.20
10.21
10.22
10.23
10.24
10.25
10.26
10.27
10.28
10.29
Office Lease Agreement, dated August 9, 2011, by and between BioSig Technologies, Inc. and Douglas Emmett 1993,
LLC (incorporated by reference to Exhibit 10.11 to the Form S-1 filed on July 22, 2013)
Employment Agreement, dated March 1, 2013, by and between BioSig Technologies, Inc. and Kenneth Londoner
(incorporated by reference to Exhibit 10.12 to the Form S-1 filed on July 22, 2013)
Indemnity Agreement, dated May 2, 2013 by and between BioSig Technologies, Inc. and Seth H. Z. Fischer (incorporated
by reference to Exhibit 10.14 to the Form S-1 filed on July 22, 2013)
Consulting Agreement, dated August 1, 2012, by and between BioSig Technologies, Inc. and Asher Holzer (incorporated
by reference to Exhibit 10.15 to the Form S-1 filed on July 22, 2013)
Unsecured Promissory Note made by BioSig Technologies, Inc. in favor of Kenneth Londoner, dated November 21, 2012
(incorporated by reference to Exhibit 10.19 to the Form S-1/A filed on September 11, 2013)
Form of 8% Senior Convertible Promissory Note issued pursuant to Bridge Loan Agreement, dated July 20, 2012
(incorporated by reference to Exhibit 10.20 to the Form S-1/A filed on September 11, 2013)
Promissory Note made by BioSig Technologies, Inc. in favor of Kenneth Londoner, dated December 6, 2012
(incorporated by reference to Exhibit 10.21 to the Form S-1/A filed on September 11, 2013)
Amendment Agreement No. 4 to Securities Purchase Agreement, dated October 14, 2013, by and between BioSig
Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.23 to the Form S-1/A
filed on January 21, 2014)
Securities Purchase Agreement, dated December 31, 2013, by and between BioSig Technologies, Inc. and certain
purchasers set forth therein (incorporated by reference to Exhibit 10.24 to the Form S-1/A filed on January 21, 2014)
Registration Rights Agreement, dated December 31, 2013, by and between BioSig Technologies, Inc. and certain
purchasers set forth therein (incorporated by reference to Exhibit 10.25 to the Form S-1/A filed on January 21, 2014)
Form of Warrant used in connection with December 31, 2013 private placement (incorporated by reference to Exhibit
10.26 to the Form S-1/A filed on January 21, 2014)
Amendment No. 1 to the BioSig Technologies, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit
10.27 to the Form S-1/A filed on March 28, 2014)
Amendment Agreement No. 5 to Securities Purchase Agreement, dated March 24, 2014, by and between BioSig
Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.28 to the Form S-1/A
filed on March 28, 2014)
Patent Assignment, dated March 17, 2014, by and among Budimir Drakulic, Thomas Foxall, Sina Fakhar and Branislav
Vlajinic and BioSig Technologies, Inc. (incorporated by reference to Exhibit 10.29 to the Form S-1/A filed on May 1,
2014)
Securities Purchase Agreement, dated April 4, 2014, by and between BioSig Technologies, Inc. and certain purchasers set
forth therein (incorporated by reference to Exhibit 10.30 to the Form S-1/A filed on May 1, 2014)
Registration Rights Agreement, dated April 4, 2014, by and between BioSig Technologies, Inc. and certain purchasers set
forth therein (incorporated by reference to Exhibit 10.31 to the Form S-1/A filed on May 1, 2014)
Form of Warrant used in connection with April 4, 2014 private placement (incorporated by reference to Exhibit 10.32 to
the Form S-1/A filed on May 1, 2014)
Consulting Agreement, dated December 10, 2010, by and between BioSig Technologies, Inc. and Jonathan Steinhouse
(incorporated by reference to Exhibit 10.33 to the Form S-1/A filed on May 22, 2014)
Executive Employment Agreement, dated July 15, 2014, by and between BioSig Technologies, Inc. and Gregory Cash
(incorporated by reference to Exhibit 10.1 to the Form 8-K filed on July 21, 2014)
53
Table of Contents
10.30
10.31
10.32
10.33
10.34
10.35
10.36
10.37
10.38
10.39
10.40
31.01
31.02
32.01
Incentive Stock Option Agreement, dated July 15, 2014, by and between BioSig Technologies, Inc. and Gregory Cash
(incorporated by reference to Exhibit 10.2 to the Form 8-K filed on July 21, 2014)
Securities Purchase Agreement, dated as of August 15, 2014, by and between BioSig Technologies, Inc. and certain
purchasers set forth therein (incorporated by reference to Exhibit 10.2 to the Form 8-K filed on August 21, 2014)
Registration Rights Agreement, dated as of August 15, 2014, by and between BioSig Technologies, Inc. and certain
purchasers set forth therein (incorporated by reference to Exhibit 10.3 to the Form 8-K filed on August 21, 2014)
Form of Warrant used in connection with August 15, 2014 private placement (incorporated by reference to Exhibit 10.2 to
the Form 8-K filed on August 21, 2014)
Letter Agreement and Release, dated as of September 1, 2014, by and between BioSig Technologies, Inc. and Asher
Holzer, Ph.D (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on September 5, 2014)
Form of Restricted Stock Award Agreement under the 2012 Equity Incentive Plan (incorporated by reference to Exhibit
10.2 to the Form 8-K filed on September 5, 2014)
Settlement and Mutual Release Agreement, dated November 3, 2014, by and between BioSig Technologies, Inc. and
David Drachman (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on November 5, 2014)
Composite of Unit Purchase Agreement, dated December 19, 2014, as amended by Supplement No. 1, dated December 17,
2014, by and between BioSig Technologies, Inc. and certain purchasers set forth therein
Registration Rights Agreement, dated December 19, 2014, by and between BioSig Technologies, Inc. and certain
purchasers set forth therein
Form of “A” Warrant used in connection with December 19, 2014 private placement.
Form of “B” Warrant used in connection with December 19, 2014 private placement
Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101 INS
XBRL Instance Document
101 SCH
XBRL Taxonomy Extension Schema Document
101 CAL
XBRL Taxonomy Calculation Linkbase Document
101 LAB
XBRL Taxonomy Labels Linkbase Document
101 PRE
XBRL Taxonomy Presentation Linkbase Document
101 DEF
XBRL Taxonomy Extension Definition Linkbase Document
54
Exhibit 10.37
COMPOSITE
UNIT PURCHASE AGREEMENT BY AND AMONG
BIOSIG TECHNOLOGIES, INC.
AND
EACH PURCHASER IDENTIFIED ON THE SIGNATURE PAGES HERETO
DISCLOSURE SCHEDULES AND EXHIBITS
TO
UNIT PURCHASE AGREEMENT
Schedule 3.1(g) Capitalization
Schedule 3.1(h) Financial Statement
Schedule 3.1(i) Material Changes; Undisclosed Events, Liabilities or Developments
Schedule 3.1(j) Litigation
Schedule 3.1(m) Title to Assets
Schedule 3.1(n) Intellectual Property
Schedule 3.1(p) Transactions With Affiliates and Employees
Schedule 3.1(r) Certain Fees
Schedule 3.1(t) Registration Rights
Schedule 3.1(y) Indebtedness
Schedule 3.1(bb) Accountants
Exhibit A Form of A Warrant
Exhibit B Form of B Warrant
Exhibit C Form of Legal Opinion of Company Counsel
Exhibit D Form of Registration Rights Agreement
UNIT PURCHASE AGREEMENT
This UNIT PURCHASE AGREEMENT (this “Agreement”) is dated as of December 19, 2014 by and among BioSig Technologies,
Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and
assigns, a “Purchaser” and collectively, the “Purchasers”).
WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of
1933, as amended (the “Securities Act”), and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and
each Purchaser, severally and not jointly, desires to purchase from the Company, Securities of the Company as more fully described in this
Agreement.
NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and
valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:
ARTICLE I.
DEFINITIONS
1 . 1 Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings set
forth in this Section 1.1:
“Action” shall have the meaning ascribed to such term in Section 3.1(j).
“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or
is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.
“Board of Directors” means the board of directors of the Company.
“Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United
States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental
action to close.
“Cap” shall have the meaning ascribed to such term in Section 5.2.
“Closing” means a closing of the purchase and sale of the Units pursuant to Section 2.1.
“Closing Date” means a Trading Day on which all of the Transaction Documents have been executed and delivered by the
Company and each of the Purchasers purchasing Units at the relevant Closing, and all conditions precedent to (i) the Purchasers’
obligations to pay the Subscription Amount and (ii) the Company’s obligations to deliver the Units, in each case, have been
satisfied or waived, but in no event later than the third Trading Day following the relevant Closing.
“Commission” means the United States Securities and Exchange Commission.
“Common Stock” means the common stock of the Company, par value $0.001 per share, and any other class of securities
into which such securities may hereafter be reclassified or changed.
“Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder
thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other
instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.
“Company Counsel” means Haynes and Boone, LLP, with offices located at 30 Rockefeller Plaza, 26th Floor, New York,
NY 10112, Fax: 212-884-8234.
“Disclosure Schedules” means the Disclosure Schedules of the Company delivered concurrently herewith.
“Effective Date” means the earliest of the date that (a) the initial Registration Statement has been declared effective by the
Commission, (b) all of the Offering Shares have been sold pursuant to Rule 144 or may be sold pursuant to Rule 144 without the
requirement for the Company to be in compliance with the current public information requirements under Rule 144 and without volume
or manner-of-sale restrictions or (c) following the one year anniversary of the final Closing Date hereunder, provided that a holder of
Offering Shares is not an Affiliate of the Company, all of the Offering Shares may be sold pursuant to an exemption from registration
under Section 4(a)(1) of the Securities Act without volume or manner-of-sale restrictions or the need for the Company to provide
current public information and Company counsel has delivered to such holders a written opinion that resales may then be made by such
holders of the Offering Shares pursuant to such exemption which opinion shall be in form and substance reasonably acceptable to such
holders.
“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder.
“FCPA” means the Foreign Corrupt Practices Act of 1977, as amended.
“Financial Statements” shall have the meaning ascribed to such term in Section 3.1(h).
“GAAP” shall have the meaning ascribed to such term in Section 3.1(h).
“Indebtedness” shall have the meaning ascribed to such term in Section 3.1(y).
“Initial Closing” shall have the meaning ascribed to such term in Section 2.1(a).
“Initial Closing Date” shall have the meaning ascribed to such term in Section 2.1(a).
“Intellectual Property Rights” shall have the meaning ascribed to such term in Section 3.1(n).
“Investor Warrants” means, collectively, the A Warrants and B Warrants, which are included in the Units delivered to the
Purchasers at each Closing in accordance with Section 2.2(a) hereof, which A Warrants and B Warrants shall be substantially in the
forms of, respectively, Exhibit A and Exhibit B attached hereto.
“Investor Warrant Shares” means the shares of Common Stock issuable upon exercise of the Investor Warrants.
“Laidlaw” means Laidlaw & Co (UK) Ltd.
4
“Liens” means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other
restriction.
“Material Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b).
“Material Permits” shall have the meaning ascribed to such term in Section 3.1(l).
“Offering Shares” means the shares of Common Stock included in the Units issued pursuant to this Agreement and shares
of Common Stock issuable or issued upon exercise of the A Warrants and B Warrants included in the Units issued pursuant to this
Agreement.
“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture,
limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
“Price Per Unit” means $100,000.
“Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an informal
investigation or partial proceeding, such as a deposition), whether commenced or threatened.
“Purchaser Party” shall have the meaning ascribed to such term in Section 4.9.
“Registration Rights Agreement” means the Registration Rights Agreement, dated the date hereof, among the Company and
the Purchasers, in the form of Exhibit D attached hereto.
“Registration Statement” means a registration statement meeting the requirements set forth in the Registration Rights
Agreement and covering the resale of the Offering Shares by each Purchaser as provided for in the Registration Rights Agreement.
“Required Approvals” shall have the meaning ascribed to such term in Section 3.1(e).
“Required Minimum” shall have the meaning ascribed to such term in Section 4.10.
“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be
amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially
the same purpose and effect as such Rule.
“Securities” means the Units, the Offering Shares, the Investor Warrants, and Investor Warrant Shares, if and as
applicable.
“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
“Subscription Amount” means, as to each Purchaser, the aggregate amount to be paid for the Units purchased hereunder as
specified below such Purchaser’s name on the signature page of this Agreement and next to the heading “Subscription Amount”.
“Subsequent Closing Date” shall have the meaning ascribed to such term in Section 2.1(a).
5
“Subsidiary” means any direct or indirect subsidiary of the Company formed or acquired after the date hereof.
“Termination Date” shall have the meaning ascribed to such term in Section 2.1(a).
“Trading Day” means a day on which the principal Trading Market is open for trading; provided, that in the event that the
Common Stock is not listed or quoted for trading on a Trading Market on the date in question, then Trading Day shall mean a Business
Day.
“Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for
trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select
Market, the New York Stock Exchange, the OTC Bulletin Board, the OTC QB Marketplace or the OTC QX Marketplace (or any
successors to any of the foregoing).
“Transaction Documents” means this Agreement, the Investor Warrants, the Registration Rights Agreement, all exhibits
and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated
hereunder.
“Transfer Agent” means a transfer agent for the Company’s Common Stock and the Offering Shares, if any, and any
successor transfer agent of the Company. If the Company does not have a transfer agent for its Common Stock on the date in question
since its shares of Common Stock are not listed for trading on a stock exchange or automated quotation service, then Transfer Agent
shall mean the Company.
“Units” means the Units issued pursuant to this Agreement, which shall consist of (a) 40,000 shares of Common Stock and
(b) two Investor Warrants: (i) an "A" Warrant to purchase 40,000 shares of Common Stock, exercisable at a price of $2.50 per share of
Common Stock for a period of 120 days from the date of the final Closing (the “A Warrant”), and (ii) a "B" Warrant to purchase 20,000
shares of Common Stock, exercisable at a price of $3.75 per share of Common Stock for a period of five (5) years from the date of the
final Closing (the “B Warrant”).
2.1 Closing.
ARTICLE II.
PURCHASE AND SALE
(a) On the initial Closing Date (the “Initial Closing Date”), upon the terms and subject to the conditions set forth herein,
substantially concurrent with the execution and delivery of this Agreement by the parties hereto, the Company agrees to sell at the initial
Closing (the “Initial Closing”), and the Purchasers, severally and not jointly, agree to purchase at the Initial Closing, an aggregate of up to
$10,000,000, but in no event less than $300,000, of Units, calculated based upon the Price Per Unit, for each Purchaser equal to such
Purchaser’s Subscription Amount as set forth on the signature page hereto executed by such Purchaser, and Investor Warrants as
determined pursuant to Section 2.2(a). Thereafter, on any subsequent Closing Date (each a “Subsequent Closing Date”), upon the terms
and subject to the conditions set forth herein, substantially concurrent with the execution and delivery of this Agreement by the
Purchasers purchasing Units on such Subsequent Closing Date, the Company agrees to sell, and each Purchaser purchasing Units at such
subsequent Closing, severally and not jointly, agrees to purchase an aggregate of up to $10,000,000 of Units, calculated as set forth
above, less the amount of Units issued and sold at all previous Closings. Each Purchaser purchasing Units on a Closing Date shall deliver
to the Company such Purchaser’s Subscription Amount by wire transfer of immediately available funds in accordance with the
Company’s written wire instructions, and the Company shall deliver to each Purchaser its respective Units, as determined pursuant to
Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the
Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, a Closing shall occur at the offices of
Company Counsel or such other location as the parties shall mutually agree. Notwithstanding anything herein to the contrary, each
Closing Date shall occur on or before December 31, 2014; provided, however, that such date may be extended, without notice, to March
31, 2015 with the consent of the Company and Laidlaw (the “Termination Date”).
6
(b) If a Closing is not held on or before the Termination Date, the Company shall cause all subscription documents and
funds to be returned, without interest or deduction, to each prospective Purchaser. The Company shall also cause any subscription
documents or funds received following the final Closing to be returned, without interest or deduction, to each applicable
prospective Purchaser. Notwithstanding the foregoing, the Company in its sole discretion may elect not to sell to any Person any or
all of the Units requested to be purchased hereunder, provided that the Company causes all corresponding subscription documents
and funds received from such Person to be promptly returned.
2.2 Deliveries.
Units on such Closing Date each of the following:
(a) On or prior to each Closing Date, the Company shall deliver or cause to be delivered to each Purchaser purchasing
(i) this Agreement duly executed by the Company;
(ii) a legal opinion of Company Counsel, substantially in the form of Exhibit C attached hereto;
(iii) the Registration Rights Agreement duly executed by the Company;
(iv) (1) instructions to the Transfer Agent authorizing the issuance of the shares of Common Stock
included in the Units purchased by such Purchaser at such Closing and (2) one A Warrant and one B Warrant, each registered in
such Purchaser’s name to purchase such number of Investor Warrant Shares included in the Units purchased by such Purchaser
at such Closing. Within ten (10) days following any Closing, the Company will deliver, unless otherwise requested by any
Purchaser, one (1) certificate registered in such Purchaser’s name representing the shares of Common Stock included in the
Units purchased by such Purchaser at such Closing; and
from the State of Delaware and the State of California.
(v) a good standing certificate of the Company, dated within four Trading Days of the Closing Date,
(b) On or prior to each Closing Date, each Purchaser purchasing Units on such Closing Date shall deliver or cause to be
delivered to the Company the following:
(i) this Agreement duly executed by such Purchaser;
(ii) the Registration Rights Agreement duly executed by such Purchaser; and
7
Company.
2.3 Closing Conditions.
(iii) such Purchaser’s Subscription Amount by wire transfer to the account specified in writing by the
(a) The obligations of the Company hereunder in connection with each Closing are subject to the following conditions
being met:
(i) the accuracy in all material respects on such Closing Date of the representations and warranties of
the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate in all material respects
as of such date);
such Closing Date shall have been performed; and
(ii) all obligations, covenants and agreements of each Purchaser required to be performed at or prior to
(iii) the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.
(b) The respective obligations of the Purchasers hereunder in connection with each Closing are subject to the following
conditions being met:
(i) the accuracy in all material respects when made and on such Closing Date of the representations and
warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate in all
material respects as of such date);
such Closing Date shall have been performed;
(ii) all obligations, covenants and agreements of the Company required to be performed at or prior to
Subscription Amount of at least $300,000 prior to the Initial Closing;
(iii) the Company shall have received executed signature pages to this Agreement with an aggregate
(iv) the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;
(v) there shall have been no Material Adverse Effect with respect to the Company since the date hereof;
and
(vi) from the date hereof to such Closing Date, trading in securities generally as reported by Bloomberg
L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are
reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United
States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other
national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market
which, in each case, in the reasonable good faith judgment of such Purchaser, makes it impracticable or inadvisable to purchase
the Units at such Closing.
8
ARTICLE III.
REPRESENTATIONS AND WARRANTIES
3.1 Representations and Warranties of the Company. Except as set forth in the Disclosure Schedules, which Disclosure Schedules
shall be deemed a part hereof and shall qualify any representation made herein only to the extent of the disclosure contained in the
corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each
Purchaser:
(a) Subsidiaries. The Company has no subsidiaries. All references to the Subsidiaries or any of them in the Transaction
Documents shall be disregarded except to the extent such reference speaks to a time in the past or future when the Company has or had a
Subsidiary, as the case may be.
(b) Organization and Qualification. Each of the Company and its Subsidiaries is an entity duly incorporated or otherwise
organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite
power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor
any Subsidiary is in violation or default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other
organizational or charter documents. Each of the Company and its Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by
it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have
or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of
the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material
respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a “Material Adverse Effect”) and no
Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power
and authority or qualification.
(c) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to
consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out
its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by
the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all
necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company’s
stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other
Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when
delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable
against the Company in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as
limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as
indemnification and contribution provisions may be limited by applicable law.
(d) No Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction
Documents, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby to
which it is a party do not and will not: (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate or
articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets
of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without
notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or
otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company
or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule,
regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a
Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a
Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to
result in a Material Adverse Effect.
9
(e) Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order
of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or
other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)
the filing with the Commission pursuant to the Registration Rights Agreement and Section 4.6, (ii) the notice and/or application(s) to
each applicable Trading Market, if any, for the issuance and sale of the Common Stock and Investor Warrant Shares and the listing of the
Offering Shares for trading thereon in the time and manner required thereby, and (iii) the filing of a Form D with the Commission and
such filings as are required to be made under applicable state securities laws (collectively, the “Required Approvals”).
(f) Issuance of the Securities. The Securities are duly authorized and, when issued and paid for in accordance with the
applicable Transaction Documents, will be duly and validly issued, fully paid and, if and as applicable, nonassessable, free and clear of
all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock a number of shares of Common
Stock for issuance of the Offering Shares at least equal to the Required Minimum on the date hereof.
(g) Capitalization. The capitalization of the Company is as set forth on Schedule 3.1(g). The Company has not issued any
capital stock and/or Common Stock Equivalents not set forth on Schedule 3.1(g). No Person has any right of first refusal, preemptive
right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as
a result of the purchase and sale of the Securities or as described on Schedule 3.1(g), there are no outstanding options, warrants, scrip
rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or
exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire any shares of Common Stock, or contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional
shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Securities will not obligate the Company to issue
shares of Common Stock or other securities to any Person (other than the Purchasers) and will not result in a right of any holder of
securities of the Company to adjust the exercise, conversion, exchange or reset price under any of such securities. All of the outstanding
shares of capital stock and other securities of the Company are duly authorized, validly issued, fully paid and nonassessable, have been
issued in material compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any
preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the
Board of Directors or others is required for the issuance and sale of the Securities. Except for the Company’s certificate of incorporation,
there are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to
which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.
10
(h) Financial Statements. Schedule 3.1(h) attached hereto contains the audited balance sheets of the Company as of
December 31, 2013 and 2012, and the related statements of operations, stockholders’ equity (deficit), and cash flows for the years then
ended and for the period from February 24, 2009 (date of inception) to December 31, 2013 (collectively, the “Financial Statements”).The
Company Financial Statements have been prepared in accordance with generally accepted accounting principles of the United States
(“GAAP”) applied on a consistent basis throughout the periods covered thereby, fairly present the financial condition, results of
operations and cash flows of the Company and the Subsidiaries as of the respective dates thereof and for the periods referred to therein
and are consistent with the books and records of the Company and the Subsidiaries, except as may be otherwise specified in such
financial statements or the notes thereto and except that the Company Financial Statements may not contain all footnotes required by
GAAP and normal year-end adjustments.
(i) Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial
statements included in Schedule 3.1(h), except as specifically disclosed on Schedule 3.1(i): (i) there has been no event, occurrence or
development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred
any material liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of
business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to
GAAP, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or
distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock, (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to
existing Company stock option plans, and (vi) no event, liability, fact, circumstance, occurrence or development has occurred or exists or
is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, properties,
operations, assets or financial condition, that would be required to be disclosed by the Company under the Exchange Act in the event that
the Company was subject to the reporting requirements set forth in Section 13(a) or Section 15(d) of the Exchange Act.
(j) Litigation. Except as described on Schedule 3.1(j), there is no action, suit, inquiry, notice of violation, proceeding or
investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their
respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state,
county, local or foreign) (collectively, an “Action”) which (i) adversely affects or challenges the legality, validity or enforceability of any
of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to
result in a Material Adverse Effect. Except as described on Schedule 3.1(j), since December 31, 2012, neither the Company nor any
Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under
federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is
not pending or contemplated, any investigation by the Commission or any state securities administrator involving the Company or any
current or former director or officer of the Company.
(k) Compliance. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has
occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary
under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any
indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is
bound (whether or not such default or violation has been waived), (x) is in violation of any judgment, decree or order of any court,
arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any
governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection,
occupational health and safety, product quality and safety and employment and labor matters, except in each case as could not have or
reasonably be expected to result in a Material Adverse Effect.
11
(l) Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by
the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as presently
conducted, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect
(“Material Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.
(m) Title to Assets. Except as described on Schedule 3.1(m), the Company and the Subsidiaries have good and
marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them
that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not
materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property
by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have
been made in accordance with GAAP, and the payment of which is neither delinquent nor subject to penalties. Any real property and
facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with
which the Company and the Subsidiaries are in compliance.
(n) Intellectual Property.
(i) The term “Intellectual Property Rights” includes:
1. the name of the Company, all fictional business names, trading names, registered and unregistered
trademarks, service marks, and applications (collectively, “Marks'');
2. all patents, patent applications, and inventions and discoveries that may be patentable (collectively,
“Patents'');
3. all copyrights in both published works and published works (collectively, “Copyrights”);
4. all rights in mask works (collectively, “Rights in Mask Works''); and
5. all know-how, trade secrets, confidential information, customer lists, software, technical information,
data, process technology, plans, drawings, and blue prints (collectively, “ Trade Secrets'') owned, used,
or licensed by the Company as licensee or licensor.
(ii) Agreements. Schedule 3.1(n) contains a complete and accurate list of all contracts relating to the Intellectual
Property Rights to which the Company is a party or by which the Company is bound, except for any license implied
by the sale of a product and perpetual, paid-up licenses for commonly available software programs with a value of
less than $10,000 under which the Company is the licensee. There are no outstanding and, to the Company’s
knowledge, no threatened disputes or disagreements with respect to any such agreement.
12
(iii) Know-How Necessary for the Business. The Intellectual Property Rights are all those necessary for the
operation of the Company’s businesses as it is currently conducted or as represented, in writing, to the Purchasers
to be conducted. The Company is the owner of all right, title, and interest in and to each of the Intellectual
Property Rights, free and clear of all liens, security interests, charges, encumbrances, equities, and other adverse
claims, and has the right to use all of the Intellectual Property Rights. To the Company’s knowledge, no employee
of the Company has entered into any contract that restricts or limits in any way the scope or type of work in which
the employee may be engaged or requires the employee to transfer, assign, or disclose information concerning his
work to anyone other than of the Company.
(iv) Know-How Necessary for the Business. Schedule 3.1(n) contains a complete and accurate list of all Patents.
Except as set forth on Schedule 3.1(j), the Company is the owner of all right, title and interest in and to each of the
Patents, free and clear of all Liens and other adverse claims. All of the issued Patents are currently in compliance
with formal legal requirements (including payment of filing, examination, and maintenance fees and proofs of
working or use), are valid and enforceable, and are not subject to any maintenance fees or taxes or actions falling due
within ninety days after the Initial Closing Date. No Patent has been or is now involved in any interference, reissue,
reexamination, or opposition proceeding. To the Company’s knowledge: (1) there is no potentially interfering patent
or patent application of any third party, and (2) no Patent is infringed or has been challenged or threatened in any
way. To the Company’s knowledge, none of the products manufactured and sold, nor any process or know-how used,
by the Company infringes or is alleged to infringe any patent or other proprietary right of any other Person.
(v) Trademarks. Schedule 3.1(n) contains a complete and accurate list and summary description of all Marks. The
Company is the owner of all right, title, and interest in and to each of the Marks, free and clear of all Liens and other
adverse claims. All Marks that have been registered with the United States Patent and Trademark Office are
currently in compliance with all formal legal requirements (including the timely post-registration filing of affidavits
of use and incontestability and renewal applications), are valid and enforceable, and are not subject to any
maintenance fees or taxes or actions falling due within ninety days after the Initial Closing Date. Except as set forth
in Schedule 3.1(n), no Mark has been or is now involved in any opposition, invalidation, or cancellation and, to the
Company’s knowledge, no such action is threatened with respect to any of the Marks. To the Company’s knowledge:
(1) there is no potentially interfering trademark or trademark application of any third party, and (2) no Mark is
infringed or has been challenged or threatened in any way. To the Company’s knowledge, none of the Marks used by
the Company infringes or is alleged to infringe any trade name, trademark, or service mark of any third party.
(vi) Copyrights. Schedule 3.1(n) contains a complete and accurate list of all Copyrights. The Company is the owner
of all right, title, and interest in and to each of the Copyrights, free and clear of all Liens and other adverse claims.
All the Copyrights have been registered and are currently in compliance with formal requirements, are valid and
enforceable, and are not subject to any maintenance fees or taxes or actions falling due within ninety days after the
date of the Initial Closing. No Copyright is infringed or, to the Company’s knowledge, has been challenged or
threatened in any way. To the Company’s knowledge, none of the subject matter of any of the Copyrights infringes
or is alleged to infringe any copyright of any third party or is a derivative work based on the work of a third party.
All works encompassed by the Copyrights have been marked with the proper copyright notice.
13
(vii) Trade Secrets. With respect to each Trade Secret, the documentation relating to such Trade Secret is current,
accurate, and sufficient in detail and content to identify and explain it and to allow its full and proper use without
reliance on the knowledge or memory of any individual. The Company has taken all reasonable precautions to
protect the secrecy, confidentiality, and value of its Trade Secrets. The Company has good title and an absolute (but
not necessarily exclusive) right to use the Trade Secrets. The Trade Secrets are not part of the public knowledge or
literature, and, to the Company’s knowledge, have not been used, divulged, or appropriated either for the benefit of
any Person (other than the Company) or to the detriment of the Company. No Trade Secret is subject to any adverse
claim or has been challenged or threatened in any way.
(o) Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against
such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are
engaged. In addition, within 60 days following the Initial Closing Date, the Company shall obtain directors and officers insurance
coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary has any reason to believe that it
will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business without a significant increase in cost.
(p) Transactions With Affiliates and Employees. Except as described on Schedule 3.1(p), none of the officers or directors
of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is
presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors),
including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or
personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or
from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such
employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $100,000
other than for: (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the
Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.
(q) No General Solicitation. Neither the Company nor any person acting on behalf of the Company has offered or sold
any of the Securities by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to
the Purchasers and certain other “accredited investors” within the meaning of Rule 501 under the Securities Act.
14
(r) Certain Fees. No brokerage, finder’s fees, commissions or due diligence fees are or will be payable by the Company or
any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with
respect to the transactions contemplated by the Transaction Documents except as set forth on Schedule 3.1(r). The Purchasers shall have
no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section 3.1(r) that may be due in connection with the transactions contemplated by the Transaction Documents.
(s) Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the
Securities, will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as
amended. The Company shall conduct its business in a manner so that it will not become an “investment company” subject to registration
under the Investment Company Act of 1940, as amended.
(t) Registration Rights. Except as described on Schedule 3.1(t), no Person other than the Purchasers has any right to cause
the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.
(u) Private Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2,
no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as
contemplated hereby.
(v) Application of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any,
in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Company’s certificate of incorporation (or similar charter documents) or
the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the
Company’s issuance of the Securities and the Purchasers’ ownership of the Securities.
(w) Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the
Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the
Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material, non-public
information which will not be publicly disclosed in the Registration Statement or within 210 days of the Initial Closing Date, whichever
occurs first. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting
transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the
Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules
to this Agreement, when taken together as a whole, is true and correct and does not contain any untrue statement of a material fact or omit
to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were
made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties
with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.
(x) No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section
3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to
be integrated with prior offerings by the Company for purposes of the Securities Act which would require the registration of any such
securities under the Securities Act.
15
(y) Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, and the Company’s
good faith estimate of the fair market value of its assets, after giving effect to the receipt by the Company of the proceeds from the sale
of the Securities hereunder: (i) the fair saleable value of the Company’s assets exceeds the amount that will be required to be paid on or
in respect of the Company’s existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the
Company’s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted
including its capital needs taking into account the particular capital requirements of the business conducted by the Company,
consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together
with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the
cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company
does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to
be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will
file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Initial
Closing Date. Schedule 3.1(y) sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any
Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, “ Indebtedness” means
(x) any liabilities for borrowed money or amounts owed in excess of $250,000 (other than trade accounts payable incurred in the
ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others,
whether or not the same are or should be reflected in the Company’s consolidated balance sheet (or the notes thereto), except guaranties
by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the
present value of any lease payments in excess of $250,000 due under leases required to be capitalized in accordance with GAAP. Neither
the Company nor any Subsidiary is in default with respect to any Indebtedness.
(z) Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to
result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local
income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)
has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for
periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount
claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for
any such claim.
(aa) Foreign Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any
Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has: (i) directly or indirectly, used any funds
for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any
unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns
from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person
acting on its behalf of which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision of
FCPA.
16
(bb) Accountants. The Company’s accounting firm is set forth on Schedule 3.1(bb). To the knowledge and belief of
the Company, such accounting firm is registered with the Public Company Accounting Oversight Board, and shall express its opinion
with respect to the financial statements to be included in the Registration Statement for the fiscal year ending December 31, 2013.
(cc) Acknowledgment Regarding Purchasers’ Purchase of Securities . The Company acknowledges and agrees that
each of the Purchasers is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the
transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of
the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any
advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and
the transactions contemplated thereby is merely incidental to the Purchasers’ purchase of the Securities. The Company further
represents to each Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents has been
based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.
(dd) Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times
in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the
“Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the
Company or any Subsidiary, threatened.
(ee) Stock Option Plans. Each stock option granted by the Company under the Company’s stock option plan was
granted (i) in accordance with the terms of the Company’s stock option plan and (ii) with an exercise price at least equal to the fair
market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No
stock option granted under the Company’s stock option plan has been backdated.
(ff) The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the
Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years
preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing
materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the
“SEC Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the
expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements
of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a
material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i)
under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with
applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of
filing. Such financial statements have been prepared in accordance with GAAP applied on a consistent basis during the periods
involved, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial
statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the
Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods
then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
17
3.2 Representations and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date hereof and as of the Closing Date on which such Purchaser is purchasing Units hereunder to the Company as follows
(unless as of a specific date therein):
(a) Organization; Authority. Such Purchaser is either an individual or an entity duly incorporated or formed,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate,
partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated
by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the
Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have
been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of
such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by
such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser,
enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally,
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.
(b) Understandings or Arrangements. Such Purchaser understands that the Securities are “restricted securities”
and have not been registered under the Securities Act or any applicable state securities law and is acquiring the Securities as principal
for its own account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the
Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the
Securities Act or any applicable state securities law and has no direct or indirect arrangements or understandings with any other
persons to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state
securities law (this representation and warranty not limiting such Purchaser’s right to sell the Securities pursuant to a Registration
Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities
hereunder in the ordinary course of its business.
(c) Purchaser Status. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is,
and on each date on which it exercises any Warrants, it will be either: (i) an “accredited investor” as defined in Rule 501(a) under the
Securities Act or (ii) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act. Such Purchaser is not
required to be registered as a broker-dealer under Section 15 of the Exchange Act.
(d) Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such
knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of
the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to
bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such
investment.
18
(e) Opportunities for Additional Information. Each Purchaser acknowledges that such Purchaser has had the
opportunity to ask questions of and receive answers from, or obtain additional information from, the executive officers of the
Company concerning the financial and other affairs of the Company, and to the extent deemed necessary in light of such Purchaser’s
personal knowledge of the Company’s affairs, such Purchaser has asked such questions and received answers to the full satisfaction
of such Purchaser, and such Purchaser desires to invest in the Company. Neither such inquiries nor any other investigation conducted
by or on behalf of such Purchaser or its representatives or counsel shall modify, amend or affect such Purchaser’s right to rely on the
truth, accuracy and completeness of the Disclosure Schedules and the Company’s representations and warranties contained in the
Transaction Documents.
(f) No General Solicitation. Each Purchaser acknowledges that the Securities were not offered to such Purchaser
by means of any form of general or public solicitation or general advertising, or publicly disseminated advertisements or sales
literature, including (i) any advertisement, article, notice or other communication published in any newspaper, magazine, or similar
media, or broadcast over television or radio or (ii) any seminar or meeting to which such Purchaser was invited by any of the
foregoing means of communications.
The Company acknowledges and agrees that the representations contained in Section 3.2 shall not modify, amend or affect such Purchaser’s
right to rely on the Company’s representations and warranties contained in this Agreement or any representations and warranties contained
in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the
consummation of the transaction contemplated hereby.
ARTICLE IV.
OTHER AGREEMENTS OF THE PARTIES
4.1 Transfer Restrictions.
(a) The Securities may only be disposed of in compliance with state and federal securities laws. In connection
with any transfer of Securities other than pursuant to an effective registration statement or Rule 144, to the Company or to an
Affiliate of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor
thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the
form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not
require registration of such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall agree
in writing to be bound by the terms of this Agreement and the Registration Rights Agreement and shall have the rights and
obligations of a Purchaser under this Agreement and the Registration Rights Agreement.
Securities in the following form:
(b) The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the
[NEITHER] THIS SECURITY [NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE] [HAS NOT]
[HAVE] BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD
EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS
AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF
WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY [AND THE SECURITIES
ISSUABLE UPON EXERCISE OF THIS SECURITY] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS
AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN
SECURED BY SUCH SECURITIES.
19
The Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin
agreement with a registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an
“accredited investor” as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this
Agreement and the Registration Rights Agreement and, if required under the terms of such arrangement, such Purchaser may transfer,
pledge or secure Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the
Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith.
Further, no notice shall be required of such pledge. At the appropriate Purchaser’s expense, the Company will execute and deliver such
reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of
the Securities, including, if the Securities are subject to registration pursuant to the Registration Rights Agreement, the preparation and
filing of any required prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the
Securities Act to appropriately amend the list of selling stockholders thereunder.
(c) Certificates evidencing the Offering Shares shall not contain any legend (including the legend set forth in
Section 4.1(b) hereof): (i) while a registration statement (including the Registration Statement) covering the resale of such security is
effective under the Securities Act, (ii) following any sale of such Offering Shares pursuant to Rule 144, (iii) if such Offering Shares are
eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information
required under Rule 144 as to such Offering Shares and without volume or manner-of-sale restrictions, (iv) if such legend is not required
under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the
Commission) or (v) following the Effective Date. Upon the receipt by the Company of any reasonable certifications from the Purchasers
requested by the Company with respect to future sales of such Offering Shares, the Company shall cause its counsel to issue a legal
opinion to the Transfer Agent if required by the Transfer Agent to effect the removal of the legend hereunder. The Company agrees that
following such time as such legend is no longer required under this Section 4.1(c), it will, as soon as practicable following the delivery
by a Purchaser to the Company or the Transfer Agent of a certificate representing Offering Shares issued with a restrictive legend and, in
each case, any reasonable certifications from the Purchaser requested by the Company or the Company’s counsel in order to effectuate a
legend removal, deliver or cause to be delivered to such Purchaser a certificate representing such shares that is free from all restrictive
and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the
restrictions on transfer set forth in this Section 4. Certificates for Offering Shares subject to legend removal hereunder shall be transmitted
by the Transfer Agent to the Purchaser by crediting the account of the Purchaser’s prime broker with the Depository Trust Company
System as directed by such Purchaser if the Company is then a participant in such system.
20
(d) Each Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such
Purchaser will sell any Securities pursuant to either the registration requirements of the Securities Act, including any applicable
prospectus delivery requirements, or an exemption therefrom, and that if Securities are sold pursuant to a Registration Statement,
they will be sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive
legend from certificates representing Securities as set forth in this Section
4.1 is predicated upon the Company’s reliance upon this understanding.
4.2 Acknowledgment of Dilution. The Company acknowledges that the issuance of the Securities may result in dilution of the
outstanding shares of Common Stock, which dilution may be substantial under certain market conditions. The Company further
acknowledges that its obligations under the Transaction Documents, including, without limitation, its obligation to issue the Investor Warrant
Shares pursuant to the Transaction Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or
reduction, regardless of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless of the
dilutive effect that such issuance may have on the ownership of the other stockholders of the Company.
4.3 Furnishing of Information; Public Information. Commencing on the Effective Date, and until the earliest of the time that (a)
no Purchaser owns Securities or (b) the Investor Warrants have expired, the Company covenants to have obtained and will thereafter maintain
the registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect
thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the
Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.
4.4 Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require
the registration under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of the Securities for
purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other
transaction unless shareholder approval is obtained before the closing of such subsequent transaction.
4.5 Exercise Procedures. The form of Notice of Exercise included in the Investor Warrants sets forth the totality of the procedures
required of the Purchasers in order to exercise the Investor Warrants. No additional legal opinion, other information or instructions shall be
required of the Purchasers to exercise their Investor Warrants. The Company shall honor exercises of the Investor Warrants and shall deliver
Investor Warrant Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.
4.6 Securities Laws Disclosure; Publicity. The Registration Statement will disclose the material terms of the transactions
contemplated hereby, and shall include the Transaction Documents as exhibits thereto. From and after the filing of the Registration
Statement, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to
any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in
connection with the transactions contemplated by the Transaction Documents. The Company and each Purchaser shall consult with each
other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser
shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to
any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which
consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall
promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company
shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any
regulatory agency or Trading Market, without the prior written consent of such Purchaser, except: (a) as required by federal securities law in
connection with the filing of the Registration Statement and (b) to the extent such disclosure is required by law or Trading Market
regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b).
21
4.7 Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the
Transaction Documents, the Company covenants and agrees that neither it, nor any other Person acting on its behalf, will provide any
Purchaser or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior
thereto such Purchaser shall have executed a written agreement with the Company regarding the confidentiality and use of such information
or is an Affiliate of the Company. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in
effecting transactions in securities of the Company.
4.8 Use of Proceeds. The Company shall use the net proceeds from the sale of the Securities hereunder for general corporate
purposes including, but not limited to, growth initiatives and capital expenditures, and shall not use such proceeds: (a) for the satisfaction of
any portion of the Company’s debt (other than payment of trade payables in the ordinary course of the Company’s business and prior
practices), or (b) for the redemption of any Common Stock or Common Stock Equivalents.
4.9 Indemnification of Purchasers. Subject to the provisions of this Section 4.9, the Company will indemnify and hold each
Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents,
members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a
lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”) harmless from any and all losses, liabilities,
obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and
reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any
breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other
Transaction Documents or (b) any action instituted against Purchaser Parties in any capacity, or any of them or their respective Affiliates, by
any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the
Transaction Documents (unless such action is based upon a breach of such Purchaser Party’s representations, warranties or covenants under
the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations
by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which constitutes fraud, gross negligence,
willful misconduct or malfeasance). If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought
pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to
assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the
right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at
the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in
writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action
there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position
of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such
separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party
effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to
the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s breach of its representations, warranties or covenants
under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any
violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which constitutes fraud, gross
negligence, willful misconduct or malfeasance. The indemnification required by this Section 4.9 shall be made by periodic payments of the
amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements
contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any
liabilities the Company may be subject to pursuant to law.
22
4.10 Reservation and Listing of Securities.
(a) The Company shall maintain a reserve from its duly authorized shares of Common Stock for issuance
pursuant to the Transaction Documents in such amount as may then be required to fulfill its obligations in full under the Transaction
Documents (the “Required Minimum”).
(b) If, on any date, the number of authorized but unissued (and otherwise unreserved) shares of Common Stock
is less than the Required Minimum on such date, then the Board of Directors shall use commercially reasonable efforts to amend the
Company’s certificate of incorporation to increase the number of authorized but unissued shares of Common Stock to at least the
Required Minimum at such time, as soon as possible and in any event not later than the 60th day after such date.
actually listed on the Company’s principal Trading Market, if any.
(c) The Company shall take all steps necessary to cause the Offering Shares to be approved for listing and
4.11 Equal Treatment of Purchasers. No consideration (including any modification of any Transaction Document) shall be offered
or paid to any Person to amend or consent to a waiver or modification of any provision of any of this Agreement unless the same
consideration is also offered to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right
granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the
Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase,
disposition or voting of Securities or otherwise.
4.12 Form D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the Securities as required under
Regulation D. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption
for, or to qualify the Securities for, sale to the Purchasers at each Closing under applicable securities or “Blue Sky” laws of the states of the
United States, and shall provide evidence of such actions promptly upon request of any Purchaser.
23
ARTICLE V.
MISCELLANEOUS
5.1 Termination. This Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only and
without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Initial Closing has not been consummated on or before December 31, 2014; provided, however, that such date may be extended, without
notice, to March 31, 2015 with the consent of the Company and Laidlaw; provided, further, however, that such termination will not affect the
right of any party to sue for any breach by any other party (or parties).
5.2 Fees and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees
and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees, stamp taxes
and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.
Notwithstanding the foregoing, the Company agrees to pay promptly all of Laidlaw’s legal fees reasonably incurred in connection
with the negotiation, preparation, execution, delivery and performance of this Agreement and the other Transaction Documents. Subject to
the following qualifications, such legal fees shall not exceed $50,000 in the aggregate, and are exclusive of disbursements and any fees
incurred in connection with the contemplated Registration Statement (the “Cap”). In the event that there should be a material change in the
transactions contemplated hereby, then Laidlaw and the Company agree to a good faith upward adjustment in the Cap. Such legal fees will
be due and payable as follows: fifty percent (50%) of such legal fees incurred to date shall be paid at the Initial Closing and the remainder
shall be paid at each subsequent Closing together with any additional legal fees incurred from the date of the prior Closing until such
subsequent Closing, subject always to the Cap. Notwithstanding the foregoing, if there be no Closing hereunder, then such legal fees shall be
due and payable on demand. Laidlaw shall deliver an itemized invoice from Laidlaw’s counsel detailing such legal fees at least two (2)
Business Days prior to the Initial Closing and each subsequent Closing.
5.3 Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire
understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral
or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.
5.4 Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a
Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the
facsimile number set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City
time) on any Trading Day, (c) the second (2 nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight
courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and
communications shall be as set forth on the signature pages attached hereto.
5.5 Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a
written instrument signed, in the case of an amendment, by the Company and the Purchasers holding at least 67% in interest of the Securities
then outstanding, or in the case of a waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of
any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future
or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of
any party to exercise any right hereunder in any manner impair the exercise of any such right.
24
5.6 Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.
5.7 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such
Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred
Securities, by the provisions of the Transaction Documents that apply to the “Purchasers.”
5.8 No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set
forth in Section 4.9.
5.9 Governing Law. The Transaction Documents will be governed by and construed under the laws of the State of New York as
applied to agreements among New York residents entered into and to be performed entirely within New York. The parties hereto (1) agree
that any legal suit, action or proceeding arising out of or relating to this Agreement will be instituted exclusively in New York State Supreme
Court, County of New York, or in the United States District Court for the Southern District of New York, (2) waive any objection which the
parties may have now or hereafter to the venue of any such suit, action or proceeding, and (3) irrevocably consent to the jurisdiction of the
New York State Supreme Court, County of New York, and the United States District Court for the Southern District of New York in any
such suit, action or proceeding. Each of the parties hereto further agrees to accept and acknowledge service of any and all process which may
be served in any such suit, action or proceeding in the New York State Supreme Court, County of New York, or in the United States District
Court for the Southern District of New York and agrees that service of process upon it mailed by certified mail to its address will be deemed
in every respect effective service of process upon it, in any such suit, action or proceeding. If either party shall commence an action or
proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section 4.9,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs
and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. THE PARTIES HERETO AGREE
TO WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR
ARISING OUT OF THIS AGREEMENT OR ANY DOCUMENT OR AGREEMENT CONTEMPLATED HEREBY.
5.10 Survival. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.
5.11 Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be
considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each
other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile
transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an
original thereof.
25
5.12 Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.
5.13 Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar
provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a
Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such
Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand
or election in whole or in part without prejudice to its future actions and rights; provided, however, that in the case of a rescission of an
exercise of an Investor Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such
rescinded conversion or exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company
for such shares and the restoration of such Purchaser’s right to acquire such shares pursuant to such Purchaser’s Investor Warrant (including,
issuance of a replacement warrant certificate evidencing such restored right).
5.14 Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the
Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu
of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such
loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party
costs (including customary indemnity) associated with the issuance of such replacement Securities.
5.15 Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of
damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties
agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense
that a remedy at law would be adequate.
5.16 Payment Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any
Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such
enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any
law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of
any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if
such payment had not been made or such enforcement or setoff had not occurred.
5.17 Independent Nature of Purchasers’ Obligations and Rights . The obligations of each Purchaser under any Transaction
Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the
performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in
any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any
way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this
Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party
in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the
Transaction Documents. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the
convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and
agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser,
solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.
26
5.18 Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.
5.19 Construction. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to
revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and
forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this
Agreement.
5.20 WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT
BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE
GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.
(Signature Pages Follow)
27
IN WITNESS WHEREOF, the parties hereto have caused this UNIT PURCHASE AGREEMENT to be duly executed by
their respective authorized signatories as of the date first indicated above.
BIOSIG TECHNOLOGIES, INC.
Address for Notice:
12424 Wilshire Blvd., Suite 745
Los Angeles, CA 90025
Fax: 310-820-8115
By: /s/ Kenneth L. Londoner
Name: Kenneth L. Londoner
Title: Executive Chairman
With a copy to (which shall not constitute notice):
Rick Werner, Esq.
Haynes and Boone, LLP
30 Rockefeller Plaza
26th Floor
New York, NY 10112
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
SIGNATURE PAGE FOR PURCHASER FOLLOWS]
PURCHASER SIGNATURE PAGES TO BIOSIG UNIT PURCHASE AGREEMENT
IN WITNESS WHEREOF, the undersigned have caused this UNIT PURCHASE AGREEMENT to be duly executed by their
respective authorized signatories as of the date first indicated above.
Name of Purchaser:
Signature of Authorized Signatory of Purchaser:
Name of Authorized Signatory:
Title of Authorized Signatory:
Email Address of Authorized Signatory:
Facsimile Number of Authorized Signatory:
Address for Notice to Purchaser:
Address for Delivery of Securities to Purchaser (if not same as address for notice):
Subscription Amount:
Shares of Common Stock:
Investor Warrant Shares:
EIN Number:
[SIGNATURE PAGES CONTINUE]
Exhibit A: Form of A Warrant
Exhibit B: Form of B Warrant
Exhibit C: Form of Legal Opinion of Company Counsel
Exhibit D: Registration Rights Agreement
REGISTRATION RIGHTS AGREEMENT
Exhibit 10.38
This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 19, 2014 among BioSig Technologies, Inc., a Delaware corporation (the “Company”),
and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
This Agreement is made pursuant to the Unit Purchase Agreement, dated as of the date hereof, among the Company and each Purchaser (the “Purchase Agreement”).
The Company and each Purchaser hereby agree as follows:
1. Definitions.
Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As
used in this Agreement, the following terms shall have the following meanings:
“Advice” shall have the meaning set forth in Section 6(d).
“Cut-Off Date” shall have the meaning set forth in Section 2(a).
“Effectiveness Date” means, with respect to the Initial Registration Statement required to be filed hereunder, the 180th calendar day following the Filing Date and with respect to
any additional Registration Statements which may be required pursuant to Section 2(c) or Section 3(c), the 90th calendar day following the date on which an additional Registration
Statement is required to be filed hereunder; provided, however, that in the event the Company is notified by the Commission that one or more of the above Registration Statements will not
be reviewed or is no longer subject to further review and comments, the Effectiveness Date as to such Registration Statement shall be the 30th calendar day following the date on which the
Company is so notified if such date precedes the dates otherwise required above (unless the Company is required to update its financial statements prior to requesting acceleration of such
Registration Statement, which will require the Company to file an amendment to such Registration Statement, in which case the Company shall file any necessary amendment to such
Registration Statement and request effectiveness thereof as soon as reasonably practicable and in no event later than the 60th calendar day following the Filing Date); provided, further, if
such Effectiveness Date falls on a day that is not a Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.
“Effectiveness Period” shall have the meaning set forth in Section 2(a).
“Event” shall have the meaning set forth in Section 2(d).
“Event Date” shall have the meaning set forth in Section 2(d).
“Filing Date” means, with respect to the Initial Registration Statement required hereunder, the 45 th calendar day following the final Closing Date and, with respect to any
additional Registration Statements which may be required pursuant to Section 2(c) or Section 3(c), the earliest practical date on which the Company is permitted by SEC Guidance to file
such additional Registration Statement related to the Registrable Securities.
“Holder” or “Holders” means the holder or holders, as the case may be, from time to time of Registrable Securities.
“Indemnified Party” shall have the meaning set forth in Section 5(c).
“Indemnifying Party” shall have the meaning set forth in Section 5(c).
“Initial Registration Statement” means the initial Registration Statement filed pursuant to this Agreement.
“Laidlaw Warrants” means the warrants issued by the Company to Laidlaw, and/or its employees and affiliates, pursuant to the transactions contemplated under the Purchase
Agreement.
“Losses” shall have the meaning set forth in Section 5(a).
“Plan of Distribution” shall have the meaning set forth in Section 2(a).
“Prospectus” means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a
prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission pursuant to the Securities Act), as amended or supplemented by
any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and
supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.
“Purchase Agreement Shares” means the shares of Common Stock issued to the Purchasers pursuant to the Purchase Agreement (and shall not include the Investor Warrants or the
Investor Warrant Shares).
“Registrable Securities” means, as of any date of determination, (a) all of the Purchase Agreement Shares, (b) all Investor Warrant Shares then issuable upon exercise of the
Investor Warrants (assuming on such date the Investor Warrants are exercised in full without regard to any exercise limitations therein), (c) the shares of Common Stock underlying the
Laidlaw Warrants; (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the Investor Warrants and the Laidlaw Warrants (in each case,
without giving effect to any limitations on exercise set forth in the Investor Warrants and the Laidlaw Warrants), and (e) any securities issued or then issuable upon any stock split, dividend
or other distribution, recapitalization or similar event with respect to the foregoing; provided, however, that any such Registrable Securities shall cease to be Registrable Securities (and the
Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect thereto) for so long as (a) a Registration Statement with
respect to the sale of such Registrable Securities is declared effective by the Commission under the Securities Act and such Registrable Securities have been disposed of by the Holder in
accordance with such effective Registration Statement, (b) such Registrable Securities have been previously sold in accordance with Rule 144, or (c) such securities become eligible for
resale without volume or manner-of-sale restrictions and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144, as
determined by counsel to the Company pursuant to a written opinion letter to such effect, addressed, delivered and acceptable to the Transfer Agent and the affected Holders (assuming that
such securities, any securities upon the exercise, conversion or exchange of or as a dividend upon which such securities were issued, or any securities issuable upon the exercise, conversion
or exchange of, or as a dividend upon such securities, were at no time held by any Affiliate of the Company, and all B Warrants are exercised by “cashless exercise” as provided in Section
2(c) of each of the B Warrants), as reasonably determined by the Company, upon the advice of counsel to the Company. For the avoidance of doubt, any such Registrable Securities shall
cease to be Registrable Securities after the Cut-Off Date.
2
“Registration Statement” means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional registration statements contemplated by
Section 2(c) or Section 3(c), including (in each case) the Prospectus, amendments and supplements to any such registration statement or Prospectus, including pre- and post-effective
amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in any such registration statement.
“Rule 415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or
regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.
“Rule 424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or
regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.
“Selling Stockholder Questionnaire” shall have the meaning set forth in Section 3(a).
“SEC Guidance” means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements or requests of the Commission staff and (ii)
the Securities Act.
2. Shelf Registration.
(a) On or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale of all of the Registrable Securities
that are not then registered on an effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be
on Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form in
accordance herewith, subject to the provisions of Section 2(e)) and shall contain (unless otherwise directed by at least 85% in interest of the Holders) substantially the “Plan of Distribution”
attached hereto as Annex A. Subject to the terms of this Agreement, the Company shall use its reasonable best efforts to cause a Registration Statement filed under this Agreement
(including, without limitation, under Section 3(c)) to be declared effective under the Securities Act as promptly as possible after the filing thereof, but in any event no later than the
applicable Effectiveness Date, and shall use its reasonable best efforts to keep such Registration Statement continuously effective under the Securities Act until the first to occur of: (A) the
date that is one (1) year from the date the Registration Statement is declared effective by the Commission (the “ Cut-Off Date”) and (B) the date that all Registrable Securities covered by
such Registration Statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the
requirement for the Company to be in compliance with the current public information requirement under Rule 144, as determined by the counsel to the Company pursuant to a written
opinion letter to such effect, addressed, delivered and acceptable to the Transfer Agent and the affected Holders (assuming that such securities, any securities upon the exercise, conversion
or exchange of or as a dividend upon which such securities were issued, or any securities issuable upon the exercise, conversion or exchange of, or as a dividend upon such securities, were at
no time held by any Affiliate of the Company, and all B Warrants are exercised by “cashless exercise” as provided in Section 2(c) of each of the B Warrants) (the “ Effectiveness Period”).
The Company shall telephonically request effectiveness of a Registration Statement as of 5:00 p.m. Eastern Time on a Trading Day. The Company shall immediately notify the Holders via
facsimile or by e-mail of the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically confirms effectiveness with the Commission, which shall
be the date requested for effectiveness of such Registration Statement. The Company shall, by 9:30 a.m. Eastern Time on the Trading Day after the effective date of such Registration
Statement, file a final Prospectus with the Commission as required by Rule 424. Failure to so notify the Holder within one (1) Trading Day of such notification of effectiveness or failure to
file a final Prospectus as foresaid shall be deemed an Event under Section 2(d).
3
(b) Notwithstanding the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the Registrable Securities cannot, as a result of
the application of Rule 415, be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly inform each of the Holders thereof and use its
commercially reasonable efforts to file amendments to the Initial Registration Statement as required by the Commission, covering the maximum number of Registrable Securities permitted
to be registered by the Commission, on Form S-3 or such other form available to register for resale the Registrable Securities as a secondary offering, subject to the provisions of Section
2(e); provided, however, that prior to filing such amendment, the Company shall be obligated to use diligent efforts to advocate with the Commission for the registration of all of the
Registrable Securities in accordance with the SEC Guidance, including without limitation, Compliance and Disclosure Interpretation 612.09.
(c) Notwithstanding any other provision of this Agreement and subject to the payment of liquidated damages pursuant to Section 2(d), if the Commission or any SEC
Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration Statement as a secondary offering (and notwithstanding that
the Company used diligent efforts to advocate with the Commission for the registration of all or a greater portion of Registrable Securities), unless otherwise directed in writing by a Holder
as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will be reduced as follows:
(i) First, the Company shall reduce or eliminate any securities to be included by any Person other than a Holder;
(ii) Second, the Company shall reduce Registrable Securities represented by Investor Warrant Shares and the shares of Common Stock underlying the Laidlaw Warrants (applied, in
the case that some Investor Warrant Shares and shares of Common Stock underlying the Laidlaw Warrants may be registered, to the Holders and Laidlaw on a pro rata basis
based on the total number of unregistered Investor Warrant Shares and shares of Common Stock underlying the Laidlaw Warrants held by such Holders and Laidlaw,
collectively); and
4
(iii) Third, the Company shall reduce Registrable Securities represented by the Purchase Agreement Shares (applied, in the case that some Purchase Agreement Shares may be
registered, to the Holders on a pro rata basis based on the total number of unregistered Purchase Agreement Shares held by such Holders).
In the event of a cutback hereunder, the Company shall give the Holder at least five (5) Trading Days prior written notice along with the calculations as to such Holder’s allotment. In the
event the Company amends the Initial Registration Statement in accordance with the foregoing, the Company will use its reasonable best efforts to file with the Commission, as promptly
as allowed by Commission or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or such other form
available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement, as amended.
(d) If: (i) the Initial Registration Statement is not filed on or prior to its Filing Date (if the Company files the Initial Registration Statement without affording the Holders the
opportunity to review and comment on the same as required by Section 3(a) herein, the Company shall be deemed to have not satisfied this clause (i)), or (ii) the Company fails to file with
the Commission a request for acceleration of a Registration Statement in accordance with Rule 461 promulgated by the Commission pursuant to the Securities Act, within five Trading Days
of the date that the Company is notified (orally or in writing, whichever is earlier) by the Commission that such Registration Statement will not be “reviewed” or will not be subject to
further review, or (iii) prior to the effective date of a Registration Statement, the Company fails to file a pre- effective amendment and otherwise respond in writing to comments made by the
Commission in respect of such Registration Statement within thirty (30) calendar days after the receipt of comments by or notice from the Commission that such amendment is required in
order for such Registration Statement to be declared effective, or (iv) a Registration Statement registering for resale all of the Registrable Securities is not declared effective by the
Commission by the Effectiveness Date of the Initial Registration Statement, or (v) after the effective date of a Registration Statement, such Registration Statement ceases for any reason to
remain continuously effective as to all Registrable Securities included in such Registration Statement, or the Holders are otherwise not permitted to utilize the Prospectus therein to resell
such Registrable Securities, for more than ten (10) consecutive calendar days or more than an aggregate of fifteen (15) calendar days (which need not be consecutive calendar days) during
any 12-month period (any such failure or breach being referred to as an “Event”, and for purposes of clauses (i) and (iv), the date on which such Event occurs, and for purpose of clause (ii)
the date on which such five (5) Trading Day period is exceeded, and for purpose of clause (iii) the date which such thirty (30) calendar day period is exceeded, and for purpose of clause (v)
the date on which such ten (10) or fifteen (15) calendar day period, as applicable, is exceeded being referred to as an “Event Date”), then, in addition to any other rights the Holders may
have hereunder or under applicable law, on each such Event Date and on each thirty (30) calendar day anniversary of each such Event Date (if the applicable Event shall not have been cured
by such date) until the applicable Event is cured, the Company shall pay to each Holder an amount in cash, as partial liquidated damages and not as a penalty, equal to 1.0% of the aggregate
purchase price paid by such Holder pursuant to the Purchase Agreement; provided, however, that the Company shall not be required to make any payments pursuant to this Section 2(d) if an
Event occurred at such time that all Registrable Securities are eligible for resale pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated
by the Commission pursuant to the Securities Act; provided, further, that the Company shall not be required to make any payments pursuant to this Section 2(d) with respect to any
Registrable Securities the Company is unable to register due to limits imposed by the Commission’s interpretation of Rule 415 under the Securities Act. The parties agree that the maximum
aggregate liquidated damages payable to a Holder under this Agreement shall be 6.0% of the aggregate Subscription Amount paid by such Holder pursuant to the Purchase Agreement. If the
Company fails to pay any partial liquidated damages pursuant to this Section in full within seven (7) days after the date payable, the Company will pay interest thereon at a rate of 18% per
annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the Holder, accruing daily from the date such partial liquidated damages are due until such
amounts, plus all such interest thereon, are paid in full. The partial liquidated damages pursuant to the terms hereof shall apply on a daily pro rata basis for any portion of a thirty (30)
calendar day period prior to the cure of an Event.
5
(e) If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register the resale of the Registrable Securities on
another appropriate form and (ii) undertake to register the Registrable Securities on Form S-3 as soon as such form is available, provided that the Company shall maintain the effectiveness
of the Registration Statement then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the Commission.
3. Registration Procedures.
In connection with the Company’s registration obligations hereunder, the Company shall:
(a) Not less than five (5) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior to the filing of any related Prospectus or
any amendment or supplement thereto (including any document that would be incorporated or deemed to be incorporated therein by reference), the Company shall (i) furnish to each Holder
copies of all such documents proposed to be filed, which documents (other than those incorporated or deemed to be incorporated by reference) will be subject to the review of such Holders,
and (ii) cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of respective
counsel to each Holder, to conduct a reasonable investigation within the meaning of the Securities Act. Notwithstanding the above, the Company shall not be obligated to provide the
Holders advance copies of any universal shelf registration statement registering securities in addition to those required hereunder, or any Prospectus prepared thereto. The Company shall not
file a Registration Statement or any such Prospectus or any amendments or supplements thereto to which the Holders of 67% or more of the Registrable Securities shall reasonably object in
good faith, provided that, the Company is notified of such objection in writing no later than five (5) Trading Days after the Holders have been so furnished copies of a Registration
Statement or one
(1) Trading Day after the Holders have been so furnished copies of any related Prospectus or amendments or supplements thereto. Each Holder agrees to furnish to the Company a
completed questionnaire in the form attached to this Agreement as Annex B (a “Selling Stockholder Questionnaire”) on a date that is not less than two (2) Trading Days prior to the Filing
Date or by the end of the fourth (4th) Trading Day following the date on which such Holder receives draft materials in accordance with this Section.
(b) (i) Prepare and file with the Commission such amendments, including post- effective amendments, to a Registration Statement and the Prospectus used in connection
therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable Registrable Securities for the Effectiveness Period and prepare and file with the
Commission such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities, (ii) cause the related Prospectus to be amended or
supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as
promptly as reasonably possible to any comments received from the Commission with respect to a Registration Statement or any amendment thereto and provide as promptly as reasonably
possible to the Holders true and complete copies of all correspondence from and to the Commission relating to a Registration Statement (provided that, the Company shall excise any
information contained therein which would constitute material non-public information regarding the Company or any of its Subsidiaries), and (iv) comply in all material respects with the
applicable provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration Statement during the applicable period
in accordance (subject to the terms of this Agreement) with the intended methods of disposition by the Holders thereof set forth in such Registration Statement as so amended or in such
Prospectus as so supplemented.
6
(c) If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common Stock then registered in a
Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case prior to the applicable Filing Date, an additional Registration Statement covering the
resale by the Holders of not less than the number of such Registrable Securities.
(d) Notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied by an instruction to suspend the
use of the Prospectus until the requisite changes have been made) as promptly as reasonably possible (and, in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing)
and (if requested by any such Person) confirm such notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus or any Prospectus supplement or post-
effective amendment to a Registration Statement is proposed to be filed, (B) when the Commission notifies the Company whether there will be a “review” of such Registration Statement
and whenever the Commission comments in writing on such Registration Statement, and (C) with respect to a Registration Statement or any post-effective amendment, when the same has
become effective, (ii) of any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for
additional information, (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration
Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose, (iv) of the receipt by the Company of any notification with respect to the
suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such
purpose, (v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any statement made
in a Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to a
Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not
misleading, and (vi) of the occurrence or existence of any pending corporate development with respect to the Company that the Company believes may be material and that, in the
determination of the Company, makes it not in the best interest of the Company to allow continued availability of a Registration Statement or Prospectus, provided, however, in no event
shall any such notice contain any information which would constitute material, non-public information regarding the Company or any of its Subsidiaries.
7
(e) Use its reasonable best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending the effectiveness of a Registration
Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.
(f) Furnish to each Holder, without charge, at least one conformed copy of each such Registration Statement and each amendment thereto, including financial statements and
schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested by such Person, and all exhibits to the extent requested by such Person
(including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission; provided, that any such item which is available on the
EDGAR system (or successor thereto) need not be furnished in physical form.
(g) Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by each of the selling
Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto, except after the giving of any notice
pursuant to Section 3(d).
(h) The Company shall cooperate with any broker-dealer through which a Holder proposes to resell its Registrable Securities in effecting a filing with the FINRA Corporate
Financing Department pursuant to FINRA Rule 5110, as requested by any such Holder, and the Company shall pay the filing fee required by such filing within two (2) Business Days of
request therefor.
(i) Prior to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate with the selling Holders in connection
with the registration or qualification (or exemption from the Registration or qualification) of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of
such jurisdictions within the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during the Effectiveness
Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement;
provided, that, the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such
jurisdiction where it is not then so subject or file a general consent to service of process in any such jurisdiction.
(j) If requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be delivered to a
transferee pursuant to a Registration Statement, which certificates shall be free, to the extent permitted by the Purchase Agreement and applicable law, of all restrictive legends, and to enable
such Registrable Securities to be in such denominations and registered in such names as any such Holder may request.
(k) Upon the occurrence of any event contemplated by Section 3(d), as promptly as reasonably possible under the circumstances taking into account the Company’s good
faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure of such event, prepare a supplement or amendment, including a post-effective
amendment, to a Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other
required document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Company notifies the Holders in
accordance with clauses (iii) through (vi) of Section 3(d) above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall
suspend use of such Prospectus. The Company will use its reasonable best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company shall
be entitled to exercise its right under this Section 3(k) to suspend the availability of a Registration Statement and Prospectus, subject to the payment of partial liquidated damages otherwise
required pursuant to Section 2(d), for a period not to exceed 60 calendar days (which need not be consecutive days) in any 12-month period.
8
(l) Comply with all applicable rules and regulations of the Commission.
(m) The Company shall use its reasonable best efforts to maintain eligibility for use of Form S-3 (or any successor form thereto) for the registration of the resale of Registrable
Securities.
(n) The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common Stock beneficially owned by such Holder
and, if required by the Commission, the natural persons thereof that have voting and dispositive control over the shares. During any periods that the Company is unable to meet its
obligations hereunder with respect to the registration of the Registrable Securities solely because any Holder fails to furnish such information within three Trading Days of the Company’s
request, any liquidated damages that are accruing at such time as to such Holder only shall be tolled and any Event that may otherwise occur solely because of such delay shall be suspended
as to such Holder only, until such information is delivered to the Company.
4. Registration Expenses. All fees and expenses incident to the performance of or compliance with, this Agreement by the Company shall be borne by the Company whether or not any
Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees
(including, without limitation, fees and expenses of the Company’s counsel and independent registered public accountants) (A) with respect to filings made with the Commission, (B) with
respect to filings required to be made with any Trading Market on which the Common Stock is then listed for trading, (C) in compliance with applicable state securities or Blue Sky laws
reasonably agreed to by the Company in writing (including, without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of
the Registrable Securities) and (D) if not previously paid by the Company, with respect to any filing that may be required to be made by any broker through which a Holder intends to make sales
of Registrable Securities with FINRA pursuant to FINRA Rule 5110, so long as the broker is receiving no more than a customary brokerage commission in connection with such sale, (ii)
printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of
counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection
with the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the
consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties),
the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. Notwithstanding
the foregoing, the Company shall be responsible for the legal fees or other costs of the Holders (including the reasonable counsel fees of Laidlaw, as representative of the Holders; provided,
however, that any such counsel fees of Laidlaw shall not exceed $10,000 in the aggregate and any related expenses shall not exceed $10,000 in the aggregate) incurred in connection with the
transactions contemplated hereby.
9
5. Indemnification.
(a) Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder, the officers,
directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as principal as a result of a pledge or any failure to perform under a margin call of
Common Stock), investment advisors and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any
other title) of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors,
members, stockholders, partners, agents and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any
other title) of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without
limitation, reasonable attorneys’ fees) and expenses (collectively, “Losses”), as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in
a Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission
or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the
circumstances under which they were made) not misleading or (2) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or
any rule or regulation thereunder, in connection with the performance of its obligations under this Agreement, except to the extent, but only to the extent, that (i) such untrue statements or
omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent that such information
relates to such Holder or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a
Registration Statement, such Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this purpose) or (ii) in the case of
an occurrence of an event of the type specified in Section 3(d)(iii)-(vi), the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after the Company has notified
such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice contemplated in
Section 6(d), but only if and to the extent that following the receipt of the Advice the misstatement or omission giving rise to such Loss would have been corrected. The Company shall
notify the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the
Company is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified person and shall survive the transfer of any
Registrable Securities by any of the Holders in accordance with Section 6(h).
(b) Indemnification by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents and employees, each
Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such
controlling Persons (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title), to the fullest extent
permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon: (x) such Holder’s failure to comply with any applicable prospectus
delivery requirements of the Securities Act or the plan of distribution in any Registration Statement through no fault of the Company or (y) any untrue or alleged untrue statement of a
material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any
omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the
circumstances under which they were made) not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained in any information so furnished in
writing by such Holder to the Company expressly for inclusion in such Registration Statement or such Prospectus or (ii) to the extent, but only to the extent, that such information relates to
such Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement (it
being understood that the Holder has approved Annex A hereto for this purpose), such Prospectus or in any amendment or supplement thereto or (iii) in the case of an occurrence of an event
of the type specified in Section 3(d)(iii)- (vi), to the extent, but only to the extent, related to the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after the
Company has notified such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice
contemplated in Section 6(d), but only if and to the extent that following the receipt of the Advice the misstatement or omission giving rise to such Loss would have been corrected. In no
event shall the liability of any selling Holder under this Section 5(b) be greater in amount than the dollar amount of the net proceeds actually received by such Holder upon the sale of the
Registrable Securities giving rise to such indemnification obligation.
10
(c) Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an “Indemnified Party”), such
Indemnified Party shall promptly notify the Person from whom indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have the right to assume the
defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with defense thereof;
provided, that, the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to
the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially and
adversely prejudiced the Indemnifying Party.
An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel
shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have
failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to any
such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to the Indemnified Party shall reasonably believe that a
material conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the
Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense
thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any
settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written
consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional
release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.
11
Subject to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection
with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within ten Trading Days of
written notice thereof to the Indemnifying Party; provided, that, the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses
applicable to such actions for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) not to
be entitled to indemnification hereunder.
(d) Contribution. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless for any Losses,
then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying
Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of
such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of
a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any
Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys’ or other fees or expenses incurred by such party in connection with any
Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with
its terms.
The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata allocation or by any other method of
allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. Notwithstanding the provisions of this Section 5(d), no Holder
shall be required to contribute pursuant to this Section 5(d), in the aggregate, any amount in excess of the amount by which the net proceeds actually received by such Holder from the sale
of the Registrable Securities subject to the Proceeding exceeds the amount of any damages that such Holder has otherwise been required to pay by reason of such untrue or alleged untrue
statement or omission or alleged omission.
The indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties.
12
6. Miscellaneous.
(a) Remedies. In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder or the Company, as the case may be, in
addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, shall be entitled to specific performance of its rights under this
Agreement. Each of the Company and each Holder agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the
provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall not assert or shall waive the defense that a
remedy at law would be adequate.
(b) No Piggyback on Registrations; Prohibition on Filing Other Registration Statements. Except as set forth on Schedule 6(b) attached hereto, neither the Company nor any of its
security holders (other than the Holders in such capacity pursuant hereto) may include securities of the Company in any Registration Statements other than the Registrable Securities. The
Company shall not file any other registration statements until all Registrable Securities are registered pursuant to a Registration Statement that is declared effective by the Commission, provided
that this Section 6(b) shall not prohibit the Company from filing amendments to registration statements filed prior to the date of this Agreement.
(c) Compliance. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable to it (unless an exemption
therefrom is available) in connection with sales of Registrable Securities pursuant to a Registration Statement.
(d) Discontinued Disposition. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company of the occurrence of any event of the
kind described in Section 3(d)(iii) through (vi), such Holder will forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the
“Advice”) by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will use its reasonable best efforts to ensure
that the use of the Prospectus may be resumed as promptly as is practicable. The Company agrees and acknowledges that any periods during which the Holder is required to discontinue the
disposition of the Registrable Securities hereunder shall be subject to the provisions of Section 2(d).
(e) Piggy-Back Registrations. If, at any time during the Effectiveness Period, there is not an effective Registration Statement covering all of the Registrable Securities and the
Company shall determine to prepare and file with the Commission a registration statement relating to an offering for its own account or the account of others under the Securities Act of any of its
equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with
any acquisition of any entity or business or equity securities issuable in connection with the Company’s stock option or other employee benefit plans, then the Company shall deliver to each
Holder a written notice of such determination and, if within fifteen days after the date of the delivery of such notice, any such Holder shall so request in writing, the Company shall include in
such registration statement all or any part of such Registrable Securities such Holder requests to be registered; provided, however, that the Company shall not be required to register any
Registrable Securities pursuant to this Section 6(e) that are eligible for resale pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated by the
Commission pursuant to the Securities Act or that are the subject of a then effective Registration Statement.
(f) Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, and waivers or consents to
departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and the Holders of 67% or more of the then outstanding Registrable
Securities (for purposes of clarification, this includes any Registrable Securities issuable upon exercise or conversion of any Security). If a Registration Statement does not register all of
the Registrable Securities pursuant to a waiver or amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for each Holder shall be
reduced pro rata among all Holders and each Holder shall have the right to designate which of its Registrable Securities shall be omitted from such Registration Statement. Notwithstanding the
foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of a Holder or some Holders and that does not directly or
indirectly affect the rights of other Holders may be given only by such Holder or Holders of all of the Registrable Securities to which such waiver or consent relates; provided, however, that the
provisions of this sentence may not be amended, modified, or supplemented except in accordance with the provisions of the first sentence of this Section 6(f). No consideration shall be offered or
paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration also is offered to all of the parties to this Agreement.
13
(g) Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered as set forth in the Purchase Agreement.
(h) Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit
of each Holder. The Company may not assign (except by merger) its rights or obligations hereunder without the prior written consent of all of the Holders of the then outstanding Registrable
Securities. Each Holder may assign their respective rights hereunder in the manner and to the Persons as permitted under Section 5.7 of the Purchase Agreement.
(i) No Inconsistent Agreements. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company or any of its Subsidiaries, on or after the
date of this Agreement, enter into any agreement with respect to its securities, that would have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts
with the provisions hereof. Except as set forth on Schedule 6(i), neither the Company nor any of its Subsidiaries has previously entered into any agreement granting any registration rights with
respect to any of its securities to any Person that have not been satisfied in full.
(j) Execution and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event
that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on
whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.
(k) Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined in accordance with the provisions of the
Purchase Agreement.
(l) Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.
(m) Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the
remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto
shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without
including any of such that may be hereafter declared invalid, illegal, void or unenforceable.
14
(n) Headings. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be deemed to limit or affect any of the provisions
hereof.
(o) Independent Nature of Holders’ Obligations and Rights . The obligations of each Holder hereunder are several and not joint with the obligations of any other Holder hereunder,
and no Holder shall be responsible in any way for the performance of the obligations of any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at
any closing, and no action taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture or any other kind of group or
entity, or create a presumption that the Holders are in any way acting in concert or as a group or entity with respect to such obligations or the transactions contemplated by this Agreement or any
other matters, and the Company acknowledges that the Holders are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or
transactions. Each Holder shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Holder
to be joined as an additional party in any proceeding for such purpose. The use of a single agreement with respect to the obligations of the Company contained was solely in the control of the
Company, not the action or decision of any Holder, and was done solely for the convenience of the Company and not because it was required or requested to do so by any Holder. It is expressly
understood and agreed that each provision contained in this Agreement is between the Company and a Holder, solely, and not between the Company and the Holders collectively and not between
and among Holders.
********************
(Signature Pages Follow)
15
IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.
BIOSIG TECHNOLOGIES, INC., A DELAWARE CORPORATION
By:
Name:
Title:
[SIGNATURE PAGE OF HOLDERS FOLLOWS]
SIGNATURE PAGE OF HOLDERS TO BIOSIG REGISTRATION RIGHTS AGREEMENT
Name of Holder: ______________________________
Signature of Authorized Signatory of Holder: ______________________________
Name of Authorized Signatory: ______________________________
Title of Authorized Signatory: ______________________________
[SIGNATURE PAGES CONTINUE]
Annex A
Plan of Distribution
Each Selling Stockholder (the “Selling Stockholders”) of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their
securities covered hereby on the OTC Bulletin Board or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at
fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities:
· ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
· block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;
· purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
· an exchange distribution in accordance with the rules of the applicable exchange;
· privately negotiated transactions;
· settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part;
· in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;
· through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
· a combination of any such methods of sale; or
· any other method permitted pursuant to applicable law.
The Selling Stockholders may also sell securities under Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”), if available, rather than under this prospectus.
Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the
Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this
Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or
markdown in compliance with FINRA IM-2440.
In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which
may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close
out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with
broker- dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this
prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters” within the meaning of the Securities Act in
connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be
underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities. In no event shall any broker- dealer receive fees, commissions and markups which, in the aggregate, would exceed eight
percent (8%).
The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling
Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.
Because Selling Stockholders may be deemed to be “underwriters” within the meaning of the Securities Act, they will be subject to the prospectus delivery requirements of the
Securities Act including Rule 172 thereunder. In addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule
144 rather than under this prospectus. The Selling Stockholders have advised us that there is no underwriter or coordinating broker acting in connection with the proposed sale of the resale
securities by the Selling Stockholders.
We agreed to keep this prospectus effective until the earliest of (i) one (1) year from the date the Registration Statement is declared effective by the Commission, (ii) the date on which
the securities may be resold by the Selling Stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for
the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (iii) all of the securities have been sold
pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if
required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the
applicable state or an exemption from the registration or qualification requirement is available and is complied with.
Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making
activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders
will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of securities of
the common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver
a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).
2
Annex B
BIOSIG TECHNOLOGIES, INC.
Selling Stockholder Notice and Questionnaire
The undersigned beneficial owner of common stock (the “Registrable Securities”) of BioSig Technologies, Inc., a Delaware corporation (the “Company”), understands that the
Company has filed or intends to file with the Securities and Exchange Commission (the “Commission”) a registration statement (the “Registration Statement”) for the registration and resale
under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of the Registrable Securities, in accordance with the terms of the Registration Rights Agreement (the
“Registration Rights Agreement”) to which this document is annexed. A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth below.
All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.
Certain legal consequences arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly, holders and beneficial owners of
Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling stockholder in the Registration
Statement and the related prospectus.
The undersigned beneficial owner (the “Selling Stockholder”) of Registrable Securities hereby elects to include the Registrable Securities owned by it in the Registration Statement.
NOTICE
The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:
QUESTIONNAIRE
1. Name.
(a) Full Legal Name of Selling Stockholder
(b) Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:
(c) Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities
covered by this Questionnaire):
2. Address for Notices to Selling Stockholder:
Telephone:
Fax:
Contact Person:
3. Broker-Dealer Status:
(a) Are you a broker-dealer?
Yes o No o
(b) If “yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to the Company?
Yes o No o
Note:
If “no” to Section 3(b), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.
(c) Are you an affiliate of a broker-dealer?
Yes o No o
2
(d) If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase of
the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?
Yes o No o
Note: If “no” to Section 3(d), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.
4. Beneficial Ownership of Securities of the Company Owned by the Selling Stockholder.
Except as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable pursuant to the
Purchase Agreement.
(a) Type and amount of other securities beneficially owned by the Selling Stockholder:
3
5. Relationships with the Company:
Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities of the
undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.
State any exceptions here:
The undersigned agrees to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof at any
time while the Registration Statement remains effective.
By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion of such information in
the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied upon by the
Company in connection with the preparation or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.
IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly
authorized agent.
Date:
Beneficial Owner:
By:
Name:
Title:
PLEASE FAX A COPY (OR EMAIL A .PDF COPY) OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY
OVERNIGHT MAIL, TO:
4
Exhibit 10.39
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN
REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO
AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE
REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A
REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED
INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH
SECURITIES.
COMMON STOCK A WARRANT
BIOSIG TECHNOLOGIES, INC.
A Warrant Shares: ______
Initial Exercise Date: _______, 2014
THIS COMMON STOCK A WARRANT (the “ A Warrant”) certifies that, for value received, _____________ or its assigns
(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on July 31, 2015 (the “Termination Date”) but not
thereafter, to subscribe for and purchase from BioSig Technologies, Inc., a Delaware corporation (the “Company”), up to ______ shares (as
subject to adjustment hereunder, the “A Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this A
Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that
certain Unit Purchase Agreement (the “Purchase Agreement”), dated December 19, 2014, among the Company and the purchasers signatory
thereto.
Section 2. Exercise.
a) Exercise of the purchase rights represented by this A Warrant may be made, in whole or in part, at any time or
times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or
agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the
books of the Company) of a duly executed facsimile copy of the Notice of Exercise Form annexed hereto. Within five (5) Trading
Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the
applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank. Notwithstanding anything herein to
the contrary, the Holder shall not be required to physically surrender this A Warrant to the Company until the Holder has purchased all
of the A Warrant Shares available hereunder and the A Warrant has been exercised in full, in which case, the Holder shall surrender
this A Warrant to the Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to
the Company. Partial exercises of this A Warrant resulting in purchases of a portion of the total number of A Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of A Warrant Shares purchasable hereunder in an amount equal to
the applicable number of A Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of A
Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form
within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of the A Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the A
Warrant Shares hereunder, the number of A Warrant Shares available for purchase hereunder at any given time may be less
than the amount stated on the face hereof.
1
b) Exercise Price. The exercise price per share of the Common Stock under this A Warrant shall be $2.50, subject to
adjustment hereunder (the “Exercise Price”).
c) Mechanics of Exercise.
i. Delivery of Certificates Upon Exercise. Certificates for shares purchased
hereunder shall be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s prime
broker with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the
Company is then a participant in such system and there is an effective registration statement permitting the issuance
of the A Warrant Shares to or resale of the A Warrant Shares by the Holder or otherwise by physical delivery to the
address specified by the Holder in the Notice of Exercise by the date that is five (5) Trading Days after the latest of
(A) the delivery to the Company of the Notice of Exercise, (B) surrender of this A Warrant (if required) and (C)
payment of the aggregate Exercise Price as set forth above (such date, the “A Warrant Share Delivery Date ”). The
A Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named
therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the A
Warrant has been exercised, with payment to the Company of the Exercise Price and all taxes required to be paid by
the Holder, if any, pursuant to Section 2(c)(vi) prior to the issuance of such shares, having been paid.
ii. Delivery of New A Warrants Upon Exercise . If this A Warrant shall have
been exercised in part, the Company shall, at the request of a Holder and upon surrender of this A Warrant
certificate, at the time of delivery of the certificate or certificates representing A Warrant Shares, deliver to the
Holder a new A Warrant evidencing the rights of the Holder to purchase the unpurchased A Warrant Shares called
for by this A Warrant, which new A Warrant shall in all other respects be identical with this A Warrant.
iii. Rescission Rights. If the Company fails to cause the Transfer Agent to
transmit to the Holder a certificate or the certificates representing the A Warrant Shares pursuant to Section 2(c)(i) by
the A Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.
2
iv. Compensation for Buy-In on Failure to Timely Deliver Certificates Upon
Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to
transmit to the Holder a certificate or the certificates representing the A Warrant Shares pursuant to an exercise on or
before the A Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in
an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the A Warrant Shares which the Holder anticipated
receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any,
by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of A Warrant Shares that the
Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which
the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either
reinstate the portion of the A Warrant and equivalent number of A Warrant Shares for which such exercise was not
honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of
Common Stock that would have been issued had the Company timely complied with its exercise and delivery
obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of
$11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale
price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of
the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it
hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief
with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock upon
exercise of the A Warrant as required pursuant to the terms hereof.
v. No Fractional Shares or Scrip. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of this A Warrant. As to any fraction of a share which the Holder
would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash
adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.
vi. Charges, Taxes and Expenses. Issuance of certificates for A Warrant Shares
shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the
issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall
be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however,
that in the event certificates for A Warrant Shares are to be issued in a name other than the name of the Holder, this
A Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly
executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to
reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for
same-day processing of any Notice of Exercise.
3
records in any manner which prevents the timely exercise of this A Warrant, pursuant to the terms hereof.
vii. Closing of Books. The Company will not close its stockholder books or
d) Holder’s Exercise Limitations. The Company shall not affect any exercise of this A Warrant, and a Holder shall
not have the right to exercise any portion of this A Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to
such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any
other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of the
Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock
beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this
A Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which
would be issuable upon (i) exercise of the remaining, nonexercised portion of this A Warrant beneficially owned by the Holder or any
of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company
(including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to
the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence,
for purposes of this Section 2(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and
the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the
Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(d) applies, the
determination of whether this A Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates)
and of which portion of this A Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of
Exercise shall be deemed to be the Holder’s determination of whether this A Warrant is exercisable (in relation to other securities
owned by the Holder together with any Affiliates) and of which portion of this A Warrant is exercisable, in each case subject to the
Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such
determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(d), in
determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common
Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a
more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting
forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two
Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the
number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of
the Company, including this A Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of
Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this A Warrant. The
Holder, upon not less than 61 days’ prior notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(d), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this A
Warrant held by the Holder and the provisions of this Section 2(d) shall continue to apply. Any such increase or decrease will not be
effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this Section 2(d) to correct this paragraph (or any
portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make
changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this A Warrant.
4
Section 3. Certain Adjustments.
a) Stock Dividends and Splits. If the Company, at any time while this A Warrant is outstanding: (i) pays a stock
dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent
securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by
the Company upon exercise of this A Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares,
(iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)
issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise
Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury
shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common
Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this A Warrant shall be
proportionately adjusted such that the aggregate Exercise Price of this A Warrant shall remain unchanged. Any adjustment made
pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to
receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision,
combination or re-classification.
b) Fundamental Transaction. If, at any time while this A Warrant is outstanding, (i) the Company, directly or
indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the
Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or
substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or
exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any
reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the
Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or
indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of
Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any
shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other
Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental
Transaction”), then, upon any subsequent exercise of this A Warrant, the Holder shall have the right to receive, for each A Warrant
Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the
option of the Holder (without regard to any limitation in Section 2(d) on the exercise of this A Warrant), the number of shares of
Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of
shares of Common Stock for which this A Warrant is exercisable immediately prior to such Fundamental Transaction (without regard
to any limitation in Section 2(d) on the exercise of this A Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise
Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the
Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a
Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any
exercise of this A Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a
Fundamental Transaction that is (1) an all cash transaction, (2) a “Rule 13e-3 transaction” as defined in Rule 13e-3 under the Exchange
Act, or (3) a Fundamental Transaction involving a person or entity not traded on a Trading Market, the Company or any Successor
Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the
consummation of the Fundamental Transaction, purchase this A Warrant from the Holder by paying to the Holder an amount of cash
equal to the Black Scholes Value of the remaining unexercised portion of this A Warrant on the date of the consummation of such
Fundamental Transaction. “Black Scholes Value” means the value of this A Warrant based on the Black and Scholes Option Pricing
Model obtained from the “OV” function on Bloomberg, L.P. (“ Bloomberg”) determined as of the day of consummation of the
applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury
rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the
Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the “HVT” function
on Bloomberg as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C)
the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the
value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to
the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date. The
Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor
Entity”) to assume in writing all of the obligations of the Company under this A Warrant and the other Transaction Documents in
accordance with the provisions of this Section 3(b) pursuant to written agreements in form and substance reasonably satisfactory to the
Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the
Holder, deliver to the Holder in exchange for this A Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this A Warrant which is exercisable for a corresponding number of shares of capital stock
of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
A Warrant (without regard to any limitations on the exercise of this A Warrant) prior to such Fundamental Transaction, and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of
the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of
shares of capital stock and such exercise price being for the purpose of protecting the economic value of this A Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the
Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so
that from and after the date of such Fundamental Transaction, the provisions of this A Warrant and the other Transaction Documents
referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and
shall assume all of the obligations of the Company under this A Warrant and the other Transaction Documents with the same effect as
if such Successor Entity had been named as the Company herein.
5
c) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a
share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and
outstanding.
d) Notice to Holder.
i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant
to any provision of this Section 3, the Company shall promptly mail to the Holder a notice setting forth the Exercise
Price after such adjustment and any resulting adjustment to the number of A Warrant Shares and setting forth a brief
statement of the facts requiring such adjustment.
ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a
dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special
nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting
to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any
class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any
reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or
transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the
Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary
or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company,
at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the
date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or
if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such
dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such
reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and
the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their
shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect
therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such
notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the
Commission pursuant to a Current Report on Form 8-K if the Company is then subject to the reporting requirements
of Section 13 or 15(d) of the Exchange Act. The Holder shall remain entitled to exercise this A Warrant during the
period commencing on the date of such notice to the effective date of the event triggering such notice except as may
otherwise be expressly set forth herein.
6
Section 4. Transfer of A Warrant.
a) Transferability. This A Warrant and all rights hereunder (including, without limitation, any registration rights) are
transferable, in whole or in part, upon surrender of this A Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this A Warrant substantially in the form attached hereto duly executed by the Holder or its agent
or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if
required, such payment, the Company shall execute and deliver a new A Warrant or A Warrants in the name of the assignee or
assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the
assignor a new A Warrant evidencing the portion of this A Warrant not so assigned, and this A Warrant shall promptly be
cancelled. The A Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of A
Warrant Shares without having a new A Warrant issued.
b) New A Warrants. This A Warrant may be divided or combined with other A Warrants upon presentation hereof at
the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new A Warrants
are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be
involved in such division or combination, the Company shall execute and deliver a new A Warrant or A Warrants in exchange for the
A Warrant or A Warrants to be divided or combined in accordance with such notice. All A Warrants issued on transfers or exchanges
shall be dated the initial issuance date of this A Warrant and shall be identical with this A Warrant except as to the number of A
Warrant Shares issuable pursuant thereto.
c) Warrant Register. The Company shall register this A Warrant, upon records to be maintained by the Company for
that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat
the registered Holder of this A Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the
Holder, and for all other purposes, absent actual notice to the contrary.
Section 6. Miscellaneous.
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(c)(i).
a) No Rights as Stockholder Until Exercise. This A Warrant does not entitle the Holder to any voting rights,
b) Loss, Theft, Destruction or Mutilation of A Warrant . The Company covenants that upon receipt by the Company
of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this A Warrant or any stock certificate relating to
the A Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the A Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such A Warrant or stock
certificate, if mutilated, the Company will make and deliver a new A Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such A Warrant or stock certificate.
7
c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any
right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.
d) Authorized Shares.
The Company covenants that, during the period the A Warrant is outstanding, it will reserve from its
authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the A Warrant Shares
upon the exercise of any purchase rights under this A Warrant. The Company further covenants that its issuance of this A
Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute
and issue the necessary certificates for the A Warrant Shares upon the exercise of the purchase rights under this A
Warrant. The Company will take all such reasonable action as may be necessary to assure that such A Warrant Shares may be
issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market
upon which the Common Stock may be listed. The Company covenants that all A Warrant Shares which may be issued upon
the exercise of the purchase rights represented by this A Warrant will, upon exercise of the purchase rights represented by this
A Warrant and payment for such A Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and
nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than
taxes in respect of any transfer occurring contemporaneously with such issue).
Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including,
without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this A Warrant, but will at all times in good faith assist in the carrying out of all such
terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of the Holder as set forth in
this A Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the
par value of any A Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase
in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally
issue fully paid and nonassessable A Warrant Shares upon the exercise of this A Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having
jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this A Warrant.
Before taking any action which would result in an adjustment in the number of A Warrant Shares for which this A
Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or
consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.
8
shall be determined in accordance with the provisions of the Purchase Agreement.
e) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this A Warrant
not registered, will have restrictions upon resale imposed by state and federal securities laws.
f) Restrictions. The Holder acknowledges that the A Warrant Shares acquired upon the exercise of this A Warrant, if
g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part
of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any
other provision of this A Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any
provision of this A Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of
appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder.
the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.
h) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by
i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this
A Warrant to purchase A Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any
liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is
asserted by the Company or by creditors of the Company.
j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of
damages, will be entitled to specific performance of its rights under this A Warrant. The Company agrees that monetary damages
would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this A Warrant and hereby
agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.
k) Successors and Assigns. Subject to applicable securities laws, this A Warrant and the rights and obligations
evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the
successors and permitted assigns of Holder. The provisions of this A Warrant are intended to be for the benefit of any Holder from
time to time of this A Warrant and shall be enforceable by the Holder or holder of A Warrant Shares.
l) Amendment. This A Warrant may be modified or amended or the provisions hereof waived with the written
consent of the Company and holders holding A Warrants to acquire 67% of the A Warrant Shares issuable pursuant to the A Warrants
that were issued under the Purchase Agreement.
9
m) Severability. Wherever possible, each provision of this A Warrant shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this A Warrant shall be prohibited by or invalid under applicable law,
such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this A Warrant.
purpose, be deemed a part of this A Warrant.
n) Headings. The headings used in this A Warrant are for the convenience of reference only and shall not, for any
********************
(Signature Page Follows)
10
as of the date first above indicated.
IN WITNESS WHEREOF, the Company has caused this A Warrant to be executed by its officer thereunto duly authorized
BIOSIG TECHNOLOGIES, INC.
By:__________________________________________
Name:
Title:
11
TO: BIOSIG TECHNOLOGIES, INC.
NOTICE OF EXERCISE
(1) The undersigned hereby elects to purchase ________ A Warrant Shares of the Company pursuant to the terms of the
attached A Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.
(2) Payment shall take the form of lawful money of the United States.
(3) Please issue a certificate or certificates representing said A Warrant Shares in the name of the undersigned or in such
other name as is specified below:
_______________________________
The A Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:
_______________________________
_______________________________
_______________________________
[SIGNATURE OF HOLDER]
Name of Investing Entity: ________________________________________________________________________
Signature of Authorized Signatory of Investing Entity: _________________________________________________
Name of Authorized Signatory: ___________________________________________________________________
Title of Authorized Signatory: ____________________________________________________________________
Date: ________________________________________________________________________________________
ASSIGNMENT FORM
(To assign the foregoing A Warrant, execute
this form and supply required information.
Do not use this form to exercise the A Warrant.)
are hereby assigned to
FOR VALUE RECEIVED, [____] all of or [_______] shares of the foregoing A Warrant and all rights evidenced thereby
_______________________________________________ whose address is
_______________________________________________________________.
_______________________________________________________________
Dated: ______________, _______
Holder’s Signature: _____________________________
Holder’s Address: _____________________________
_____________________________
Signature Guaranteed: ___________________________________________
NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the A Warrant, without alteration
or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a
fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing A Warrant.
Exhibit 10.40
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN
REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO
AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE
REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A
REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED
INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH
SECURITIES.
COMMON STOCK B WARRANT
BIOSIG TECHNOLOGIES, INC.
B Warrant Shares: ______
Initial Exercise Date: _______, 2014
THIS COMMON STOCK B WARRANT (the “ B Warrant”) certifies that, for value received, _____________ or its assigns
(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on March 31, 2020 (the “Termination Date”) but not
thereafter, to subscribe for and purchase from BioSig Technologies, Inc., a Delaware corporation (the “Company”), up to ______ shares (as
subject to adjustment hereunder, the “B Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this B
Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that
certain Unit Purchase Agreement (the “Purchase Agreement”), dated December 19, 2014, among the Company and the purchasers signatory
thereto.
Section 2. Exercise.
a) Exercise of the purchase rights represented by this B Warrant may be made, in whole or in part, at any time or
times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or
agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the
books of the Company) of a duly executed facsimile copy of the Notice of Exercise Form annexed hereto. Within five (5) Trading
Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the
applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless this B Warrant may be
exercised on a cashless basis and the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of
Exercise. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this B Warrant to
the Company until the Holder has purchased all of the B Warrant Shares available hereunder and the B Warrant has been exercised in
full, in which case, the Holder shall surrender this B Warrant to the Company for cancellation within three (3) Trading Days of the
date the final Notice of Exercise is delivered to the Company. Partial exercises of this B Warrant resulting in purchases of a portion of
the total number of B Warrant Shares available hereunder shall have the effect of lowering the outstanding number of B Warrant
Shares purchasable hereunder in an amount equal to the applicable number of B Warrant Shares purchased (or cancelled, in the event
of a cashless exercise). The Holder and the Company shall maintain records showing the number of B Warrant Shares purchased and
the date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within one (1) Business Day of
receipt of such notice. The Holder and any assignee, by acceptance of the B Warrant, acknowledge and agree that, by reason of
the provisions of this paragraph, following the purchase of a portion of the B Warrant Shares hereunder, the number of B
Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.
1
adjustment hereunder (the “Exercise Price”).
b) Exercise Price. The exercise price per share of the Common Stock under this B Warrant shall be $3.75, subject to
c) Cashless Exercise. Except if the Company redeems this B Warrant in accordance with Section 4 hereof, this B
Warrant may be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to
receive a number of B Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:
(A) = the VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this B Warrant by means
of a “cashless exercise,” as set forth in the applicable Notice of Exercise;
(B) = the Exercise Price of this B Warrant, as adjusted hereunder; and
(X) = the number of B Warrant Shares that would be issuable upon exercise of this B Warrant in accordance with
the terms of this B Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.
“VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the
nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P.
(based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not
then listed or quoted for trading on a Trading Market and if prices for the Common Stock are then reported on an over-the-counter
market maintained by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the
most recent closing price per share of the Common Stock so reported, or (c) in all other cases, the fair market value of a share of
Common Stock as determined by an independent appraiser selected in good faith by the Holders.
Notwithstanding anything herein to the contrary, on the Termination Date, this B Warrant shall be automatically exercised via
cashless exercise pursuant to this Section 2(c).
2
d) Mechanics of Exercise.
i. Delivery of Certificates Upon Exercise. Certificates for shares purchased
hereunder shall be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s prime
broker with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the
Company is then a participant in such system and either (A) there is an effective registration statement permitting the
issuance of the B Warrant Shares to or resale of the B Warrant Shares by the Holder or (B) this B Warrant is being
exercised via cashless exercise at a time when the B Warrant Shares may subsequently sold pursuant to Rule 144
without the requirement for the Company to be in compliance with the current public information required under
Rule 144 and without volume or manner-of-sale restrictions, and otherwise by physical delivery to the address
specified by the Holder in the Notice of Exercise by the date that is five (5) Trading Days after the latest of (A) the
delivery to the Company of the Notice of Exercise, (B) surrender of this B Warrant (if required) and (C) payment of
the aggregate Exercise Price as set forth above (including by cashless exercise, if permitted) (such date, the “B
Warrant Share Delivery Date”). The B Warrant Shares shall be deemed to have been issued, and Holder or any
other person so designated to be named therein shall be deemed to have become a holder of record of such shares for
all purposes, as of the date the B Warrant has been exercised, with payment to the Company of the Exercise Price (or
by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi)
prior to the issuance of such shares, having been paid.
ii. Delivery of New B Warrants Upon Exercise . If this B Warrant shall have
been exercised in part, the Company shall, at the request of a Holder and upon surrender of this B Warrant
certificate, at the time of delivery of the certificate or certificates representing B Warrant Shares, deliver to the
Holder a new B Warrant evidencing the rights of the Holder to purchase the unpurchased B Warrant Shares called
for by this B Warrant, which new B Warrant shall in all other respects be identical with this B Warrant.
iii. Rescission Rights. If the Company fails to cause the Transfer Agent to
transmit to the Holder a certificate or the certificates representing the B Warrant Shares pursuant to Section 2(d)(i) by
the B Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.
iv. Compensation for Buy-In on Failure to Timely Deliver Certificates Upon
Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to
transmit to the Holder a certificate or the certificates representing the B Warrant Shares pursuant to an exercise on or
before the B Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in
an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the B Warrant Shares which the Holder anticipated
receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any,
by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of B Warrant Shares that the
Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which
the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either
reinstate the portion of the B Warrant and equivalent number of B Warrant Shares for which such exercise was not
honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of
Common Stock that would have been issued had the Company timely complied with its exercise and delivery
obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of
$11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale
price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of
the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it
hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief
with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock upon
exercise of the B Warrant as required pursuant to the terms hereof.
3
v. No Fractional Shares or Scrip. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of this B Warrant. As to any fraction of a share which the Holder
would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash
adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.
vi. Charges, Taxes and Expenses. Issuance of certificates for B Warrant Shares
shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the
issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall
be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however,
that in the event certificates for B Warrant Shares are to be issued in a name other than the name of the Holder, this B
Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed
by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it
for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day
processing of any Notice of Exercise.
records in any manner which prevents the timely exercise of this B Warrant, pursuant to the terms hereof.
vii. Closing of Books. The Company will not close its stockholder books or
e) Holder’s Exercise Limitations. The Company shall not affect any exercise of this B Warrant, and a Holder shall
not have the right to exercise any portion of this B Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to
such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any
other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of the
Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock
beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this
B Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which
would be issuable upon (i) exercise of the remaining, nonexercised portion of this B Warrant beneficially owned by the Holder or any
of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company
(including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to
the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence,
for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and
the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the
Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the
determination of whether this B Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates)
and of which portion of this B Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of
Exercise shall be deemed to be the Holder’s determination of whether this B Warrant is exercisable (in relation to other securities
owned by the Holder together with any Affiliates) and of which portion of this B Warrant is exercisable, in each case subject to the
Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such
determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in
determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common
Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a
more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting
forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two
Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the
number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of
the Company, including this B Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of
Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this B Warrant. The
Holder, upon not less than 61 days’ prior notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this B
Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any such increase or decrease will not be
effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any
portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make
changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this B Warrant.
4
Section 3. Certain Adjustments.
a) Stock Dividends and Splits. If the Company, at any time while this B Warrant is outstanding: (i) pays a stock
dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent
securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by
the Company upon exercise of this B Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares,
(iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)
issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise
Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury
shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common
Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this B Warrant shall be
proportionately adjusted such that the aggregate Exercise Price of this B Warrant shall remain unchanged. Any adjustment made
pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to
receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision,
combination or re-classification.
b) Fundamental Transaction. If, at any time while this B Warrant is outstanding, (i) the Company, directly or
indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the
Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or
substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or
exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any
reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the
Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or
indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of
Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any
shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other
Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental
Transaction”), then, upon any subsequent exercise of this B Warrant, the Holder shall have the right to receive, for each B Warrant
Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the
option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this B Warrant), the number of shares of
Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of
shares of Common Stock for which this B Warrant is exercisable immediately prior to such Fundamental Transaction (without regard
to any limitation in Section 2(e) on the exercise of this B Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise
Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the
Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a
Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any
exercise of this B Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a
Fundamental Transaction that is (1) an all cash transaction, (2) a “Rule 13e-3 transaction” as defined in Rule 13e-3 under the Exchange
Act, or (3) a Fundamental Transaction involving a person or entity not traded on a Trading Market, the Company or any Successor
Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the
consummation of the Fundamental Transaction, purchase this B Warrant from the Holder by paying to the Holder an amount of cash
equal to the Black Scholes Value of the remaining unexercised portion of this B Warrant on the date of the consummation of such
Fundamental Transaction. “Black Scholes Value” means the value of this B Warrant based on the Black and Scholes Option Pricing
Model obtained from the “OV” function on Bloomberg, L.P. (“ Bloomberg”) determined as of the day of consummation of the
applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury
rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the
Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the “HVT” function
on Bloomberg as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C)
the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the
value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to
the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date. The
Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor
Entity”) to assume in writing all of the obligations of the Company under this B Warrant and the other Transaction Documents in
accordance with the provisions of this Section 3(b) pursuant to written agreements in form and substance reasonably satisfactory to the
Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the
Holder, deliver to the Holder in exchange for this B Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this B Warrant which is exercisable for a corresponding number of shares of capital stock
of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
B Warrant (without regard to any limitations on the exercise of this B Warrant) prior to such Fundamental Transaction, and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of
the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of
shares of capital stock and such exercise price being for the purpose of protecting the economic value of this B Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the
Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so
that from and after the date of such Fundamental Transaction, the provisions of this B Warrant and the other Transaction Documents
referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and
shall assume all of the obligations of the Company under this B Warrant and the other Transaction Documents with the same effect as
if such Successor Entity had been named as the Company herein.
5
c) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a
share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and
outstanding.
d) Notice to Holder.
i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant
to any provision of this Section 3, the Company shall promptly mail to the Holder a notice setting forth the Exercise
Price after such adjustment and any resulting adjustment to the number of B Warrant Shares and setting forth a brief
statement of the facts requiring such adjustment.
ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a
dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special
nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting
to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any
class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any
reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or
transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the
Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary
or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company,
at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the
date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or
if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such
dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such
reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and
the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their
shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect
therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such
notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the
Commission pursuant to a Current Report on Form 8-K if the Company is then subject to the reporting requirements
of Section 13 or 15(d) of the Exchange Act. The Holder shall remain entitled to exercise this B Warrant during the
period commencing on the date of such notice to the effective date of the event triggering such notice except as may
otherwise be expressly set forth herein.
Section 4.
Redemption of B Warrant. Commencing at any time following the effectiveness of the Registration
Statement covering the resale of the shares issuable upon exercise of the B Warrants, after the date on which the Common Stock closing bid
price reported by Bloomberg LP remains at an amount over Six Dollars and Twenty-Five Cents ($6.25) per share (as adjusted for forward or
reverse stock splits, stock dividends or other similar proportionately-applied change) for at least twenty (20) consecutive Trading Days (the
“Call Condition”), the Company shall have the right, upon sixty (60) Business Days’ notice to the Holder given not later than sixty (60)
Trading Days after the date on which the Call Condition is satisfied (the “Redemption Notice”), to redeem the number of B Warrant Shares
specified in the Redemption Notice, less any amount previously exercised, at a price of $0.01 per B Warrant Share (the “Redemption Price”),
on the date set forth in the Redemption Notice, but in no event earlier than sixty (60) Business Days following the date that the Company
delivers the Redemption Notice to the Holder (the “Redemption Date”). The Redemption Notice shall be provided to the Holder promptly
and in all events within five (5) Trading Days after the Company announces its intention to exercise its redemptions rights under this
section. The Holder may exercise this B Warrant at any time (in whole or in part) prior to the Redemption Date. Any portion of the B Warrant
that is subject to the Call Condition which is not exercised by 5:30 p.m. (Eastern time) on the Redemption Date shall no longer be exercisable
and shall be returned to the Company (and, if not so returned, shall automatically be deemed canceled), and the Company, upon its receipt of
the unexercised portion of this B Warrant, shall issue therefore in full and complete satisfaction of its obligations under such called but
unexercised portion of this B Warrant to the Holder an amount equal to the number of shares of Common Stock called but remaining
unexercised multiplied by the Redemption Price. The Redemption Price shall be mailed to such Holder at its address of record, and the B
Warrant shall be canceled.
6
Section 5. Transfer of B Warrant.
a) Transferability. This B Warrant and all rights hereunder (including, without limitation, any registration rights) are
transferable, in whole or in part, upon surrender of this B Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this B Warrant substantially in the form attached hereto duly executed by the Holder or its agent
or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if
required, such payment, the Company shall execute and deliver a new B Warrant or B Warrants in the name of the assignee or
assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the
assignor a new B Warrant evidencing the portion of this B Warrant not so assigned, and this B Warrant shall promptly be
cancelled. The B Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of B
Warrant Shares without having a new B Warrant issued.
b) New B Warrants. This B Warrant may be divided or combined with other B Warrants upon presentation hereof at
the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new B Warrants
are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 5(a), as to any transfer which may be
involved in such division or combination, the Company shall execute and deliver a new B Warrant or B Warrants in exchange for the
B Warrant or B Warrants to be divided or combined in accordance with such notice. All B Warrants issued on transfers or exchanges
shall be dated the initial issuance date of this B Warrant and shall be identical with this B Warrant except as to the number of B
Warrant Shares issuable pursuant thereto.
c) Warrant Register. The Company shall register this B Warrant, upon records to be maintained by the Company for
that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat
the registered Holder of this B Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the
Holder, and for all other purposes, absent actual notice to the contrary.
7
Section 6. Miscellaneous.
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).
a) No Rights as Stockholder Until Exercise. This B Warrant does not entitle the Holder to any voting rights,
b) Loss, Theft, Destruction or Mutilation of B Warrant . The Company covenants that upon receipt by the Company
of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this B Warrant or any stock certificate relating to
the B Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the B Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such B Warrant or stock
certificate, if mutilated, the Company will make and deliver a new B Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such B Warrant or stock certificate.
c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any
right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.
d) Authorized Shares.
The Company covenants that, during the period the B Warrant is outstanding, it will reserve from its
authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the B Warrant Shares
upon the exercise of any purchase rights under this B Warrant. The Company further covenants that its issuance of this B
Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute
and issue the necessary certificates for the B Warrant Shares upon the exercise of the purchase rights under this B
Warrant. The Company will take all such reasonable action as may be necessary to assure that such B Warrant Shares may be
issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market
upon which the Common Stock may be listed. The Company covenants that all B Warrant Shares which may be issued upon
the exercise of the purchase rights represented by this B Warrant will, upon exercise of the purchase rights represented by this
B Warrant and payment for such B Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and
nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than
taxes in respect of any transfer occurring contemporaneously with such issue).
Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including,
without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this B Warrant, but will at all times in good faith assist in the carrying out of all such terms
and in the taking of all such actions as may be necessary or appropriate to protect the rights of the Holder as set forth in this B
Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value
of any B Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par
value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue
fully paid and nonassessable B Warrant Shares upon the exercise of this B Warrant and (iii) use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this B Warrant.
8
Before taking any action which would result in an adjustment in the number of B Warrant Shares for which this B
Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or
consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.
shall be determined in accordance with the provisions of the Purchase Agreement.
e) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this B Warrant
f) Restrictions. The Holder acknowledges that the B Warrant Shares acquired upon the exercise of this B Warrant, if
not registered, and the Holder does not utilize cashless exercise at a time when the B Warrant Shares may be sold pursuant to Rule 144
without the requirement for the Company to be in compliance with the current public information requirements under Rule 144 and
without volume or manner-of-sale restrictions, will have restrictions upon resale imposed by state and federal securities laws.
g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part
of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any
other provision of this B Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any
provision of this B Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as
shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate
proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers
or remedies hereunder.
the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.
h) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by
i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this
B Warrant to purchase B Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any
liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is
asserted by the Company or by creditors of the Company.
j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of
damages, will be entitled to specific performance of its rights under this B Warrant. The Company agrees that monetary damages
would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this B Warrant and hereby
agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.
9
k) Successors and Assigns. Subject to applicable securities laws, this B Warrant and the rights and obligations
evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the
successors and permitted assigns of Holder. The provisions of this B Warrant are intended to be for the benefit of any Holder from
time to time of this B Warrant and shall be enforceable by the Holder or holder of B Warrant Shares.
l) Amendment. This B Warrant may be modified or amended or the provisions hereof waived with the written
consent of the Company and holders holding B Warrants to acquire 67% of the B Warrant Shares issuable pursuant to the B Warrants
that were issued under the Purchase Agreement.
m) Severability. Wherever possible, each provision of this B Warrant shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this B Warrant shall be prohibited by or invalid under applicable law,
such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this B Warrant.
purpose, be deemed a part of this B Warrant.
n) Headings. The headings used in this B Warrant are for the convenience of reference only and shall not, for any
********************
(Signature Page Follows)
10
as of the date first above indicated.
IN WITNESS WHEREOF, the Company has caused this B Warrant to be executed by its officer thereunto duly authorized
BIOSIG TECHNOLOGIES, INC.
By:__________________________________________
Name:
Title:
11
TO: BIOSIG TECHNOLOGIES, INC.
NOTICE OF EXERCISE
(1) The undersigned hereby elects to purchase ________ B Warrant Shares of the Company pursuant to the terms of the
attached B Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.
(2) Payment shall take the form of (check applicable box):
[ ] in lawful money of the United States; or
[ ] [if permitted] the cancellation of such number of B Warrant Shares as is necessary, in accordance with the
formula set forth in subsection 2(c), to exercise this B Warrant with respect to the maximum number of B Warrant
Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).
(3) Please issue a certificate or certificates representing said B Warrant Shares in the name of the undersigned or in such
other name as is specified below:
_______________________________
The B Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:
_______________________________
_______________________________
_______________________________
[SIGNATURE OF HOLDER]
Name of Investing Entity: ________________________________________________________________________
Signature of Authorized Signatory of Investing Entity: _________________________________________________
Name of Authorized Signatory: ___________________________________________________________________
Title of Authorized Signatory: ____________________________________________________________________
Date: ________________________________________________________________________________________
ASSIGNMENT FORM
(To assign the foregoing B Warrant, execute
this form and supply required information.
Do not use this form to exercise the B Warrant.)
are hereby assigned to
FOR VALUE RECEIVED, [____] all of or [_______] shares of the foregoing B Warrant and all rights evidenced thereby
_______________________________________________ whose address is
_______________________________________________________________.
_______________________________________________________________
Dated: ______________, _______
Holder’s Signature: _____________________________
Holder’s Address: _____________________________
_____________________________
Signature Guaranteed: ___________________________________________
NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the B Warrant, without alteration
or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a
fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing B Warrant.
EXHIBIT 31.01
I, Gregory D. Cash, certify that:
CERTIFICATION
1.
2.
3.
4.
I have reviewed this annual report on Form 10-K of BioSig Technologies, Inc.;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
in this report;
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the
equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonable likely to adversely affect the registrant’s ability to record, process, summarize and report
financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal controls over financial reporting.
Date: February 20, 2015
/s/ GREGORY D. CASH
Gregory D. Cash
Chief Executive Officer
EXHIBIT 31.02
I, Steven Chaussy, certify that:
CERTIFICATION
1.
2.
3.
4.
I have reviewed this annual report on Form 10-K of BioSig Technologies, Inc.;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
in this report;
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the
equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonable likely to adversely affect the registrant’s ability to record, process, summarize and report
financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal controls over financial reporting.
Date: February 20, 2015
/s/ STEVEN CHAUSSY
Steven Chaussy
Chief Financial Officer
EXHIBIT 32.01
CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Gregory Cash, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that the Annual Report of BioSig Technologies, Inc. on Form 10-K for the fiscal year ended December 31, 2014 fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Annual Report on Form
10-K fairly presents in all material respects the financial condition and results of operations of BioSig Technologies, Inc.
Date: February 20, 2015
/s/ GREGORY D. CASH
By:
Name: Gregory D. Cash
Title: Chief Executive Officer
I, Steven Chaussy, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that the Annual Report of BioSig Technologies, Inc. on Form 10-K for the fiscal year ended December 31, 2014 fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Annual Report on Form
10-K fairly presents in all material respects the financial condition and results of operations of BioSig Technologies, Inc.
Date: February 20, 2015
/s/ STEVEN CHAUSSY
By:
Name: Steven Chaussy
Title: Chief Financial Officer